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1 Summary 
 
The neural crest (NC) is a transient embryonic stem/progenitor cell population and a 
hallmark of vertebrate development. The NC is induced during neurulation at the 
border between the neuronal and non-neuronal ectoderm. Upon induction NC cells 
undergo an epithelial to mesenchymal transition (EMT), delaminate from the neural 
folds and migrate extensively through the developing embryo. NC cells give rise to a 
broad variety of cell types including the sensory and autonomic neurons of the 
peripheral nervous system, the myelinating Schwann cells and the melanocytes, 
among others. Despite the broad differentiation potential of NC cells it has been 
highly debated whether the NC consisted of multipotent cells or whether it was rather 
a heterogeneous population of restricted progenitors. In fact, although several earlier 
studies have described multipotency of NC cells, the existence of multipotent NC 
cells has been questioned both by cell culture experiments and in recent in vivo 
studies performed in chick embryos. In this study, we solved a longstanding 
controversy regarding a pivotal question in the field of stem cells. Using genetic 
lineage tracing in the mouse, we revealed for the first time the broad developmental 
potential of NC cells in a mammalian system and we demonstrated that the majority 
of premigratory and migratory NC cells are multipotent in vivo. 
 
Embryogenesis and tumorigenesis share several mechanisms in common and it has 
become more and more evident that knowledge in developmental biology can 
provide further insights into tumor biology. For instance, melanoma, a malignancy of 
NC-derived melanocytes, can exploit various NC developmental programs for 
disease progression. Malignant melanoma cells can indeed aberrantly activate EMT 
master regulators, such as members of the Snail, Twist and Zeb families, which are 
normally activated by NC cells during migration in the embryo. In the course of 
melanoma progression malignant cells brake through the basament membrane, 
invade the underlying mesenchyme, reach blood and lymphatic vessels and 
metastasize to distant organs. Moreover, similar to NC cells, melanoma cells can 
possess multipotency features and be able to express different lineage markers.  
We discovered that the zinc-finger transcription factor Sall4 is expressed in NC cells 
and it is downregulated upon differentiation. Sall4 is a crucial factor for the 
maintenance of self-renewal and pluripotency of embryonic stem cells. Moreover, 
SALL4 has been associated with tumorigenesis and to worse patient outcome in 
various cancer types. However, whether SALL4 may also play a role in melanoma 
	  2	  
formation and progression has not been addressed so far. We observed that SALL4 
was mostly expressed in human proliferative melanoma cell lines, while it was absent 
in more invasive melanoma cell lines or upon EMT induction. Interestingly, SALL4 
downregulation induced, in turn, an EMT signature in a proliferative melanoma cell 
line, suggesting that there may be a regulatory feedback loop. In vivo we induced 
Sall4 loss in the Tyr::NRasQ61K Ink4a-/- Tyr::CreERT2 Sall4lox/lox R26R::GFP melanoma 
mouse model and could observed that primary tumor formation was impaired. 
However, Sall4 loss was linked to a reduced survival of the knock out animals and 
recombined cells were detected in lymph nodes and in some lungs. Further 
investigations now urge to be performed to prove whether Sall4 loss is necessary 
and sufficient for EMT induction.  
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 2 Zusammenfassung 
 
Die Neuralleiste ist eine temporäre embryonale Stammzellenpopulation und ein 
Charakteristikum der Wirbeltierentwicklung. Die Neuralleiste wird während der 
Neurulation an der Grenze zwischen dem neuronalen und dem nicht neuronalen 
Ektoderm gebildet. Nach der Entstehung der Neuralleiste durchleben die 
Neuralleistenzellen einen epithelialen zu mesenchymalen Wandel (EMT). Nach 
Ablösung der Neuralleistenzellen vom neuronalen Epithelium wandern die Zellen 
ausgiebig durch den sich entwickelnden Embryo. Die Neuralleiste bringt viele 
verschiedene Zelltypen hervor, wie zum Beispiel Neuronen und Gliazellen des 
peripheren Nervensystems sowie Melanozyten. Trotzt dem hohen 
Differenzierungspotential der Neuralleistenzellen war es höchst umstritten, ob 
Neuralleistenzellen multipotent sind oder, ob die Neuralleiste eher aus einer 
heterogenen Population von spezialisierten Mutterzellen besteht. Auch wenn 
Pionierstudien die Neuralleiste zuvor als multipotent charakterisiert hatten, ließen 
andere in vitro Studien und in vivo Studien an Hühnerembryonen an deren Existenz 
zweifeln. Durch unsere Studie ist es uns nun gelungen, diese langandauernde 
Debatte der Stammzellenforschung zu beenden. Mit Hilfe von Mausgenetik haben 
wir zum ersten Mal gezeigt, dass die Neuralleiste der Säugetiere ein 
beeindruckendes Differenzierungspotential besitzt und, dass die Mehrheit der 
Neuralleistenzellen vor und während der Besiedelung des Embryos multipotent ist. 
 
Die Embryogenese und die Karzinogenese haben viele Gemeinsamkeiten und es 
wird zunehmend ersichtlich, dass detaillierte Kenntnisse der mechanistischen 
Prozessen während der embryonalen Entwicklung die Grundlage für ein besseres 
Verständnis der Tumorbiologie ist. Das Melanom, ein bösartiger Tumor der 
Melanozyten, hat zum Beispiel seinen Ursprung in der Neuralleiste. Dieser schwarze 
Hautkrebs (Krebsart) nutzt viele Prozesse, die während der embryonalen 
Entwicklung essentiell sind, zu seiner Etablierung aus. Das maligne Melanom 
exprimiert unter anderen Transkritionsfaktoren der Snail, Zeb und Twist Familie, die 
für die EMT verantwortlich  sind und die normalerweise in der Neuralleiste aktiviert 
werden, um deren Wanderung durch den Embryo während der Entwicklung 
gewährleisten zu können. Auf diese Weise können maligne Melanomzellen die 
Basalmembran der Haut durchbrechen, in das unterliegende Mesenchym eindringen 
und so die Blut- und Lymphgefässe erreichen, um zu metastasieren. Zudem können 
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Melanomzellen, vergleichbar mit der Neuralleiste, einige multipotente Eigenschaften 
besitzen und Merkmale verschiedener differenzierter Zellenlinien exprimieren.  
Wir haben entdeckt, dass der Transkriptionsfaktor Sall4 spezifisch in 
Neuralleistenzellen exprimiert ist und, dass die Sall4 Expression nach der 
Differenzierung der Neuralleistenzellen herunterreguliert wird. Sall4 ist für die 
uneingeschränkte Teilung und die Pluripotenz von embryonalen Stammzellen 
notwendig. Außerdem ist SALL4 oft mit Karzinogenese und einer schlechteren 
Patientenprognose in verschiedenen Krebsarten assoziiert. Ob SALL4 auch eine 
Rolle in der Entwicklung maligner Melanome spielen könnte, ist es bis jetzt  jedoch 
noch nicht untersucht geworden. In unserer Studie haben wir nun beobachtet, dass 
SALL4 am  häufigsten in Zellen schnell wachsender Melanomen vorhanden ist, aber 
dass es in invasiven Melanomen oder nach der EMT Induktion nicht mehr 
detektierbar ist. Bemerkenswerterweise löst die Herunterregulierung von SALL4 in 
proliferativen, wenig invasiven Melanomzellen typische Kennzeichen der EMT aus. 
Insgesamt deuten diese Resultate darauf hin, dass eine negative 
Rückkopplungsregulierung existieren könnte. Mit Hilfe des transgenen Mausmodels 
Tyr::NRasQ61K Ink4a-/- Tyr::CreERT2 Sall4lox/lox R26R::GFP konnten wir außerdem 
zeigen, dass der Verlust von Sall4 die Entstehung maligner Tumore verhindert. Der 
Verlust von Sall4 war jedoch mit einem schlechteren Überleben der Versuchstiere 
und mit der Präsenz rekombinierte Melanozyten in Lymphknoten und einigen Lungen 
verbunden. Weitere Untersuchungen sind jetzt notwendig, um zu verstehen, ob die 
Herunterregulierung der Sall4 Expression ein notwendiger und ausreichender 
Vorgang ist, um die EMT zu ermöglichen. 	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3 Introduction 
 
3.1 The neural crest 
 
The neural crest (NC) is an embryonic stem/progenitor cell population typical of 
vertebrate embryos. It is induced during neurulation at the border between the 
neuronal and non-neuronal ectoderm. Upon induction, NC cells undergo an epithelial 
to mesenchymal transition (EMT), delaminate from the dorsal neural tube and 
migrate extensively through the embryo. NC cells possess one of the broadest 
developmental potential in the vertebrate embryo. They are able to differentiate into a 
broad variety of cell types responsible for the generation of the peripheral nervous 
system (PNS), the enteric nervous system and the craniofacial skeleton, among 
others. 
 
3.1.1 NC formation 
 
The NC is induced at the border between the prospective neural and non-neural 
ectoderm. Signals from the ectoderm and from the underlying mesoderm create a 
complex gene regulatory network responsible for NC induction, delamination from 
the dorsal neural tube and the correct migration of NC cells throughout the 
developing embryo (Figure 1, Sauka-Spengler and Bronner-Fraser, 2008). In 
particular, bone morphogenetic protein (BMP), fibroblast growth factor (FGF) and 
Wnts regulate the expression of the neural tube specifiers Msx1, Msx2, Pax3, Pax7 
and Zic1. Pax3 and Zic1, in turn, induce the expression of NC specifiers including 
Snail1, Snail2, Sox9, Sox10, AP-2, Twist, c-Myc, Id and FoxD3, in the dorsal neural 
tube in a Wnt-dependent manner. Upon NC induction, NC cells undergo EMT, during 
which the cells loose their apical-basal cell polarity, reorganize their cytoskeleton, 
upregulate adhesion molecules and delaminate from the neural folds (Sauka-
Spengler and Bronner-Fraser, 2008). NC cells then vastly migrate through the 
embryonic body following migratory paths defined and regulated mostly by inhibitory 
molecules such as the SEMA3F-NPL2 and the Slit-Robo signaling molecules 
(Gammill et al., 2007; Jia et al., 2005). Chemoattractant molecules can, however, 
also guide migratory NC cells, such as the glial-cell-derived neurotrophic factor 
(GDNF) that regulates the migration of vagal NC cells to the developing enteric 
nervous system (Young et al., 2001; Sauka-Spengler and Bronner-Fraser, 2008). 	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Figure 1. The regulatory network that controls NC formation 
BMP, FGF and Wnts are the key regulators of the neural tube specifiers Pax3 and Zic1. The 
neural tube specifiers Pax3 and Zic1, in turn, induce NC specification in the dorsal neural 
tube through activation of Snail and FoxD3. Once the NC is segregated from the dorsal 
neuroepithelium, NC cells undergo EMT and migrate through the vertebrate embryo and 
differentiate into a broad range of diverse cells types (adapted from: Sauka-Spengler and 
Bronner-Fraser, 2008). 
 
3.1.2 The NC populations  
 
          
Figure.2 NC functional domains 
The schematic drawing depicts the cranial 
(blue), the cardiac (green), the vagal 
(yellow) and the trunk (orange) NC. 
The NC is subdivided into four groups 
depending on the rostro-caudal axis 
level from which the NC cells 
delaminate. 
Cranial NC cells (Figure 2, in blue) 
emigrate from the neuroepithelium 
before neural tube closure and give 
rise to the osteocytes and the 
chondrocytes 
Nature Reviews | Molecular Cell Biology
Neural plate border
Non-neural
ectoderm
Neuroectoderm
Endoderm
Notochord
Paraxial mesoderm
Wnt FGF
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Msx1, Msx2, Pax3, Pax7, Zic1
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The process of NC formation entails reiterated input 
of canonical metazoan signalling pathways as well as the 
introduction of novel vertebrate-specific receptor–ligand-
mediated pathways that act at the level of survival and 
cell-fate specification of the NC lineages (BOX 2). Within 
this GRN, each step is temporally and spatially connected 
by transcription factors that cross-regulate each other and 
sometimes act redundantly.
Figure 1 | Regulatory steps in neural crest formation. Induction initiates at the neural plate border and is mediated by 
signals including fibroblast growth factor (FGF) from the underlying mesoderm as well s Wnts from mesoderm and 
adjacent non-neural ectoderm. One or both of these signals independently induce the expression of individual neural 
plate border specifiers, such as Pax3 and Zic1, in a manner that is dependent on intermediate levels of bone 
morphogenetic protein (BMP). Pax3 and Zic1 in urn act synergistically, in a Wnt-dep ndent manner, to up-regul te neural 
crest (NC) specifiers such as Snail and FoxD3 in the neural folds and/or dorsal neural tube. These interactions have been 
primarily derived from work in Xenopus laevis and as such may not uniformly apply to other organisms. The c-Myc–Id 
cassette is a network switch that mediates cell-fate decisions by controlling the cell cycle, but also may maintain the NC 
progenitor pool in a multipotent state. Sox9 confers survival properties to trunk NC precursors through up-regulation of 
Snail, an anti-apoptotic factor. Expression of these early NC specifiers in the NC progenitor population segregates them 
from the dorsal neuroepithelium, as these genes control the events of cell proliferation, delamination and the onset of the 
epithelial to mesenchymal transition (EMT). Other NC specifiers, such as FoxD3 and Sox10, persist in delaminating and 
migrating NC cells, where they control expression of downstream effector genes such as type II cadherin, cadherin-7 
(Cad7), matrix metalloproteases (MMPs; including a disintegrin and metalloprotease-10 (ADAM10)), integrins, neuropilins 
(Npl), Eph and other transmembrane receptors. 
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558 | JULY 2008 | VOLUME 9  www.nature.com/reviews/molcellbio
2"
The Neural Crest (NC)!
Premigratory NC cells!
Short Article
Premigratory a d Migr t ry Neur l Crest Cells Are
Multipotent In Vivo
Graphical Abstract
Highlights
d We traced single NC cells in vivo by using the R26R-Confetti
mouse model
d Most premigratory and migratory NC cells are multipotent
d Multipotency is confirmed by differentiation marker analysis
d Our results point to the existence of neural crest stem cells
(NCSCs) in vivo
Authors
Arianna Baggiolini, Sandra Varum, ...,
Reinhard Furrer, Lukas Sommer
Correspondence
lukas.sommer@anatom.uzh.ch
In Brief
The neural crest (NC) gives rise to a broad
variety of neural and non-neural cell types
during vertebrate development, but
whether NC cells aremultipotent or rather
a heterogeneous population of restricted
progenitors is unclear. Baggiolini et al.
performed an in vivo lineage tracing study
of single premigratory and migrating NC
cells and demonstrated that the majority
of NC cells are multipotent in vivo.
Baggiolini et al., 2015, Cell Stem Cell 16, 314–322
March 5, 2015 ª2015 Elsevier Inc.
http://dx.doi.org/10.1016/j.stem.2015.02.017
The trunk NC! •  Melanocytes in the dorsal lateral pathway (DLP)!
•  Sensory neurons and lia 
cells in the dorsal root ganglia 
(DRG)!
•  Autonomic neurons and 
glia cells in the sympathetic 
ganglia (SG)!
•  Glia cells of the ventral root 
(VR)!
DLP!
VR!
SG!
DRG!
NT!
The cranial NC!
The cardiac NC!
The vagal NC!
!
The trunk NC!
Epithelial to 
mesenchymal 
transition (EMT)!
	   7	  
that build up the craniofacial skeleton of the vertebrate embryo. In particular, cranial 
NC cells give rise to the pharyngeal apparatus (PA), a transient embryonic structure, 
which is eventually remodeled into the final structures of the jaws (Cordero et al., 
2011). Cranial NC cells also differentiate into sensory neurons, Schwann cells, 
smooth muscle cells and the melanocytes of the head.  
The cardiac NC (Figure 2, in green) originates from the area between the otic vesicle 
and the third somite. These cells differentiate into the smooth muscle cells of the 
cardiac outflow tract and give rise to the aorticopulmonary septum (Jiang et al., 2000; 
Sieber-Blum, 2004). 
The vagal NC (Figure 2, in yellow) originates between somites 1 and 7 and gives rise 
to the enteric nervous system (Heanue and Pachnis, 2007). 
Finally, the trunk NC (Figure 2, in orange) arises at somite 7 level until the most 
caudal region of the neural tube. After delamination from the dorsal neural tube trunk 
NC cells migrate ventrally to differentiate into various cell types: autonomic neurons 
and glia of the sympathetic ganglia (SG), glia cells of the ventral root (VR) and 
sensory neurons and glia of the dorsal root ganglia (DRG). Trunk NC cells that 
migrate on the dorsal lateral pathway (DLP) give rise to the melanocytic lineage of 
the skin (Figure 3). Moreover, the chromaffin cells of the adrenal glands also 
originate from the trunk NC (Crane and Trainor, 2006). 
 
 
Figure 3. The derivatives of the trunk NC. 
After delamination from the dorsal neural tube trunk NC cells give rise to a vast range of 
different cell types. At the forelimbs level the trunk NC creates the entire peripheral nervous 
system, including neuronal and glial cells of the DRG and of the SG, glial cells of the VR. 
Moreover, trunk NC cells that migrate along the DLP generate the melanocytes of the skin.  
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3.1.3 The fate of NC cells 
 
Initial studies that investigated the developmental fate of NC cells were conducted 
performing quail-chick transplantations of premigratory NC cells. The NC of quail 
embryos was grafted at different levels along the rostro-caudal axis of the chick 
embryos (Couly and Le Douarin, 1985). Subsequent analysis of the chimeras 
revealed that the fate of the NC cells was not dependent on the rostro-caudal domain 
from where the cells were isolated, but rather on local cues provided from 
surrounding tissue at the site of transplantation. This result was one of the first 
indications for the multipotency of NC cells in vivo (Couly and Le Douarin, 1985; 
Dupin and Le Douarin, 2014). First evidence for the multipotency of the NC was 
generated by pioneer lineage tracing studies in the chick embryo in which single 
premigratory trunk NC cells were labeled by intracellular injection of a vital dye 
(Bronner-Fraser and Fraser, 1988; Bronner-Fraser and Fraser 1989). The majority of 
labeled trunk NC cells was located in multiple NC derivatives and it was, thus, 
assumed that these cells were able to differentiate into diverse cell types. Similarly, 
lineage tracing of mouse trunk NC cells by intracellular injection of vital dye 
suggested that this observation was also true for mammals (Serbedzija et al., 1990). 
Consistent with these results, in vitro investigations proved that NC cells were 
multipotent and able to self-renew (Stemple and Anderson, 1993). 
More recent studies further investigated the developmental fate of the NC in vivo. 
Kalcheim and colleagues used a semi-open book preparation to mark single 
premigratory trunk NC cells by either vital dye microinjection or plasmid 
electroporation in the chick embryo (Krispin et al., 2010). Interestingly, they found 
that NC cells were restricted in their differentiation potential and that they were 
segregated inside the dorsal NT in a spatio-temporal manner. Accordingly single NC 
cells were restricted to a specific lineage and the fate of each cell could be 
anticipated depending on its location inside of the dorsal neural tube and the time of 
its emigration (Krispin et al., 2010a; Krispin et al., 2010b). However, such an early 
restriction of the premigratory NC and spatio-temporal segregation inside the dorsal 
neural tube could not be confirmed by neither time-lapse nor two-photon microscopic 
imaging of fluorescent dye labeled chick NC cells (McKinney et al., 2013).  
The discrepancies of these results could be explained by stage differences at the 
moment of cell labeling or by technical differences in the injection procedures (Dupin 
and Sommer, 2012).  
Recent work from our lab addressed this issue investigating the trunk NC in a 
mammalian embryo. Using genetic multicolor single cell tracing in the mouse, 
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combined with lineage differentiation analysis and extensive biostatistical 
examination, we revealed for the first time the broad developmental potential of NC 
cells in a mammalian system in vivo. Indeed, the vast majority of premigratory and, 
surprisingly, also migratory NC cells was able to generate sensory and autonomic 
neurons, glia and melanocytes (Baggiolini et al., 2015; Bronner, 2015; 4.1 
Premigratory and migratory neural crest cells are multipotent in vivo). 
 
3.1.4 NC-derived stem cells 
 
The NC is a multipotent transient embryonic cell population. However, NC-derived 
stem cells exist in several NC derivatives and persist at later developmental stages 
and in the adult organism (Shakhova and Sommer, 2008).  
p75NTR+/P0− cells can in fact be isolated from the sciatic nerve of rat embryos at 
embryonic day (E) 14.5. These cells show self-renewal capacity both in vitro and in 
vivo and can differentiate into neurons, glia and myofibroblasts in vitro (Morrison et 
al., 1999). Similarly, NC-derived precursor cells exist in the adult DRG (Li et al., 
2007; Nagoshi et al., 2008), bone marrow (Nagoshi et al., 2008), gut (Kruger et al., 
2002), heart (Tomita et al., 2005; El-Helou et al., 2008), cornea (Yoshida et al., 2006; 
Brandl et al., 2009), and finally also in the bulge region of the hair follicle in the skin 
(Toma et al., 2001; Wong et al., 2006). 
 
 
Figure 4. NC-like stem cells. 
NC-derived precursor cells exist also in the adult organism. Cells with NC-like properties like 
self-renewal capacity and differentiation potential exist in almost all NC-derived structures. 
Neural crest-derived stem cells
DRG
trunk
skin
cornea
gut
bone marrow heart
Figure 2. Postmigratory NCSCs. In the adult organism, several different tissues contain cells with a self-renewal capacity and differentiation potential
resembling those of neural crest cells during embryonic development. NCSCs have been described in DRG, gut, cornea, heart, bone marrow, and skin. In the
gut, NCSCs have been associated with the submucosal plexus, myenteric plexus, and the outer muscle layer. In the cornea, neural crest-derived cells with
stem cell features are thought to be located in the corneal stroma and epithelium. In the heart, NCSCs appear to be concentrated at the outflow tract and at
the intramuscular and subepicardial layers of ventricles, as well as within the atrial wall. In the bone marrow, NCSCs are tightly associated with the bone
marrow surface. In the trunk skin, NCSCs are locat d in the bulge regio of th hair follicle and are associated with nerve endings s rrounding the hair
follicle.
FGF2 and EGF allowed prolonged propagation of p75NTR-positive cells in culture. Similar to this study, Lawlor and
colleagues also achieved the derivation of multipotent neural crest-like cells from human ES cells (Jiang et al., 2009).
These authors co-cultured ES cells with the PA6 cell line followed by fluorescence-activated cell sorting (FACS) of
p75NTR-expressing cells that were capable of generating neurons, glia, and smooth muscle actin (SMA)-expressing
cells. It remains to be investigated whether these protocols could be applied as such to mouse ES cells. However,
the possibility to produce human cells with NCSC features offers an exciting strategy for modeling human disease.
Indeed, the Studer group has recently applied its protocol to iPS cells derived from human patients suffering from
familial dysautonomia, a disease characterized by the depletion of autonomic and sensory neurons (Lee et al., 2009).
Using this system, defects in neurogenesis and migration of patient-specific neural crest precursors were revealed that
were treatable in culture with appropriate drugs. Thus, the iPS cell technology is suitable to provide new insights into
pathogenesis and potential treatment of human neurocristopathies.
3. Postmigratory NCSCs
As the neural crest represents a transitory embryonic cell population, it has been assumed that NCSCs represent
“in vitro stem cells” similar to ES cells isolated from the blastomere, displaying stem cell features in culture, but only
transiently found in the living organism. The discovery of NCSC-like cells in postmigratory targets of embryonic
neural crest, such as the sciatic nerve, dorsal root ganglia (DRG), the gut, and the skin was therefore surprising
(Delfino-Machin et al., 2007) (see Table 1; Figure 2). A major breakthrough in the field came with the demonstration
that even the adult organism contains multipotent, self-renewing populations of neural crest-derived cells with a
developmental potential resembling that of embryonic NCSCs (Kruger et al., 2002). However, although they are able
to generate neuronal, glial, and non-neural cell types, postmigratory NCSCs from different regions as well as NCSCs
isolated at different time points display cell-intrinsic differences in response to microenvironmental factors (Bixby
et al., 2002; Wong et al., 2006). The mechanisms underlying these intrinsic changes are ill defined, but can involve
changes in growth factor receptor expression levels (White et al., 2001). Moreover, we showed that NCSCs undergo
stage-dependent transitions with respect to their growth requirements: As mentioned above, self-renewal of early
migratory NCSCs is controlled by combinatorial Wnt and BMP signaling (Kleber et al., 2005). In contrast, later stage
postmigratory NCSCs loose Wnt responsiveness and acquire responsiveness to mitogenic EGF acting upstream of the
5
stembook.org
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These precursor cells can be found in the adult DRG, gut, skin, cornea, bone marrow and 
heart (adapted from: Shakhova and Sommer, 2008). 
 
3.1.5 NC as a hallmark of vertebrate evolution 
 
Vertebrates, together with Tunicates and Cephalocordates, belong to and represent 
the vast majority of the phylum of Chordates. In fact, vertebrates seem to have had a 
considerable evolutionary advantage compared to the other members of the Philum. 
The major trait that distinguished the vertebrates from the other Chordates was the 
appearance of the NC. All vertebrates possess a premigratory NC that arises in the 
dorsal neural tube, or at least adjacent to it. Moreover, the gene regulatory network 
controlling NC induction is very conserved among vertebrates (Sauka-Spengler and 
Bronner-Fraser, 2008). In all vertebrates, NC cells undergo EMT, delaminate from 
the neuroepithelium and migrate extensively through the embryo to give rise to a vast 
variety of cell types and structures. 
In particular, the NC allowed the formation of a craniofacial skeleton and the 
appearance of a novel sensory system, which availed the vertebrates of a “New 
Head”; a concept that was coined by Gans and Northcutt (1983) to define the 
contributions of the NC to the vertebrates. These innovations enabled the vertebrates 
to develop from filter feeders to predators (Green et al., 2015) and, thus, to 
drastically change their life style and diet. Beyond the innovations of the jaws and of 
the sensory system, other NC-derived traits arose including pigment cells, 
pharyngeal cartilage and muscles, chromaffin cells and the outflow tract of the heart. 
All these evolutionary new features enabled vertebrate animals to adopt a more 
active behavior and furthermore profoundly changed their perception of environment. 
Finally, a change in metabolism, blood circulation and respiration definitively set 
vertebrates apart and rendered them unique (Green et al., 2015).  
 
3.1.6 NC and disease 
 
During development NC cells are induced in the dorsal neural tube and eventually 
delaminate from the dorsal neuroepithelium and migrate through the embryonic body 
to reach diverse locations where they have to differentiate, proliferate and survive. 
Whenever one or more of these processes are not correctly accomplished, organ 
defects and dysplasias may arise. Such developmental anomalies of the NC are 
termed neurocristopathies. 
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Many neurocristopathies are birth defects such as Hirschsprung disease, cleft 
lip/palate malformations, heart malformations and congenital nevi (Etchevers et al., 
2006). 
Congenital nevi occur in one of every 100 newborns and it is a dermal hyperplesia of 
the melanocytes, which arises during embryonic development. Congenital nevi are 
caused by the gain-of-function NRASQ61K mutation, which aberrantly activates the 
mitogen-activated kinase (MAPK) pathway (Bauer et al., 2006). Of importance, 
patients affected by congenital giant nevi are more prone to develop melanoma (3.2 
Melanoma), due to the constitutive activation of NRAS and the aberrant number of 
melanocytes, and need to be kept under observation (Lyon, 2010). 
Besides congenital birth defects various cancer types can arise from NC-derived 
cells. Those malignancies include among others neuroblastoma, one of the most 
common childhood tumors derived from the symphatetic compartment of the PNS; 
and schwannoma, that arises from the glia of the sympathetic nervous system. 
Furhtermore, medullary thyroid carcinoma arises form the tyroid gland. 
Pheochromocytomas arise from the chromaffin cells of the adrenal medulla and 
paragangliomas derive from the non-chromaffin cell chemoreceptors of the head and 
neck. Moreover melanoma, a highly aggressive cancer deriving from the melanocytic 
lineage, also belongs to the acquired neurocristopathies (3.2 Melanoma; Etchevers 
et al., 2006).  	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3.2 Melanoma 
 
3.2.1 Epidemiology of cutaneous melanoma 
 
Cutaneous melanoma is an aggressive cancer that arises from the abnormal 
behavior of the melanocytic lineage. Cutaneous melanoma is the most aggressive 
skin cancer and it is responsible of 75% of the skin cancer-related deaths. It is a 
disease particularly common in the Western world (Figure 5) affecting 15-25 per 
100’000 individuals (Schadendorf and Hauschild, 2014) every year. Cutaneous 
melanoma affects principally individuals with fair skin, blue eyes and red hair, while 
more pigmented populations from e.g. Africa or Asia are more likely to develop other 
types of melanoma, such as the more rare acral and mucosal melanomas 
(Schadendorf et al., 2015). 
 
 
Figure 5. Worldwide incidence and mortality rates of cutaneous melanoma. 
Incidence and mortality rates of cutaneous melanoma vary among countries, being the 
Western countries the most affected (adapted from: Schadendorf et al., 2015). 
 
Beyond individual genetic susceptibility, such as fair skin and red hair, familial 
genetic background can also play a role. Familial melanoma, which accounts for 8% 
of all melanoma cases, is mostly caused by a germline mutation in the Cyclin-
for melanoma development17. Sun exposure in geneti-
cally susceptible individuals — mainly during childhood 
and adolescence — induces melanocytic naevi, which are 
often also referred to as ‘moles’, high numbers of which 
are associated with increased risk for melanoma develop-
ment. Individuals with ≥100 melanocytic naevi carry a 
sevenfold increased risk for lifelong melanoma develop-
ment, according to one meta-analysis18. Furthermore, 
the presence of atypical melanocytic naevi that repre-
sent larger and more asymmetric and irregular forms of 
naevi are an additional risk factor. The use of sunbeds 
during youth significantly increases the relative risk for 
melanoma development19,20. Consequently, several coun-
tries have banned the use of artificial tanning devices by 
children and adolescents.
Clinically, cutaneous melanoma occurs most com-
monly in individuals who are between the ages of 40 years 
and 60 years, but it can affect those in adolescence and 
in late life (≥80 years). The median age at diagnosis is 
57 years6, which is almost one decade before most solid 
tumours — for example, breast, colon or lung tumours 
— typically arise. Cutaneous melanoma is one of the 
most common cancers in young adults aged 20–29 years. 
Consequently, the calculated loss of life in years is among 
the highest for this subtype of melanoma when considered 
alongside other subtypes21. The most frequent locations of 
melanoma are the back in males and the lower extremities 
in females. Women have an unexplained survival advan-
tage compared with men for all tumour stages22,23.
Mechanisms/pathophysiology
Transformation of melanocytes into melanoma requires 
a complex interplay of exogenous and endogenous 
events (FIG. 2). Tremendous progress has been made in 
unravelling the genetic basis of melanoma, which we 
are now beginning to understand24. The first genetic 
evidence came from germline alterations in families 
with two or more close relatives affected by melanoma. 
A familial background occurs in ~8% of all patients 
with melanoma and, of these, 40% carry high-risk, 
high-penetrance germline mutations in the cyclin-
dependent kinase inhibitor 2A (CDKN2A) locus25,26. The 
CDKN2A gene encodes two distinct tumour suppressors 
— p16INK4A and p14ARF — through the use of alternative 
promoters and through translation in different reading 
frames. Wild-type p16INK4A maintains cell-cycle control 
by inhibiting cyclin-dependent kinase 4 (CDK4)- or 
CDK6-mediated phosphorylation and inactivation of 
retinoblastoma-associated protein (RB), whereas func-
tional p14ARF prevents ubiquitylation mediated by the 
E3 ubiquitin-protein ligase MDM2 and the subsequent 
degradation of cellular tumour antigen p53 (which is 
encoded by TP53)27. Thus, inactivating mutations in 
CDKN2A promote G1–S cell-cycle transition by loss of 
two important regulators of cellular homeostasis, RB 
and p53 (REF. 28). Germline mutations in CDK4 have also 
been found in melanoma-prone families, further under-
scoring the relevance of defective cell-cycle control for 
melanoma transformation29. Other germline mutations 
— for example, in BAP1, which encodes a deubiquitylat-
ing enzyme involved in the DNA damage response and 
chromatin modification30, or in the telomere shelterin 
gene POT1 (REFS 31,32) — are also rare; thus, >50% of 
all familial melanomas have an unknown genetic basis24.
Sporadic melanomas, which comprise ~90% of 
all melanomas, are frequently driven by low-risk or 
moderate-risk alleles that have high prevalence and low 
penetrance, pointing to a causative role of environmental 
factors for malignant transformation33–35. Several popu-
lation studies have revealed that inactivating variants of 
the highly poly morphic melanocortin 1 receptor gene 
(MC1R; which has >100 allelic variants) are associ-
ated with red hair, poor tanning ability and increased 
melanoma risk36,37. MC1R encodes a G protein-cou-
pled receptor that signals through adenylate cyclase 
to induce the master regulator of pigmentation MITF 
(which encodes micropthalmia-associated transcrip-
tion factor) and, thereby, the production of melanin in 
response to binding of α-melanocyte stimulating hor-
mone (α-MSH)37. MITF alone is amplified in 4–21% of 
all melanomas38,39. Additional germline polymorphisms 
have also been found in other pigmentation-related 
genes including ASIP (which encodes agouti signalling 
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Dependent Kinase Inhibitor 2A (CDKN2A) locus (FitzGerald et al., 1996). However, 
sporadic melanoma, which represents 90% of all melanoma cases, can not 
exclusively be explained by genetics. It is rather caused by a combination of frequent 
low-risk alleles together with environmental mutagenic factors (Eggermont et al., 
2014). One of the highest environmental risk factors is the exposure to UV light. UVA 
and UVB light indeed play a mutagenic role and cause UV-signature mutations such 
as the C>T (UVB-induced) or G>T (UVA-induced) transitions (Hodis et al., 2012) that 
in turn can also account for some driver gene mutations. For example the activating 
mutation of RAC1P29S that leads to the downstream activation of PAK (p21-activated 
protein kinase) signaling, and the loss-of-function mutation of cell cycle regulator 
p16Ink4a, express a UV-signature (Hodis et al., 2012). 
 
3.2.2 Driver mutations in melanoma 
 
However, not all mutations in melanoma show a UV-signature. Most of the mutations 
that affect the mitogen-activated protein kinase (MAPK) cascade indeed do not 
express a typical UV-signature, even though a role of UV damage can not be 
completely excluded. Among these oncogenic mutations there are common 
mutations such as BRAFV600E, which is present in 50% of all melanomas, and 
NRASQ61R and NRASQ61L, which affect between 15-20% of all melanomas (Hodis et 
al., 2012). Interestingly, BRAF and NRAS mutations, as well as mutations of other 
MAPK members, are mostly mutually exclusive. 
The MAPK signaling pathway is initiated by RTKs (receptor tyrosine kinases, e.g. 
KIT), which activate the small GTPase RAS (HRAS, KRAS or NRAS), which in turn 
regulates the downstream kinases RAFs (ARAF, BRAF or CRAF). This results in 
activation of the MAP/ERK kinase (MEK1 and MEK2) and MAPKs (also known as 
ERK2 and ERK1) (Figure 6). Upon phosphorylation ERK translocates to the nucleus 
and regulates transcription factors responsible for cell growth, survival, cell motility 
and metabolism (Schadendorf et al., 2015). Under disease conditions, the MAPK 
signaling pathway is constitutively active resulting in aberrant regulation of the cell 
cycle and tumor growth (Figure 6). Moreover, eventual loss of PTEN aberrantly 
activates phosphatidylinositol 3-kinase (PI3K)-AKT signaling, which leads to further 
loss of control of normal cellular functions (Cristofano et al., 1998; Podsypanina et 
al., 1999). 
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Figure 6. Major signaling pathways in melanoma. 
(a) The MAPK and (PI3)-AKT signaling pathways normally control cellular functions by 
regulating cell growth, survival, motility and metabolisms. (b) However, under conditions of 
malignancy, such as melanoma, these pathways are constitutively activated (indicated by the 
thick arrows), which leads to aberrant cellular behavior (adapted from: Schadendorf et al., 
2015).  
 
3.2.3 Melanoma formation and progression 
 
Classically melanoma has been explained as a linear and stepwise process. The 
Clark model for melanoma progression (Clark et al., 1984) describes how epidermal 
melanocytes undergo a neoplastic transformation that results in the formation of 
benign nevi. Eventually, upon further genetic mutations, some benign nevi develop 
into a dysplatic nevus. The Clark model further predicts that dysplatic nevi first 
undergo a radial growth phase and subsequently a vertical growth phase of tumor 
growth characterized by invasion of the dermis. Ultimately, the vertical growth phase 
results in metastases formation (Clark et al., 1984). Even though the Clark model 
may correctly depict the development of some melanomas, not all melanomas follow 
such a linear model of progression. Indeed, melanoma formation and progression to 
metastasis is often much more complex and less linear (Figure 7). A normal 
epidermal melanocyte does not always follow all the sequential steps described by 
the Clark model to progress into a primary tumor. Similarly, also metastasis formation 
is not necessarily the result of a vertical tumor growth phase, but can also occur at 
different steps of tumor development (Figure 7). Thus, a tumor can metastasize 
without previous progression through the vertical growth phase (Lomuto et al., 2004; 
protein), OCA2 (oculocutaneous albinism II), PAX3 
(paired box 3), EDNRB (endothelin receptor type B), 
SLC45A2 (solute carrier family 45 member 2), SOX10, 
TYRP1 (tyrosinase-related protein 1) and TYR (tyrosi-
nase)34,35. D pending on the mutation l activity of 
MC1R or downstream pigmentation genes, melano-
cytes produce different levels of highly UV-protective 
dark-brown eumelanin or less-protective yellow-red 
pheomelanin. Consequently, in the red hair pheno-
type, individual genetic susceptibility and exposure to 
additional mutagens, such as intermittent sunburns, 
increase the individual’s risk of developing melanoma34.
Contemporary advances in cancer genome deep 
sequencing have revealed that, with a median number 
of >10 mutations per megabase of DNA, melanomas 
carry the highest mutational load of all human tumours 
and harbour an overwh lming number of UV-sig atur  
mutations, such as C>T or G>T transitions, which are 
induced by UVB and UVA, respectively39–41. Current 
landscape genetic analyses provide compelling evi-
dence for a direct mutagenic role of UVB and UVA 
light, not only in the mutational background noise of 
melanoma cells (so-called passenger mutations), but 
also in 46% of attested driv r g ne mutations; fo  exam-
ple, in RAC1, STK19 (which encodes serine/threonine 
kinase 19), FBXW7 and IDH1 (which encodes isocitrate 
dehydrogenase 1; the full list of driver genes has been 
published elsewhere39,41,42). Such analyses have enabled 
the direct linkage of UVB-mediated damage with a fitness 
advantage in melanoma cells. For example, the activating 
mutati n RAC1P29S keeps it  ge e product (a small RHO 
GTPase) preferentially in the GTP-bound form, leading 
to downstream activation of p21-activated protein kinase 
(PAK) signalling39. TP53, one of the most prominent 
human cancer genes, showed the highest number of total 
p tative UV-related mutations39, challenging the dogma 
that emphasizes its characteristic wild-type status in 
elanoma27,43. Also, the cell-cycle regulators p14ARF nd 
p16INK4A harbour presumed UV-induced loss-of-function 
mutations39. Thus, adding up all of the known germline 
and sporadic mutations, deletions and epigenetic silenc-
ing events in the p16INK4A–CDK4/CDK6–RB pathway 
(which are found in 90% of all melanomas28,44,45), resto-
ration of disabled cell-cycle control emerges as a prime 
therapeutic goal for the majority of patients with mela-
noma. Indeed, pharmacological targeting of the cell cycle 
— for example, by the dual CDK4 and CDK6 inhibitor 
palbociclib — is currently in clinical development46.
Several observations complicate the hypothesis that 
elanoma is exclusively UV-dependent. For example, 
melanomas can develop in non-sun-exposed skin or 
in internal organs24. Moreover, most mutations in the 
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Taran and Heenan, 2001). Remarkably, 4-12% of patients have a metastasis burden 
without any detectable primary tumor (Giuliano et al., 1980; Norman et al., 1990; 
Reintgen et al., 1983), suggesting that disseminating capacities of malignant 
melanocytes may be independent of previous formation of an advanced primary 
melanoma. Of note, even benign melanocytes can be detected in lymph nodes from 
non-melanoma patients (Bautista et al., 1994; Carson et al., 1996; Fisher et al., 
1994). The fact that some cells of the melanocytic lineages possess such an 
extraordinary migratory capacity elicits the comparison to the great migratory 
capacity of the NC cells during embryonic development (Damsky et al., 2014). 
 
 
Figure 7. Linear and non-linear model of melanoma formation and progression. 
The Clark’s model depicts the linear progression of some melanomas. However, melanoma 
often follows a more complex non-linear model of progression and it eventually bypasses 
some steps of the Clark’s model before progressing to an advanced primary tumor. Similarly, 
a tumor can metastasize before reaching the vertical growth phase and in some patients 
metastases are observed without any detectable primary tumor (adapted from: Damsky et al., 
2014). 	  
uveal melanoma will have metastatic disease in the liver,
which is often the only site of metastasis.20 In cutaneous
melanomas, this principle is also important with common sites
of clinically detectable visceral metastasis including: lung, brain,
liver and bone, while metastases to other sites are either less
common or rarely encountered clinically.3 Even among common
sites of melanoma metastasis, certain epidemiologic patterns
suggest additional biological complexity. For example, liver
metastasis and brain metastasis are inversely correlated.3 Our
current understanding of the molecular mechanisms underlying
melanoma metastasis to different organs has been recently
reviewed.21
PREMALIGNANT DISSEMINATION AND PARALLEL
PROGRESSION
In traditional models of metastasis, spread to spatially restricted
sites is thought to be a unique feature of a subset of particularly
aggressive tumor cells that arise late in the course of disease.
However, some observations in melanoma and other cancers
argue that spread of tumor cells can occur much earlier during
primary tumor formation. For example, kinetic models of uveal
melanoma based on tumor doubling times estimate that on
average, metastatic spread of tumor cells to the liver is initiated up
to 5 years before identification and removal of the primary
tumor.22 Genetically engineered mouse models (GEMMs) of
epithelial cancers have even demonstrated that spread of
abnormal cells can precede primary tumor formation.23,24 These
disseminated epithelial cells are capable of persisting and
subsequently transforming to overt metastatic growths at these
distant sites.23,25 In this context, it is notable that 4–12% of
patients with metastatic melanoma do not have a clinically
identifiable primary tumor.26–28 There are different explanations
for this observation, though one is that some of these metastatic
lesions represent malignant progression of abnormal melanocytes
that had spread previously.
In fact, non-malignant melanocytes are routinely visualized
outside of their normal epidermal location in humans. In
compound melanocytic nevi, benign proliferations of melanocytes
are found within the dermis, demonstrating that spread through
the basement membrane is not a unique feature of malignant
cells. Melanocytes can even be visualized in a subset of lymph
nodes from normal, non-melanoma bearing patients.29–32 These
melanocyte clusters in normal lymph nodes are referred to as
nodal nevi. Interestingly, many nodal nevi bear BRAFV600E-
activating mutations.33 BRAFV600E mutations are also found in
most benign cutaneous melanocytic nevi (mutations in melanoma
are discussed in more detail below),34 leading some authors to
speculate that nodal nevi could represent cells that have spread
from these benign lesions.35 However, it is very difficult to
definitely exclude the possibility that nodal melanocytes are
instead remnants of embryonic development, or embryonic rests.
Figure 1. Melanoma formation and progression. Melanoma formation and metastasis are complex processes. Primary tumor formation has
classically been depicted using a linear model in which normal melanocytes progress through several precursor lesions and ultimately to
melanoma (individual steps colored in blue). However, substantial evidence suggests that such linear progression is only one pathway to
malignancy and that not all steps always occur during progression of individual melanomas. Other pathways to primary tumor formation are
also depicted (non-linear). There is additional evidence to suggest that dissemination of cells away from the primary lesion may not be a
unique feature of invasive melanomas. The possibility of spread from these lesions is depicted with question marks. Approximately 4–12% of
metastatic lesions are not associated with a primary cutaneous melanoma (depicted in orange). The individual steps in metastasis are
depicted in green. Unlike primary tumor formation, steps in metastasis are likely to always occur in a linear fashion; although it is unclear
whether passage of tumor cells through lymphatics is absolutely required for systemic dissemin tion. Direct entry of umor cells into venous
return may also be possible and is depicted with a question mark. The transition from micrometastasis to macrometastasis is likely a critical,
rate-limiting step in the pathogenesis of many disseminated melanocytic lesions. This transition may take months to years (if it occurs at all)
and is preceded by metastatic dormancy. Macroscopic metastatic lesions are thought to be able to seed additional metastases (21 spread). It is
unclear whether 21 spread can also occur from micrometastatic lesions, which is depicted with a question mark.
Mela oma etastasis
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3.3 Sall4 in development 
 
The homeotic spalt (sal) gene family was first identified in Drosophila melanogaster 
(Jürgens et al., 1988). In the fly it is required for patterning of the wing and of the 
embryonic termini (de Celis and Barrio 2009). The spalt gene family is highly 
conserved from invertebrates to humans (Figure 8) and its members encode 
transcription factors characterized by multiple double zinc finger motifs of the C2H2 
type. 
 
 
Figure 8. The spalt gene family in invertebrates and vertebrates.  
The sal gene family can be divided into four different groups based on sequence comparison, 
named after the human gene: SALL1, SALL2, SALL3 and SALL4 group. (adapted from 
Sweetman and Münsterberg, 2006). 
 
Four Sal-like genes are known in humans (SALL1-4) and mice (Sall1-4). Sall4 is 
ubiquitously expressed in the embryo and particularly enriched in the inner cell mass, 
where it plays a critical role in maintaining the pluripotency of ES cells (Zhang et al., 
2006). 
During development Sall4 is required for embryo patterning as well as for limb and 
organ development (de Celis and Barrio, 2009). In vertebrate embryos, Sall4 
regulates NC cells that populate the sensory ganglia and it is also expressed in the 
branchial arches (Barembaum and Bronner-Fraser, 2004). Additionally, Sall4 
controls the invagination of the sensory placodes (Barembaum and Bronner-Fraser, 
2007). 
In adult animals, however, Sall4 is present in adult stem or stem like cell 
compartments, in particular it is enriched in the e.g. bone marrow, testis and ovary 
(Sweetman and Münsterberg, 2006).  
et al., 2005). These genes are expressed in overlapping patterns
and may well affect limb patterning and development in a co-
coordinated way. Very little is known about the regulation of
spalt genes in the developing limb; however, it has been shown
that endogenous csall1 expression in the distal part of the limb
bud requires FGF and Wnt signaling (Farrell and Münsterberg,
2000). In the proximal limb, csall1 expression can be induced
ectopically by BMP-2 although this may reflect an induction of
distal limb fate in this case rather than endogenous regulation
(Capdevila et al., 1999). The range of possible interactions
between different spalt proteins will vary across the limb bud
depending on the precise combination of spalt proteins present
and it is tempting to speculate that this could modulate function
and produce diffe ent a tivities i different areas. For example
in part of the chick limb bud, csall1 is coexpressed with csall3.
It is known that the chick protein csall3 is cytoplasmic and can
remove full-length spalt protein from the nucleus, providing
another possible level of regulation of protein activity (Sweet-
man et al., 2003). In the mouse limb, no defects are observed in
loss of function Sall1 mutations but patterning is disrupted in
the presence of truncated Sall1 protein (McLeskey Kiefer et al.,
2003; Nishinakamura et al., 2001). These findings are discussed
further in the section on SALL1 in Townes–Brocks syndrome
(TBS) below. In Xenopus, Xsall4a is expressed both during
normal limb development and regeneration (Neff et al., 2005).
Recent evidence has also shown that in zebrafish sall1 and sall4
are regulated by tbx5 in pectoral fin development and are
required for regulation of FGF signaling (Harvey and Logan,
2006). The control of these genes by tbx5 may explain the
clinical overlap between Holt–Oram syndrome and Okihiro
syndrome with mutations in TBX5 and SALL4 giving
remarkably similar phenotypes (see SALL4 in developmental
disorders).
The details of how spalt proteins affect limb patterning are
unclear but one possibility is that they interact genetically with
members of the Iroquois gene family. These genes are expressed
during vertebrate limb development (Houweling et al., 2001;
Zulch et al., 2001) and in Drosophila it is known that
interactions between the spalt and iroquois gene families are
required in wing patterning (de Celis and Barrio, 2000).
Nomenclature
Vertebrate spalt proteins fall into four groups, with four genes in human called SALL1-4 (Kohlhase et al., 1996, 1999,
2002b). Four genes have been identified in mouse, Sall1-4 (Buck et al., 2001; Kohlhase et al., 2000, 2002a; Ott et al., 1996,
2001), three in chick (Barembaum and Bronner-Fraser, 2004; Farrell and Münsterberg, 2000; Farrell et al., 2001), five in
Xenopus (Hollemann et al., 1996; Neff et al., 2005; Onai et al., 2004; Onuma et al., 1999), three in zebrafish (Camp et al., 2003)
and one in Medaka (Koster et al., 1997). A phylogenetic tree indicating the relationship of these homologues is shown in Fig. 1.
The nomenclature for these genes is not entirely consistent and for the purposes of clarity in this review we will refer to all
vertebrate spalt genes as spalt like (abbreviated sall). Table 1 shows our proposed nomenclature based on this phylogeny.
Human and mouse genes retain their current names while those of other species have been changed to correspond to these
genes. As Fig. 1 shows, the spalt genes fall into four distinct groups with the SALL1 and SALL3 groups being most closely
related. This phylogeny suggests that an ancestral spalt diverged to produce the SALL2 group with further duplications
producing the SALL4 group and then the SALL1 and SALL3 groups. The status of the zebrafish sall1b is least clear. Comparison
of protein sequences shows that it has 55.2% identity with zebrafish sall1 and 52.4% identity with zebrafish sall3 and it is
possible that this gene is of a subfamily unique to zebrafish.
Fig. 1. Clustal alignment of vertebrate spalt protein sequences. Four orthologous groups can be identified based on sequence similarity, which are termed SALL1,
SALL2, SALL3 and SALL4 groups based on the human gene.
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3.3.1 Sall4 in embryonic stem cells 
 
In the blastocyst, a first lineage commitment leads to the development of the inner 
cell mass and of the trophectoderm. The trophectoderm then generates the 
trophoblast that is responsible for providing nutrients to the embryo and to build up 
the extraembryonic tissues. Embryonic stem (ES) cells derive from the inner cell 
mass and they are able to differentiate into all embryonic germ layers. They are 
characterized by their pluripotency and ability to propagate (self-renewal).  
 
Sall4 is enriched in ES cells and it was found to be a crucial factor in the 
mechanisms that regulate ES cell pluripotency. Sall4 interacts with Nanog and 
regulates Oct4 expression by directly activating the Pouf5f1 promoter (Figure 9).  
 
 
 
Figure 9. Schematic summary of the role of Sall4 in maintaining ES cell self-renewal 
and pluripotency. Sall4 directly regulates Oct4 by binding and transcriptionally activating the 
Pou5f1 promoter. Sall4, Oct4 and Nanog are required for the maintenance of ES cell self-
renewal and to prevent ES cell differentiation into trophectoderm or primitive endoderm. 
Positive regulation is indicated in red; repression is indicated in blue (adapted from: Zhang et 
al., 2006). 
 
Moreover, genome-wide analysis demonstrated that Sall4 is a major transcriptional 
regulator of pluripotency in mouse ES cells (Yang et al., 2008). Interestingly, Sall4 
can bind many more annotated genes within the promoter region than Oct4 or Nanog 
(Tanimura et al., 2013; Yang et al., 2008) (Figure 10), and it regulates a range of 
pathways that have explicit roles during development (Figure 11). 
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Having demonstrated the essential role of Sall4 in maintaining the 
undifferentiated state of ES cells, we examined the importance of 
Sall4 during mouse preimplantation development. Previously, micro-
array studies revealed that Sall4 and Oct4 share similar expression 
patterns during early embryo development10. We have further vali-
dated this by TaqMan real-time PCR (Fig. 5a). There is an abundance 
of both Sall4 and Oct4 transcripts in the fertilized one-cell embryo. 
These maternally inherited transcripts are significantly degraded by 
the two-cell stage. Significant zygotic transcription only occurs after 
the four-cell stage, as indicated by increased transcript levels in the 
eight-cell embryo. After this stage, both Sall4 and Oct4 mRNA lev-
els continue to increase to the blastocyst stage. Sall4 expression is 
localized within the ICM of the blastocyst, similarly to that of Oct4 
(ref. 17). Furthermore, significant levels of expression in an extra-
embryonic endoderm (XEN) cell line (P.R. and B.L., unpublished 
observations) suggest that Sall4 is also expressed in the primitive 
endoderm of the blastocyst.
To determine whether reducing the level of Sall4 in the preim-
plantation embryo can alter Oct4 expression, and subsequently line-
age commitment, Sall4 siRNA was injected into the cytoplasm of 
the one-cell embryo. This removed both the maternal and zygotic 
transcripts of Sall4. When cultured, control embryos injected with a 
scrambled siRNA maintained Sall4 and Oct4 expression levels through-
out preimplantation development, consistent with freshly harvested 
uninjected embryos (Fig. 5a). Conversely, Sall4 siRNA injection resulted 
in decreased Sall4 levels throughout preimplantation development. 
Maternal levels of Pou5f1 were unaffected, but there was delayed and 
reduced zygotic transcription from Pou5f1 consistent with this gene 
being a target of Sall4 transactivation. All blastocysts with reduced Sall4 
also had reduced Pou5f1 in the range of 30–50% of control-injected 
embryos (Fig. 5a). Strikingly, in eight out of 26 (~31%) blastocysts 
derived from Sall4 siRNA-injected embryos, Cdx2-positive cells were 
observed in the ICM — unlike in control siRNA-injected embryos 
in which normal Cdx2 expression was observed throughout the 
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Figure 5 Sall4 and Pou5f1 gene expression in the early mouse embryo are 
tightly coregulated and act in tandem with Nanog to control ES cell fate. 
(a) Transcript levels of Sall4 and Pou5f1 after injection with either Sall4 
or control siRNA during the fertilized egg stage. Transcripts were measured 
using Taqman-based real-time PCR and expressed relative to 18s RNA. The 
y-axis represents the inverse mean CT values of Pou5f1 or Sall4, relative 
to 18s RNA to obtain a positive graphical representation. The asterisk 
indicates significant difference from Pou5f1 (in control shRNA), P <0.01; 
n ≥8. Survival rate of embryos post-injection was >90%. F: fertilized egg, 
2: two-cell, 4: four-cell, 8: eight-cell, M: morula, B: blastocyst. The error 
bars represent s.e.m. (b) Knockdown of Sall4 by siRNA injection into 
fertilized mouse oocytes led to the contribution of Cdx2 (red) positive cells 
within the epiblast (green; Nanog positive) during the blastocyst stage. 
Eight out of 26 Sall4 siRNA injected oocytes showed varying degrees of 
Cdx2 positive cells in the epiblast of the blastocyst. For control siRNA 
injected oocytes, 32 out of 32 blastocysts did not show Cdx2 positive 
cells in the epiblast. (c) Schematic representation of the interplay of Oct4, 
Sall4 and Nanog in sustaining ES cell self-renewal versus differentiation 
into either the trophectoderm or prim tive endod rm. Red indicates 
positive regulation; blue indicates repression. Sall4, Oct4 and Nanog are 
absolutely required for maintenance of self-renewal, and Sall4 directly 
regulates Oct4. Loss of Sall4 or Oct4 caused ES cell differentiation 
into the trophectoderm lineage, but it is unclear whether Sall4 also 
regulates Cdx2 directly. Overexpression of Oct4 led to differentiation into 
primitive endoderm8. When ES cells overexpressing Sall4 were induced 
to differentiate (by LIF withdrawal or addition of retinoic acid), this led to 
specific enhancement of the  expression of primitive endodermal markers 
such as Gata4, Gata6 and Sox17, but not markers of other germ lineages 
(see Supplementary Information, Fig. S4c). In extraembryonic endoderm 
cells (XEN) derived from mouse blastocysts, Sall4 was found to be highly 
expressed (data not shown). Recent evidence further showed that Sall4 is a 
binding partner of Nanog27. 
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Figure 10. Target genes that are bound within the promoter region by Sall4, Oct4 and 
Nanog.  
The Venn diagram illustrates that Sall4, Oct4 and Nanog share several target genes in 
common (adapted from: Yang et al., 2008). 
 
 
Figure 11. Sall4 regulates several pathways important for embryonic development.  
Sall4 binds at the promoter region of a large number of genes that have distinct functions in 
maintaining ES cell pluripotency and in regulating differentiation (adapted from Yang et al., 
2008). 
 
3.3.2 Sall4 isoforms in ES cells 
 
Sall4 exists in two isoforms, Sall4a and Sall4b (Figure 12), which are generated by 
different internal splicing of exon 2.  
 
genes, Oct4 and Nanog. This enabled us to compare genes bound
by Oct4 and Nanog with those bound by Sall4. Interestingly,
ChIP-on-chip assays showed that Oct4 had 783 promoter binding
sites, whereas Nanog had 1,284 binding sites within the mouse
genome (18). The ChIP-on-chip data presented here revealed
that Sall4 bound !3,200 gene promoters. Given the similar
expression patterns of the transcription factors Sall4, Oct4, and
Nanog, this is remarkable. These observations suggest that Sall4
may play a similar, but broader role in regulating ES-cell
properties. However, the roles of each in vivo are not completely
understood.
Interaction and Co-Occupation of Sall4 with Oct4 and Nanog in ES
Cells.Wu et al. elegantly demonstrated that Sall4 andNanog form
a regulatory complex in ES cells (10). Liang et al. (24) recently
showed that Sall4 forms a complex (or complexes) with both
Oct4 and Nanog by using mass spectrometry and immunopre-
cipitation of endogenous proteins. We have confirmed these
observations by immunoprecipitation experiments using ES cells
transiently transfected with Sall4-HA.Western blotting detected
an overexpression of Sall4-HA protein by both anti-HA (Fig.
2A) and anti-Sall4 antibodies (data not shown). Immunoprecipi-
tation with an anti-HA antibody produced a unique endogenous
45-kDa protein, Oct4, in the precipitate. By contrast, an IgG-
negative control failed to generate the Oct4 band in the same
extract, indicating a specific Sall4–Oct4 interaction. By using the
same method, the Sall4–Nanog interaction was confirmed in the
same anti-HA-pulldown precipitate (Fig. 2A).
Because these transcription factors physically interact, one
would expect them to colocalize to some of the same gene
promoters (25). A gene bound by any two of these proteins we
will refer to as ‘‘co-occupied’’. However, Oct4 and Sall4 co-
occupied only 92 common genes representing 12% of genes
bound by Oct4. Similarly, Sall4 binding was identified at 198
Nanog target genes, representing only 15% of Nanog’s bound
genes (Fig. 2B). This suggests that Sall4–Oct4 and Sall4–Nanog
interactions may form functional complexes only at select pro-
moter regions (9, 10). There are only 45 genes that are co-
occupied by Oct4, Sall4, and Nanog (Table S2). However, this
group includes developmentally important genes, such as Dkk1,
Msx2, Fbxl10, and Epc1.
Sall4!/" ES Cells Exhibit Decreased Expression of iPS Genes. Recent
studies have shown that ectopic expression of Oct4, Sox2, Klf4,
and c-Myc is capable of reprogramming somatic cells to confer
a pluripotent state, termed induced pluripotent stem (iPS) cells
(26). It has previously been demonstrated that Sall4 binds to
Oct4 and regulates its expression (9).We show here that the Sall4
protein binds to the promoter regions of Oct4, c-Myc, Sox2, and
Klf4 through ChIP-PCR (Fig. 3A).
To determine the relationship between binding and Sall4
function, we used Q-RT-PCR to measure mRNA levels from
Sall4"/# ES cells. Expression levels of all 4 transcription factors
decreased in Sall4"/# ES cells indicating that Sall4 plays an
activating role on these genes (Fig. 3B). Because Sall4 is not
expressed in the majority of differentiated tissues including
fibroblasts, this suggests that exogenous expression of Sall4
may play a role in reprogramming somatic cells to confer a
pluripotent state. This hypothesis has recently been supported
by others (27).
Sall4 Binds to Genes Associated with H3K27 Methylation Domains as
well as to Target Genes of PRC1 and PRC2. Numerous studies have
implicated epigenetic modifications as a means for regulating
stem cell pluripotency (28–30). We have previously shown that
Bmi-1, a polycomb group member, is a downstream target of
SALL4 (31), thus, we focused on other polycomb-associated
genes for analysis. Although various covalent modifications can
Fig. 2. Coimmunoprecipitation and co-occupancy of Sall4, Oct4, andNanog.
(A) Transient transfection of W4 ES cells with a Sall4-HA construct exhibited
protein expression detected by both anti-HA and anti-Sall4 antibodies (the
latter data not shown) in the cell extract (left). Oct4 and Nanog are detected
by using respective antibodies in the whole ES cell extract (input). Immuno-
precipitation of Sall4-HA with an anti-HA antibody revealed both Oct4 and
Nanog bands, whereas immunoprecipitation with an IgG antibody detected
neither protein. (B) Venn diagram showing the overlapping target genes of
Sall4, Oct4, andNanog as determinedby ChIP-Chip andChIP-PET experiments.
These complexes may function in the regulation of stem cell pluripotency.
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Fig. 3. Decreased expression of iPS genes in Sall4"/# ES cells. Ectopic expres-
sion of 4 key transcription factors, Oct4, Sox2, c-Myc, and Klf4, produces iPS
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shownbyChIP-PCR. (B) Followingadenovirus induced removal of 1 Sall4 allele,
expression of all 4 transcription factors is decreased asmeasured byQ-RT-PCR.
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triplicate reactions, and the bars indicate SD.
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30immunoprecipitation of the HA-tag identified 88% (23:26) of
the genes identified by the anti-Sall4 antibody (Fig. S1B). This
suggests that our anti-Sall4 antibody is both sensitive and specific
for the Sall4 protein when used in immunoprec pitation. We
have also used this antibody for immunohistochemistry to detect
Sall4 protein in different tissue samples (Fig. S1C) and for flow
cytometry to identify cell populations corresponding to leukemic
blasts in patient bone marrow samples that uniquely express
Sall4 [Fig. S1D (16)].
Following binding site determination by NimbleGen, the
ChIP-on-chip duplicate assays identified roughly 5,200 Sall4-
bound genes in array 1, and 4,400 Sall4-bound genes in array 2.
The overall false discovery rate was !0.20. Comparison of the
data from arrays 1 and 2 showed that 3,223 gene promoters gave
positive hybridization signals on both arrays. Of the 1,000 genes
exhibiting the most intense hybridization signals on array 2, 947
were also positive on array 1. When only the top 200 genes were
considered, the concordance rate was 98.5%. In contrast, when
the 800 lowest intensity signals on each array were analyzed, only
37.2% (array 1) and 52.6% (array 2) of the signals were
concordant in both assays. Therefore, we selected only the 3,223
genes that were positive on both arrays for further analysis.
We next validated a subset of the putative Sall4 binding sites
by using a ChIP PCR strategy. A total of 55 genes were
interrogated. Primer pairs were prepared for a randomly se-
lected set of hybridization positive genes with varying degrees of
signal intensity. If a selected gene did not initially produce an
amplicon level above background, a new primer set was designed
200–300 bases distal to the first primer site, and the quantitative
real-time PCR (Q-RT-PCR) assay was repeated. In some cases,
a third primer set was used before designating that gene to be a
false positive. In addition, ChIP-PCR using primers located
adjacent to true positive loci were shown to give negative
amplification results, further demonstrating the specificity of
Sall4 binding-site identification. Based on the Q-RT-PCR data
(52:55 positive), we concluded that "94.5% of the 3,223 genes
common to both arrays are true positive SALL4 binding sites in
the mouse ES cell line (Fig. S2).
The full list of the 3,223 Sall4-bound genes and their respective
array hybridization data can be found within the supplemental
data (Dataset S1) and on the gene expression omnibus (GEO)
as accession number GSE11305. The number of promoter
sequences binding Sall4 is quite high, but other transcription
factor proteins, such as E2f1, have been reported to bind over
5,000 gene promoters (17). Myc has recently been reported to
bind a similar number of genes in mouse ES cells (18).
We then sought to determine the distribution of Sall4 binding
sites within the mapped regions of the genome by using DAVID
(19). Analysis of over-represented annotations for promoter
regions bound by Sall4 revealed significant representation of a
broad variety of genes that may be important for stem cell
functions (Fig. 1A). These include developmental genes and
genes necessary for signal transduction and other regulatory
processes. Further classification of the developmental genes
revealed over-representation of genes associated with organ
development, pattern specification, and brain development (Fig.
1B). Sall4 bound to promoter regions of 11 members of the Hox
gene family, and 42 other homeobox or homeobox-like genes
(Table S1). The binding of Sall4 to promoter regions of vital
developmental genes and others that govern ES cell fate support
the phenotypic consequence of Sall4 reduction in ES cells. This
also suggests that Sall4 plays a vital role in ES cells that may be
similar to Oct4 and Nanog. This hypothesis is supported by 3
lines of evidence: (a) Sall4 is expressed very early in the
developing embryo and is subsequently down-regulated in most
differentiated tissues, (b) both over- and under-expression of
Sall4 cause ES-cell differentiation, demonstrating the necessity
for tight regulation of Sall4 expression, and (c) the finding that
Sall4 modulates expression of both Oct4 and Nanog (9, 10).
Ho ever, th magnitude f the Sall4 transcriptional network is
quite striking and sugg sts that S ll4 may play a central role in
embryonic development.
Sall4 Targets Important Signals That Control ES-Cell Differentiation
and Lineage Specification. Numerous signaling pathways play
important roles in maintaining pluripotency during embryogen-
esis. For example, theWnt signaling pathway has important roles
in embryogenesis and cancer (20–23). TGF-! signaling is nec-
essary to maintain ES cell pluripotency, and PTEN signaling
plays important roles in the maintenance of hematopoetic stem
cell self-renewal. Fig. 1C shows the number of genes bound by
Sall4 within several developmentally important pathways and
examples of the genes bound within each pathway. This suggests
that Sall4 may play a broad role in regulation of ES-cell
pluripotency through interactions with key signaling pathways.
Magnitude of the Sall4 Transcriptional Network in ES Cells.Recently,
ChIP-on-chip studies have been performed on the gatekeeper
0 100 200 300 400 500 600 700
Developmental Protein
Transcription Regulation
DNA Binding
Nuclear Protein
Signal Transduction
Cell Communication
p<0.001
p<0.001
p<0.001
p<0.001
p<0.001
p<0.001
A
B
C
0 50 100 150 200
Brain
Development
Pattern
Specification
Organ
Development
p<0.05
p<0.05
Examples
Map4k4, Tlr4, Tlr7, Traf2
Birc2, Birc4, Casp6, Tnf
Dkk1, Frat1, Tcf4, Wif1
Fos, Pitx2, Smad3, Tgfb1
Brca1, Casp6, Ccnd1, Ccnd2
Abl1, Abl2, Pdgfr , Elk1
Dyrk1a, Hhip, Prkaca, Stk36
Akt3, Casp3, FoxG1, FoxO1
0 5 10 15 20 25
Sonic Hedgehog
TGF-β
p53
PDGF
PTEN
Wnt/β- ateni
Apoptosis
NF-κB
Fig. 1. Sall4 is a major regulator in mouse ES cells. (A) Sall4 bound to
promoters that over-represent abroad classificationofGOannotations. These
included various pot ntial regulatory and devel pmental annot tions. A al-
ysis was done with DAVID, and the x axis represents the gene number. (B)
Further classification of developmentally important genes over-represented
in the Sall4 binding pool. For the organ development annotation, the over-
representationwas insignificant (P! 0.074) but notable. The x axis represents
the gene number. P values are inset following each bar and were calculated
by using Fisher’s Exact Test based onover-representation in comparison to the
genome. (C) Sall4 binds promoter regions belonging to a variety of pathways
that have definitive roles in development, suggesting that Sall4 may control
a wide variety of developmental processes. Listed genes are only representa-
tiveof the Sall4-boundgenes in eachpathway.P values for this analysis arenot
presented because of the low number of genes within each pathway. Classi-
ficationwas done by using Ingenuity PathwayAnalysis (www.ingenuity.com).
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Figure 12. Genomic structure of the Sall4 gene and its two protein isoforms.  
Structure of the genomic locus of Sall4 and of the protein isoforms Sall4a and Sall4b. Both 
isoforms contain a N-terminal NuRD binding domain (black rectangle) and Zinc finger 
domains (ovals) (adapted from: Rao et al., 2010).  
 
Sall4a and Sall4b can build homo- and heterodimers with each other. Both isoforms 
can interact with Nanog to maintain ES cells pluripotency, even though they have 
slightly different functions. Sall4b builds homodimers or heterodimers together with 
Sall4a to positively regulate pluripotency genes (Figure 13). Sall4a, on the other 
hand, builds homodimers to regulate differentiation genes (Figure 13). Sall4b alone, 
but not Sall4a, can maintain pluripotency in mouse ES cells. Sall4a- Sall4b+ ES cells 
indeed show a partially rescued pluripotency, although not all differentiation markers 
are completely inhibited. On the other side, Sall4a+ Sall4b- ES cells lose pluripotency 
features and differentiate (Rao et al., 2010). 
 
 
Figure 13. Sall4a and Sall4b homodimers and heterodimers have different functions. 
Sall4b homodimers and Sall4a/Sall4b heterodimers regulate pluripotency genes, while Sall4a 
homodimers regulate differentiation genes (adapted from: Rao et al., 2010). 
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30immunoprecipitation of the HA-tag identified 88% (23:26) of
the genes identified by the anti-Sall4 antibody (Fig. S1B). This
suggests that our anti-Sall4 antibody is both sensitive and specific
for the Sall4 protein when used in immunoprec pitation. We
have also used this antibody for immunohistochemistry to detect
Sall4 protein in different tissue samples (Fig. S1C) and for flow
cytometry to identify cell populations corresponding to leukemic
blasts in patient bone marrow samples that uniquely express
Sall4 [Fig. S1D (16)].
Following binding site determination by NimbleGen, the
ChIP-on-chip duplicate assays identified roughly 5,200 Sall4-
bound genes in array 1, and 4,400 Sall4-bound genes in array 2.
The overall false discovery rate was !0.20. Comparison of the
data from arrays 1 and 2 showed that 3,223 gene promoters gave
positive hybridization signals on both arrays. Of the 1,000 genes
exhibiting the most intense hybridization signals on array 2, 947
were also positive on array 1. When only the top 200 genes were
considered, the concordance rate was 98.5%. In contrast, when
the 800 lowest intensity signals on each array were analyzed, only
37.2% (array 1) and 52.6% (array 2) of the signals were
concordant in both assays. Therefore, we selected only the 3,223
genes that were positive on both arrays for further analysis.
We next validated a subset of the putative Sall4 binding sites
by using a ChIP PCR strategy. A total of 55 genes were
interrogated. Primer pairs were prepared for a randomly se-
lected set of hybridization positive genes with varying degrees of
signal intensity. If a selected gene did not initially produce an
amplicon level above background, a new primer set was designed
200–300 bases distal to the first primer site, and the quantitative
real-time PCR (Q-RT-PCR) assay was repeated. In some cases,
a third primer set was used before designating that gene to be a
false positive. In addition, ChIP-PCR using primers located
adjacent to true positive loci were shown to give negative
amplification results, further demonstrating the specificity of
Sall4 binding-site identification. Based on the Q-RT-PCR data
(52:55 positive), we concluded that "94.5% of the 3,223 genes
common to both arrays are true positive SALL4 binding sites in
the mouse ES cell line (Fig. S2).
The full list of the 3,223 Sall4-bound genes and their respective
array hybridization data can be found within the supplemental
data (Dataset S1) and on the gene expression omnibus (GEO)
as accession number GSE11305. The number of promoter
sequences binding Sall4 is quite high, but other transcription
factor proteins, such as E2f1, have been reported to bind over
5,000 gene promoters (17). Myc has recently been reported to
bind a similar number of genes in mouse ES cells (18).
We then sought to determine the distribution of Sall4 binding
sites within the mapped regions of the genome by using DAVID
(19). Analysis of over-represented annotations for promoter
regions bound by Sall4 revealed significant representation of a
broad variety of genes that may be important for stem cell
functions (Fig. 1A). These include developmental genes and
genes necessary for signal transduction and other regulatory
processes. Further classification of the developmental genes
revealed over-representation of genes associated with organ
development, pattern specification, and brain development (Fig.
1B). Sall4 bound to promoter regions of 11 members of the Hox
gene family, and 42 other homeobox or homeobox-like genes
(Table S1). The binding of Sall4 to promoter regions of vital
developmental genes and others that govern ES cell fate support
the phenotypic consequence of Sall4 reduction in ES cells. This
also suggests that Sall4 plays a vital role in ES cells that may be
similar to Oct4 and Nanog. This hypothesis is supported by 3
lines of evidence: (a) Sall4 is expressed very early in the
developing embryo and is subsequently down-regulated in most
differentiated tissues, (b) both over- and under-expression of
Sall4 cause ES-cell differentiation, demonstrating the necessity
for tight regulation of Sall4 expression, and (c) the finding that
Sall4 modulates expression of both Oct4 and Nanog (9, 10).
However, the magnitude of the Sall4 transcriptional network is
quite striking and suggests that Sall4 may play a central role in
embryonic development.
Sall4 Targets Important Signals That Control ES-Cell Differentiation
and Lineage Specification. Numerous signaling pathways play
important roles in maintaining pluripotency during embryogen-
esis. For example, theWnt signaling pathway has im or a t roles
in embryogenesis and cancer (20–23). TGF-! signaling is nec-
essary to maintain ES cell pluripotency, and PTEN signaling
plays important roles in the maintenance of hematopoetic stem
cell self-renewal. Fig. 1C shows the number of genes bound by
Sall4 within several developmentally important pathways and
examples of the genes bound within each pathway. This suggests
that Sall4 may play a broad role in regulation of ES-cell
pluripotency through interactions with key signaling pathways.
Magnitude of the Sall4 Transcriptional Network in ES Cells.Recently,
ChIP-on-chip studies have been performed n the gatekeeper
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Fig. 1. Sall4 is a major regulator in mouse ES cells. (A) Sall4 bound to
promoters that over-represent abroad classificationofGOannotations. These
included various potential regulatory and developmental annotations. Anal-
ysis was done with DAVID, and the x axis represents the gene number. (B)
Further classification of developmentally important genes over-represented
in the Sall4 binding pool. For the organ development annotation, the over-
representationwas insignificant (P! 0.074) but notable. The x axis represents
the gene number. P values are inset following each bar and were calculated
by using Fisher’s Exact Test based onover-representation in comparison to the
genome. (C) Sall4 binds promoter regions belonging to a variety of pathways
that have definitive roles in development, suggesting that Sall4 may control
a wide variety of developmental processes. Listed genes are only representa-
tiveof the Sall4-boundgenes in eachpathway.P values for this analysis arenot
presented because of the low number of genes within each pathway. Classi-
ficationwas done by using Ingenuity PathwayAnalysis (www.ingenuity.com).
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tions suggest that the isoforms may function in multiple states
(homodimers of Sall4a, homodimers of Sall4b, and a het-
erodimer of the two) but are both able to form critical protein-
protein interactions required for regulating pluripotency-asso-
ciated genes.
Sall4 isoforms bind to overlapping and distinct loci in ES
cells. Since the two isoforms of Sall4 are highly similar, anti-
bodies selective for each are not available. Therefore, we used
in vivo metabolic biotin labeling to generate tagged versions of
Sall4a and Sall4b (21, 42). Using this approach, we generated
ES cells harboring tagged Sall4a or Sall4b to allow for isoform-
specific chromatin immunoprecipitation (ChIP). Multiple Sall4
isoform-expressing ES clones were characterized, but generally
tagged Sall4b was consistently expressed at a higher level than
Sall4a and was comparable in expression to wild-type levels of
Sall4a (Fig. 3A and data not shown).
To identify loci bound by Sall4 isoforms, we performed
genomewide location analysis using ES cells expressing tagged
Sall4a or Sall4b, as detailed in Materials and Methods. Any
peaks observed in cells expressing the BirA ligase alone as a
control for specificity were subtracted. Viewed in aggregate,
the combined binding sites of Sall4a and Sall4b yielded a total
of 1,034 peaks (Fig. 3B; see also Tables S1 and S2 in the
supplemental material), which is comparable to that previously
reported in studies that used an antibody that detects both
isoforms (25). Of particular interest, Sall4b bound to substan-
tially more targets than Sall4a (813 compared to 470); !200 of
these loci were shared. We next divided binding peaks into
three distinct subgroups for further analysis: targets bound by
both Sall4a and Sall4b (Sall4a/Sall4b), targets bound by Sall4a
alone (and not Sall4b), and targets bound by Sall4b alone (and
not Sall4a) (Fig. 3B). To verify that the differences in binding
were not simply related to relative abundance, we visualized a
total of 10 bound loci using the Affymetrix integrated genome
browser to confirm the differential binding for each subgroup
(Fig. 3C and Fig. 4). As can be seen in the figures, there were
substantial differences in peak heights, but low-level binding of
both Sall4a and Sall4b could still often be seen (such as Fig. 4,
Olfr850 and Nfe2l1), even though MAT may have identified
only one factor as binding to a given locus. This implies that
our subgroups (i.e., Sall4a alone and Sall4b alone) are not
necessarily exclusive, in that in vivo many of the sites deter-
mined by MAT to bind one isoform but not the other may in
fact bind them both, with one isoform predominating at certain
loci. To validate our data, 10 targets were selected for verifi-
cation by ChIP-qPCR (Fig. 5); 9/10 of the Sall4a peaks and
10/10 Sall4b peaks showed enrichment compared to the nega-
tive control, BirA ChIP (equivalent to an IgG control for
standard antibody based ChIP). In addition, we verified that in
our bio-ChIP approach neither Sall4a nor Sall4b bound to
FIG. 1. Sall4a and Sall4b share similar regulation. (A) Genomic structure of the Sall4 locus, with the domain structure of the long (Sall4a) and
short (Sall4b) isoform of Sall4. Zinc fingers are shown as ovals, and the N-terminal NuRD binding domain is shown as a black rectangle.
(B) Differentiation of CJ7 ES cells with retinoic acid. Whole-cell extracts were assayed by Western blotting. The two isoforms are labeled, with
the Western blot antibody labeled on the right. Sall4a, Sall4b, and Nanog diminished during differentiation, whereas GAPDH remained
unchanged. (C) RNA was harvested from ES cells differentiated with retinoic acid at various time points, and the transcript levels of Sall4a, Sall4b,
Nanog, and Oct4 were assessed. Two different primer sets were used to assess total levels of Sall4, Sall4 (endo) that is directed to the 3"
untranslated region of the transcript of both isoforms, and Sall4 (total) that is directed to the coding region of both isoforms.
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immunoprecipitation of the HA-tag identifie 88% (23:26) of
the g nes identified by the nti-Sall4 antibody (Fig. S1B). This
suggests that our anti-Sall4 antibody is both sensitive and specific
for the Sall4 protein when used in immunoprecipitation. We
have also used this antibody for immunohistochemistry to detect
Sall4 protein in different tissue samples (Fig. S1C) and for flow
cytometry to identify cell populations corresponding to leukemic
blasts in patient bone marrow samples that uniquely express
Sall4 [Fig. S1D (16)].
Following binding site determination by NimbleGen, the
ChIP-on-chip duplicate assays identified roughly 5,200 Sall4-
bound genes in array 1, and 4,400 Sall4-bound genes in array 2.
The overall false discovery rate was !0.20. Comparison of the
data from arrays 1 and 2 showed that 3,223 gene promoters gave
positive hybridization signals on both arrays. Of the 1,000 genes
exhibiting the most intense hybridization signals on array 2, 947
were also positive on array 1. Wh n only the top 200 genes wer
considered, the concordance rate was 98.5%. In contrast, when
the 800 lowest intensity si nals o each array were analyzed, only
37.2% (array 1) and 52.6% (array 2) of the signals were
concordant in both assays. Therefore, we selected only the 3,223
genes that were positive on both arrays for further analysis.
We next validated a subset of the putative Sall4 binding sites
by using a ChIP PCR strategy. A total of 55 genes were
interrogated. Primer pairs were prepared for a randomly se-
lected set of hybridization positive genes with varying degrees of
signal intensity. If a selected gene did not initially produce an
amplicon level above background, a new primer set was designed
200–300 bases distal to the first primer site, and the quantitative
real-time PCR (Q-RT-PCR) assay was repeated. In some cases,
a third primer set was used before designating that gene to be a
false positive. In addition, ChIP-PCR using primers located
adjacent to true positive loci were shown to give negative
amplification results, furt r demonstrating th specificity f
Sall4 binding-site identification. Based on the Q-RT-PCR data
(52:55 po i ive), we concluded that "94.5% of the 3,223 genes
comm n to both arrays are true positive SALL4 binding sites in
the mouse ES cell line (Fig. S2).
The full list of the 3,223 Sall4-bound genes and their respective
array hybridization data can be found within the supplemental
data (Dataset S1) and on the gene expression omnibus (GEO)
as accession number GSE11305. The number of promoter
sequences binding Sall4 is quite high, but other transcription
factor proteins, such as E2f1, have been reported to bind over
5,000 gene promoters (17). Myc has recently been reported to
bind a similar number of genes in mouse ES cells (18).
We then sought to determine the distribution of Sall4 binding
sites within the mapped regions of the genome by using DAVID
(19). Analysis of over-represented annotations for promoter
regions bound by Sall4 revealed significant representation of a
broad variety of genes that may be important for stem cell
functions (Fig. 1A). These include developmental genes and
genes necessary for signal transduction and other regulatory
processes. Further classification of the developmental genes
revealed over-representation of genes associated with organ
development, pattern specification, and brain developme t (Fi .
1B). Sall4 bound to promoter regions of 11 members of the Hox
gene family, and 42 other homeobox or homeobox-like genes
(Table S1). The binding of Sall4 to promoter regions of vital
developmental genes and others that govern ES cell fate support
the phenotypic consequence of Sall4 reduction in ES cells. This
also suggests that Sall4 plays a vital role in ES cells that may be
similar to Oct4 and Nanog. This hypothesis is supported by 3
lines of evidence: (a) Sall4 is expressed very early in th
developing embryo and is subsequently down-regulated in most
differentiated tissues, (b) both over- and under-expression of
Sall4 cause ES-cell differentiation, demonstrating the necessity
for tight regulation of Sall4 expression, and (c) the finding that
Sall4 m dul tes expression of both Oct4 and Nanog (9, 10).
However, the magnitude of the Sall4 transcriptional network is
quite striking a d suggests that Sall4 may play a central role in
embryonic development.
Sall4 Targets Important Signals That Control ES-Cell Differentiation
and Lineage Specification. Numerous signaling pathways play
important roles in maintaining pluripotency during embryogen-
esis. For example, theWnt signaling pathway has important roles
in embryogenesis and cancer (20–23). TGF-! signaling is nec-
essary to maintain ES ce l pluripotency, and PTEN signaling
plays important roles in the maintenance of hematopoetic stem
cell self-renewal. Fig. 1C shows the number of genes bound by
Sall4 within several developmentally important pathways and
examples of the genes bound within each pathway. This suggests
that Sall4 may play a broad role in regulation of ES-cell
pluripote cy through interactions with key ig aling pathw ys.
Magnitude of the Sall4 Transcriptional Network in ES Cells.Recently,
ChIP-on-chip studies have been performed on the gatekeeper
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Fig. 1. Sall4 is a major regulator in mouse ES cells. (A) Sall4 bound to
promoters that over-represent abroad classificationofGOannotations. These
included various potenti l regulatory and deve opmental an otations. Anal-
ysis was done wi DAVID, and the x axis repr sents the gene number. (B)
Further classification of developmentally important genes over-represented
in the Sall4 binding pool. For the organ development annotation, the over-
representationwas insignificant (P! 0.074) but notable. The x axis represents
the gene number. P values are inset following each bar and were calculated
by using Fisher’s Exact Test based onover-representation in comparison to the
genome. (C) Sall4 binds promoter regions belonging to a variety of pathways
that have definitive roles in development, suggesting that Sall4 may control
a wide variety of developmental processes. Listed genes are only representa-
tiveof the Sall4-boundgenes in eachpathway.P values for this analysis arenot
presented because of the low number of genes within each pathway. Classi-
ficationwas done by using Ingenuity PathwayAnalysis (www.ingenuity.com).
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tions suggest that the isoforms may function in multiple states
(homodimers of Sall4a, homodimers of Sall4b, and a het-
erodimer of the two) but are both able to form critical protein-
protein interactions required for regulating pluripotency-asso-
ciated genes.
Sall4 isoforms bind to overlapping and distinct loci in ES
cells. Since the two isoforms of Sall4 are highly similar, anti-
bodies selective for each are not available. Therefore, we used
in vivo metabolic biotin labeling to generate tagged versions of
Sall4a and Sall4b (21, 42). Using this approach, we generated
ES cells harboring tagged Sall4a or Sall4b to allow for isoform-
specific chromatin immunoprecipitation (ChIP). Multiple Sall4
isoform-expressing ES clones were characterized, but generally
tagged Sall4b was consistently expressed at a higher level than
Sall4a and was comparable in expression to wild-type levels of
Sall4a (Fig. 3A and data not shown).
To identify loci bound by Sall4 isoforms, we performed
genomewide location analysis using ES cells expressing tagged
Sall4a or Sall4b, as detailed in Materials and Methods. Any
peaks observed in cells expressing the BirA ligase alone as a
control for specificity were subtracted. Viewed in aggregate,
the combined binding sites of Sall4a and Sall4b yielded a total
of 1,034 peaks (Fig. 3B; see also Tables S1 and S2 in the
supplemental material), which is comparable to that previously
reported in studies that used an antibody that detects both
isoforms (25). Of particular interest, Sall4b bound to substan-
tially more targets than Sall4a (813 compared to 470); !200 of
these loci were shared. We next divided binding peaks into
three distinct subgroups for further analysis: targets bound by
both Sall4a and Sall4b (Sall4a/Sall4b), targets bound by Sall4a
alone (and not Sall4b), and targets bound by Sall4b alone (and
not Sall4a) (Fig. 3B). To verify that the differences in binding
were not simply related to relative abundance, we visualized a
total of 10 bound loci using the Affymetrix integrated genome
browser to confirm the differential binding for each subgroup
(Fig. 3C and Fig. 4). As can be seen in the figures, there were
substantial differences in peak heights, but low-level binding of
both Sall4a and Sall4b could still often be seen (such as Fig. 4,
Olfr850 and Nfe2l1), even though MAT may have identified
only one factor as binding to a given locus. This implies that
our subgroups (i.e., Sall4a alone and Sall4b alone) are not
necessarily exclusive, in that in vivo many of the sites deter-
mined by MAT to bind one isoform but not the other may in
fact bind them both, with one isoform predominating at certain
loci. To validate our data, 10 targets were selected for verifi-
cation by ChIP-qPCR (Fig. 5); 9/10 of the Sall4a peaks and
10/10 Sall4b peaks showed enrichment compared to the nega-
tive control, BirA ChIP (equivalent to an IgG control for
standard antibody based ChIP). In addition, we verified that in
our bio-ChIP approach neither Sall4a nor Sall4b bound to
FIG. 1. Sall4a and Sall4b share similar regulation. (A) Genomic structure of the Sall4 locus, with the domain structure of the long (Sall4a) and
short (Sall4b) isoform of Sall4. Zinc fingers are shown as ovals, and the N-terminal NuRD binding domain is shown as a black rectangle.
(B) Differentiation of CJ7 ES cells with retinoic acid. Whole-cell extracts were assayed by Western blotting. The two isoforms are labeled, with
the Western blot antibody labeled on the right. Sall4a, Sall4b, and Nanog diminished during differentiation, whereas GAPDH remained
unchang d. (C) RNA was harvested from ES cells diff rentiated wi h retinoic acid at various time points, an the transcript levels of Sall4a, Sall4b,
Nanog, and Oct4 were assessed. Two different primer sets were used to assess total levels of Sall4, Sall4 (endo) that is directed to the 3"
untranslated region of the transcript of both isoforms, and Sall4 (total) that is directed to the coding region of both isoforms.
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liminary data from our lab suggests that the isoforms of Sall4
form distinct nuclear complexes (data not shown), implying
that the two isoforms form distinct protein-protein interac-
tions. Elucidation of proteins that specifically recognize Sall4a
may lead to the identification of negative regulators of the
pluripotent state.
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3.3.3 SALL4 in epigenetics 
 
SALL4 can be a positive or negative regulator of gene expression depending on its 
interactions with the epigenetic machinery (Figure 14). 
 
Sall4 is known to actively bind and activate the Pouf5f1 promoter to positively 
regulate Oct4 expression. However, Sall4 can also act as a repressor through direct 
binding to the Mi2/NuRD HDAC complex. The Sall4-HDAC complex can prevent ES 
cell differentiation into trophectoderm through repression of the Cdx2 promoter (Yuri 
et al., 2009), epigenetically inhibit somatic cell genes in primordial germ cells 
(Yamaguchi et al., 2015). SALL4 can also epigenetically repress the transcription of 
SALL1 and PTEN (Lu et al., 2009). In particular, SALL4 has been shown to regulate 
the epigenetic machinery by directly recruiting DNA methyltransferases (DNMT), 
HDAC1 and HDAC2 (Yang et al., 2012). Moreover, in hematopoietic stem cells 
SALL4 interacts with LSD1 (histone lysine-specific demethylase 1) to regulate stem 
cell proliferation and differentiation (Liu et al., 2013) (Figure 14). 
 
 
Figure 14. SALL4 regulation of the epigenetic machinery.  
SALL4 represses transcription by actively recruiting DNA methyltransferases (DNMT), Mi-
2/nucleosome remodeling and deacetylase (NuRD) complex, the histone demethylase LSD1 
and the polycomb repression complex (PRC). SALL4 acts also as a transcriptional activator 
through regulation of the histone methyltransferase MLL (mixed-lineage leukemia) (adapted 
from: Zhang et al., 2015). 
 
Similarly, in cancer SALL4 expression was correlated to HDACs activity in 
hepatocellular carcinoma (Zeng et al., 2014) and it has been shown to promote 
leukomogenesis by repressing PTEN through its direct binding to the HDAC complex 
(Gao et al., 2013). 
demethylation in DNA and histone may distinctly regulate gene ex-
pression in stem cells and cancer. Second, SALL4 is associated with
Mi-2/nucleosome remodeling and deacetylase (NuRD) complex and
the SALL4-interacting protein complex exhibits histone deacetylase
(HDAC) activity [42]. For instance, SALL4 co-occupies the same pro-
moter regions of PTEN as HDAC2 and represses its expression in vitro,
indicating that SALL4-repressed gene transcription could be me-
diated by histone deacetylation and nucleosome remodeling.
However, there is a lack of studies about the regulatory effects of
SALL4 on non-coding RNA in epigeneti m dul tion. Therefore, the
existing data suggest that SALL4 may recruit multiple epigenetic
modifiers to synergistically remodel local ch omati structure and
coordinately regulate gene transcription (Fig. 3).
SALL4 regulation in cancer
SALL4 is regulated at multiple levels in cancer. Aberrant
hypomethylation of the promoter region of SALL4 gene is ob-
served in MDS patients and SALL4 mRNA level is highly associated
with the status of SALL4 hypomethylation, indicating that SALL4 gene
expression is dysregulated in MDS patients by epigenetic mecha-
nism [43]. The frequency of SALL4 hypomethylation is significantly
increased in higher risk MDS patients, suggesting that
hypomethylation of SALL4 gene is involved in the progression of
MDS. In addition, SALL4 gene is aberrantly hypomethylated in acute
myeloid leukemia patients and the status of SALL4 gene methyla-
tion is associated with intermediate and poor karyotypes of AML
[44]. SALL4 is also regulated by a variety of transcription factors that
are closely linked with tumor development and progression. Mul-
tiple STAT3-binding sites have been identified in the SALL4 gene
promoter region. Down-regulation of STAT3 activity remarkably de-
creased the expression of SALL4 [45]. STAT3-mediated SALL4
regulation is critical for the survival of breast cancer cells. SALL4
expression is also regulated by the canonicalWnt signaling pathway.
SALL4 promoter contains a conserved TCF/LEF-binding site. Co-
transfection of β-cateninwith LEF1 (or TCF4E) greatly increases SALL4
luciferase activity while mutation of the TCF/LEF-binding site at-
tenuates SALL4 luciferase activity, suggesting that SALL4 is a direct
transcriptional target of canonical Wnt signaling [46]. Further-
more, SALL4 interacts with β-catenin to cooperatively activate its
target genes. Therefore, the regulation of SALL4 by Wnt signaling
may form a feedback loop to fine-tune the Wnt signaling pathway.
SALL4 is identified as a direct target of caudal-related homeobox
1 (CDX1) transcription factor [47]. SALL4 is aberrantly expressed in
the CDX1-positive intestinal metaplasia of the stomach in both
humans and mice. CDX1-induced SALL4 converts gastric epitheli-
al cells into tissue stem-like progenitor cells, which then
transdifferentiate into i testinal pithelial cells, sugg sting that SALL4
is a critical component of CDX1-directed transcriptional circuitry
that promotes intestinal metaplasia. Furthermore, SALL4 is found
to be regulated by microRNA in glioma cells [48]. MiR-107 mimics
reduce while miR-107 inhibitors increase the SALL4 mRNA level.
MiR-107 overexpression inhibits cell proliferation and induces apop-
tosis in glioma cells, which are reversed by SALL4 reintroduction.
An obvious inver e correlation between miR-107 xpression and
SALL4 level is observed in clinical glioma samples, indicating that
upregulation of miR-107 inhibits glioma cell growth through direct
targeting of SALL4. SALL4B can be modified by both ubiquitination
and sumoylation at the post-translational level. However, SALL4B
sumoylation is independent of ubiquitination while lysine resi-
dues 156, 316, 374, and 401 are essential for sumoylation. It is known
so far that only SALL4 sumoylation is functionally important [49].
A constitutive sumoylation of SALL4B is readily detectable in tera-
tocarcinoma cells. SUMO-deficiency compromises the trans-
activational or trans-repressional activities of SALL4B, suggesting
that sumoylation is an important post-translational modification for
SALL4 activity.
SALL4 as cancer biomarker and target
SALL4 seems to be a sensitive and specific cancer biomarker.
SALL4 expression is reported in numerousmalignancies, such as pre-
cursor B-cell lymphoblastic lymphoma [50,51], myelodysplastic
syndromes [52], acute myeloid leukemia [11], chronic myeloid leu-
kemia [30], breast cancer [32], lung cancer [31,53], endometrial
cancer [35], liver cancer [33,38], gastrointestinal carcinoma
[34,54–56], glioma [48,57], germ cell tumors (GCTs), and yolk sac
tumors [58–60]. SALL4 expression correlates with disease progres-
sion in human AML and its expression in AML patients is correlated
with treatment status. Therefore, SALL4 may be used as a marker
for diagnosis and prognosis for AML. SALL4 is expressed at a high
level in the early clinical stages of breast cancer, indicating that SALL4
may be helpful for breast cancer screening. SALL4 expression is re-
activated in human HCC patients. HCC patients with high SALL4
expression are significantly associated with shorter survival. SALL4
is an independent prognostic factor for overall survival and early
recurrence of HCC. In endometrial cancer patients, the level of SALL4
expression is positively correlated with worse patient survival and
aggressive features such asmetastasis. In colorectal carcinoma (CRC),
significant increase in SALL4 expression is detected in 87% of tumor
Fig. 3. SALL4 and epi enetic machinery. SALL4 represses r activates gene transcription through the interaction with distinct epigenetic modifiers. SALL4 suppresses gene
transcription through recruitment of DNA methyltransferases (DNMT), Mi-2/nucleosome remodeling and deacetylase (NuRD) complex, polycomb repressive complex (PRC),
and histone demethylase (LSD1). SALL4 activates gene expression through recruitm nt of histone methyltransferase such as MLL (mixed-lineage leukemia).
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Moreover, SALL4 has been shown to play a role in the regulation of H3K27 
methylation. It can activate the transcription of BMI-1, a polycomb group member, in 
hematopoietic stem cells and in leukemia (Yang et al., 2007) and it is known to bind 
to several genes that are targeted by PRC1 and PRC2 (Yang et al., 2008) (Figure 
14). 
 
3.3.4 Sall4 in DNA damage response 
 
ES cells have a higher genomic stability compared to somatic cells, which prevents 
the passage of aberrant information to the progeny. The mechanisms that conserve 
ES cell genomic stability and that react upon DNA damage are characterized by 
Sall4 modulation of the epigenetic machinery (Xiong et al., 2015). Sall4 is in fact 
associated to heterochromatin and upon DNA damage it is relocated to the γ-H2AX 
sites around DNA double strand breaks (DSBs) (Figure 15). 
 
   
Figure 15. Sall4 relocation upon DNA damage. 
In ES cells, Sall4 (red) is relocated from the heterochromatin to sites of DNA DSBs 
characterized by γ-H2AX (green) formation (adapted from Xiong et al., 2015). 
 
In detail, Sall4 interacts with Rad50, which stabilizes the Mre11-Rad50-Nbs1 
complex. Consecutively the Mre11-Rad50-Nbs1 complex recruits and activates the 
Ataxia Telangiectasia Mutated (ATM) response to DNA damage, by 
autophosphorylation of ATM at Ser1987. Sall4 is recruited to the sites of DNA DSBs 
by interaction with Baf60, which is a member of the SWI/SNF ATP-dependent 
chromatin remodeling complex. Finally, ATM phosphorylation activates the p53-
mediated response to DNA damage (Xiong et al., 2015) (Figure 16). 
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Figure 16. Sall4-mediated response upon DNA damage. 
Sall4 activates ATM as a cellular response to DSBs in mouse ES cells. This mechanism 
protects ES cells from DSB-induced cytotoxicity and preserves their genomic stability 
(Adapted from: Xiong et al., 2015). 
 
Sall4 function in the maintenance of genomic stability and the fact that Sall4 is 
aberrantly expressed in some tumorigenic cells, could suggest a potential role of 
Sall4 in the development of resistance to chemotherapy (Leslie 2015). 
 
3.3.5 Sall4 in cell proliferation 
 
In ES cells, Sall4 controls cell proliferation and its loss results in impaired cell 
proliferation characterized by a prolonged G1 phase and a shorter S phase (Sakaki-
Yumoto et al., 2006, Yuri et al., 2009).  
Similarly, SALL4 has been shown to be pro-proliferative and to activate BMI-1, which 
in turn inhibits p16INK4a and induces aberrant proliferation in leukemia (Yang et al., 
2007). Additionally, SALL4 loss has been shown to reduce tumor proliferation in a 
517Roles of Sall4 in maintaining ESC genomic stability • Xiong et al.
that of Baf60a and Sall4 (Fig. 4 D). Therefore, Sall4 is not 
required for the recruitment of Rad50 to the site of DNA DSBs 
but works together with Baf60a to stabilize the MRN complex. 
In summary, we propose a novel model that the stemness fac-
tor Sall4 is a key transducer of DNA DSB damage-induced 
chromatin remodeling to MRN-dependent ATM signaling in 
ESCs (Fig. 4 E).
In addition to the well-established roles of Sall4 in main-
taining epigenetic landscape of ESCs, our !ndings uncover a 
pivotal role of Sall4 in activating critical DDRs in ESCs. Be-
cause Sall4 is not expressed in most normal somatic cell types 
(Kohlhase et al., 2002), the restricted expression of Sall4 in 
pluripotent stem cells provides a more robust mechanism to 
promote ef!cient DDR to ensure the genomic stability of plu-
ripotent stem cells, which is required to maintain the genomic 
stability of the population by giving rise to the germ cells. In 
addition, Northern blot analysis revealed that Sall4 is only 
expressed in ovary and testis but not in other tissues of adult 
mice, such as brain, heart, skeletal muscle, lung, liver, kidney, 
and spleen (Kohlhase et al., 2002). Therefore, the expression 
of Sall4 in the germ cells provides an additional safeguard for 
offers binding sites for SWI/SNF complexes and also serves 
as an indicator of decondensed chromatin con!guration during 
DDR, facilitating access to repair and signaling proteins. The 
histone acetyltransferase Gcn5 is responsible for H3K14ac in 
this process (Kim et al., 2009; Lee et al., 2010). To shed light 
on the function of Baf60a as a transducer of upstream chroma-
tin remodeling to Sall4-mediated ATM signaling in DDR, the 
ESCs were treated with Gcn5 inhibitor CPTH2 to reduce the 
H3K14ac in response to DNA damage (Chimenti et al., 2009). 
This treatment impaired the association of Baf60a, Sall4, and 
Rad50 with DNA DSBs in ESCs, suggesting that H3K14ac 
is required for Sall4-mediated DDR (Fig. 4 B). In support of 
this conclusion, ATM activation was also suppressed in ESCs 
after DNA DSB damage in the presence of CPTH2 (Fig. 4 C). 
To better understand the kinetics of the recruitment of Sall4, 
Rad50, and Baf60a to the site of DNA DSB damage, we used 
an integrated DNA breakage and chromatin immunoprecipita-
tion (ChIP) system based on tight control of the nuclear import 
of endonuclease I-PpoI to introduce a DNA DSB at a speci!c 
genomic site (Goldstein et al., 2013). Our !ndings indicate 
that the recruitment of Rad50 to the DNA DSB is earlier than 
Figure 4. Sall4 linking SWI/SNF-associated chromatin remodeling to MRN-dependent ATM activation. (A) Silencing of Baf60a impairs the recruitment of 
Sall4 to G-H2AX foci after DNA DSB damage. Nuclei are counterstained with DAPI (blue). For intensity correlation analysis (ICA), pixels from the Sall4 chan-
nel covarying positively with the corresponding signal from the G-H2AX channel are denoted. si-Con, control siRNA. Bar, 5 µm. (B) Inhibition of H3K14ac 
by CPTH2 disrupts the association of Baf60a, Sall4, and ATM with DNA DSBs in the cellular extract of Sall4+/ ESCs treated with 0.5 µM DOX for 4 h. 
WNE, whole nuclear extract. (C) Inhibition of H3K14ac by CPTH2 in Sall4+/ ESCs impaired ATM-dependent responses to DNA DSB damage. (D) The 
kinetics of the recruitment of Rad50, Sall4, and Balf60a to the specific DNA DSB. ChIP analysis showed the kinetics of the recruitment of Sall4, Rad50, 
and Baf60a to the single I-PpoI cleavage site at chromosome 3 in Sall4+/ cells. Time denotes the minutes after the addition of 4-hydroxytamoxifen. Values 
are means ± SEM. (E) An illustrated model for Sall4 to function as a transducer of chromatin remodeling to ATM signaling in ESCs after DNA damage. 
P, phosphorylation.
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range of various tumor types suggesting SALL4 as a potentially interesting 
therapeutic target (Kobayashi et al., 2011; Li et al., 2015; Zhang et al., 2014a). 
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3.4 SALL4 in disease 
 
3.4.1 SALL4 in developmental disorders 
 
Mutations of the SALL4 gene located on chromosome 20q13.13–q13.2 result into the 
autosomal dominantly inherited Duane-radial ray syndrome (Okhiro syndrome). This 
syndrome comprises the Duane anomaly that affects ocular motility as well as radial 
sided hand malformations (Kohlhase et al., 2002) (Figure 17). The disease often 
occurs accompanied by anal stenosis, heart, kidney and ears defects, facial 
asymmetry and pigmentation abnormalities (Al-Baradie et al., 2002; Kohlhase et al., 
2002).  
 
 
Figure 17. Patients affected by the Okihiro Syndrome. 
(A) The patient suffers from a defect in ocular mobility characterized by the unability of 
abducting the eyes without closing of the palpebra. (B-C) Hand and (D-F) limb malformations 
in patients with the Okihiro Syndrome (adapted from: Kohlhase et al., 2002).    
 
In particular, in regards to the ear malformation and defect, data obtained in chick 
embryos suggest that Sall4 plays an important role during the invagination of the 
sensory placodes and it may, thus, be involved in ear development (Barembaum and 
Bronner-Fraser, 2007). 
 
 
 
Figure 4. Clinical features of Okihiro syndrome patients. (A) Family 1 demonstrating Duane retraction anomaly. The patient is unable to abduct the left eye uni-
laterally and on adducting the same eye there is retraction of the globe and narrowing of the palpebral fissure. (B) Patient II.3, family 1 demonstrating left thenar
hypoplasia. (C–F) Limb malformations in three affected individuals of family 3. (C) I.2 has bilateral radial club hands with absence of the thumbs. (F) II.4 shows a
very rudimentary upper limb, with absence of the thumb and forearm and a short humerus. (D) III.1 has a normal humerus but short forearm and absence of the
thumb. (E) There is radiological fusion of the ulna and radius, which are foreshortened. The first metacarpals are absent.
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3.4.2 SALL4 in cancer 
 
SALL4 up-regulation has been reported in various types of tumor as in germ cell 
tumors, e.i. testicular germ cell tumor, in yolk sac tumor (Bai et al., 2013; Cao et al., 
2009), in gastrointestinal carcinonoma (Zhang et al., 2014a), in glioma (Zhang et al., 
2014b), in hepatocellular carcinoma (Yong et al., 2013), in endometrial cancer (Li et 
al., 2015), in colorectal cancer (Forghanifard et al., 2013), in breast cancer 
(Kuribayshi et al., 2011), in lung cancer (Fujimoto et al., 2014; Kobayashi et al., 
2011), in chronic myeloid leukemia (Gao et al., 2011; Lu et al., 2011), in acute 
myeloid leukemia (Ma et al., 2006) and in B cell lymphoma (Ueno et al., 2014). 
SALL4 regulates a variety of cellular functions that are responsible for tumor initiation 
and progression and high levels of protein expression have been associated with 
worse survival prognosis in the tumor types mentioned above (Figure 18). High 
SALL4 levels have been indeed linked to increased levels of BMI-1 (Yang et al., 
2007), of CyclinD1 (CCND1) and D2 (CCND2), and overall to increased tumor 
proliferation and, thus worse prognosis. Interestingly, SALL4 loss leads to decreased 
cellular proliferation and is linked to improved survival (Kobayashi et al., 2011; Li et 
al., 2015; Yang et al., 2007; Zhang et al., 2014a). Moreover, high SALL4 levels are 
correlated to an EMT signature that is characterized by elevated levels of 
mesenchymal cell markers such as TWIST and N-cadherin (CDH2) as well as 
diminished expression of epithelial cell markers such as E-cadherin (CDH1). Hence, 
high SALL4 levels account for increased number of metastases resulting in worse 
survival expectancy, while loss of SALL4 reduces cellular motility and decreases 
metastasis formation (Cao et al., 2009; Forghanifard et al., 2013; Itou et al., 2013; 
Zhang et al., 2014a).  
Of note, SALL4 expression has also been linked to the acquisition of pluripotency 
features such as expression of EpCAM in hepatocellular cancer (Zeng et al., 2014), 
and of SOX2, BMI-1, CD133 and LIN28B in gastric cancer (Zhang et al., 2014a). 
Furthermore, high SALL4 levels have been linked to the development of 
chemoresistance in several types of cancer, such as leukemia (Hupfeld et al., 2013), 
hepatocellular cancer (Oikawa et al., 2013) and endometrial cancer (Li et al., 2015; 
Liu et al., 2015). 
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Figure 18. SALL4 regulates several signaling pathways during tumorigenesis. 
SALL4 can be activated by CDX1, STAT3 and TCF/LEF. In turn, SALL4 positively or 
negatively regulates a number of signaling pathways that control cell stemness, apoptosis, 
proliferation, invasion and drug resistance. SALL4 is, thus, an important factor in cancer 
initiation and progression (adapted from: Zhang et al., 2015). 
 
3.4.3 SALL4 in melanoma 
 
SALL4 function has been extensively investigated both in development as well as in 
cancer. However, whether SALL4 may also play a role in the formation and 
progression of melanoma has not been studied so far, opening the possibility to 
future novel investigations (4.2 The roles of Sall4 in melanoma). 
 
  
myelodysplastic syndrome (MDS)-like features at ages 6–8months
and half of the monitored mice eventually progressed to AML [11].
Mice injectedwith serially transplanted SALL4B-induced AML cells
also develop aggressive AML, suggesting that SALL4B-induced AML
is transplantable. The potential signaling pathway that SALL4 may
affect in leukemogenesis has been postulated, which includes SALL4
binding to β-catenin and activating the Wnt/β-catenin signaling
pathway. The expression ofWnt/β-catenin downstream target genes,
such as c-Myc and Cyclin D1, is upregulated in SALL4B transgenic
mice. Thus, constitutive expression of SALL4 in AMLmay enable leu-
kemic blasts to gain stem cell properties, such as self-renewal and/
or lack of differentiation, and thus become leukemic stemcells (LSCs).
In addition, Bmi-1 is identified as a target gene for SALL4 in both
hematopoietic and leukemic cells [20]. Bmi-1 is a putative onco-
gene that modulates stem cell pluripotency and plays a role in
leukemogenesis. SALL4 binds to Bmi-1 promoter and directly affects
the levels of endogenous Bmi-1 expression. In vitro knockdown of
SALL4 by siRNA in leukemic cells or in vivo deletion of one copy of
SALL4 in mouse bone marrow significantly reduces Bmi-1 expres-
sion. Bmi-1 expression is up-regulated in transgenic mice that
constitutively overexpress SALL4B, and the levels of Bmi-1 in these
mice increase as they progress from normal to preleukemic
(myelodysplastic syndrome) and leukemic (acute myeloid leuke-
mia) stages. Furthermore, there is a strong positive correlation
between SALL4 andBmi-1 expression in humanAML samples. SALL4
induces high levels of H3K4 trimethylation andH3K79dimethylation
in the binding region of the Bmi-1 promoter, suggesting that SALL4
provides epigeneticmodifications at the Bmi-1 gene promoter. These
findings indicate a link between SALL4 and leukemogenesis by regu-
lating self-renewal of leukemic stem cells.
SALL4 and cell proliferation and apoptosis
SALL4 acts as a key regulator of cell proliferation and apoptosis
in cancer cells. SALL4 knockdown induces massive apoptosis and
significant growth arrest in human leukemic cells [29]. In addi-
tion, reduction of SALL4 markedly diminishes tumorigenicity of
human leukemia cells in immunodeficient mice. ChIP-chip assay for
the global gene target of SALL4 in human leukemic cells reveals that
SALL4 binds to the romoter of genes that are critically involved
in apoptosis. The expression levels of these genes change signifi-
cantly after SALL4 knockdown, indicating that SALL4 is a key
regulator of apoptosis-associated genes. In addition, SALL4 has an
important role in the proliferation and survival of chronic myeloid
leukemia (CML) cells, and its expression is associated with an ad-
vanced stage of CML disease. Downregulation of SALL4 leads to cell
cycle arrest and apoptosis in CML cells [30]. In AML and CML cells,
SALL4 knockdown-induced apoptosis and cell cycle arrest are rescued
by forced expression of Bmi-1, suggesting that SALL4 regulation of
Bmi-1 may at least be partially responsible for its effects on cell pro-
liferation and apoptosis. Moreover, HOXA9 is identified as another
downstream target of SALL4 [21]. SALL4 interacts with mixed-
lineage leukemia (MLL) and co-occupies the HOXA9 promoter region
in AML leukemic cells. Compared with wild-type controls, HOXA9
is up-regulated in SALL4B transgenic mice. In primary human AML
cells, downregulation of SALL4 also reduces HOXA9 expression and
induces cell apoptosis. Furthermore, SALL4 knockdown leads to
growth inhibition of lung cancer cells as a result of cell cycle arrest
[31]. Similarly, reduction of SALL4 expression by siRNA com-
pletely also inhibits the proliferation of breast cancer cells as a result
of cell cycle arrest [32]. Conversely, SALL4-overexpressing liver cancer
Fig. 2. Proposed model for SALL4 regulatory n twork in cancer. SALL4 regulates cell proliferation, poptosis, migration/invas on, drug re istance, and stemness by targeting
a variety of genes. SALL4 regulates cell proliferation through the β-catenin/cyclin D1, Bmi-1, and PTEN pathways. SALL4 regulates cell migration/invasion through the ZEB1/
E-cadherin and the c-Myc pathways. SALL4 inhibits apoptosis through the Bmi-1, HOXA9, and FADD pathways. SALL4 regulates the resistance of cancer cells to chemotherapy
by targeting the ABCA3, ABCG2, and c-Myc pathways. SALL4 regulates the self-renewal of cancer stem cells through the Oct4, Nanog, Sox-2, and Bmi-1 pathways. STAT3,
CDX1, and TCF/LEF are upstr am positive regulators of SALL4. SALL4 is a dow stream arget of microRNA-107. Natural compounds matrine and apigenin could inhibit the
expression of SALL4.
57X. Zhang et al./Cancer Letters 357 (2015) 55–62
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4 Results 
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4.1.1 My contribution to this work 
 
• Design of the experiment with inputs from Sandra Varum and Prof. Lukas 
Sommer 
• Execution of all the experiments and collection of the data 
• Breeding of the mice used in the study, including genotyping, time mating and 
collection of the embryos 
• Production of all the figures 
• Design of the paper outline together with Prof. Lukas Sommer. Writing of the 
manuscript with inputs and corrections provided by Sandra Varum and Prof. 
Lukas Sommer 
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4.1.2 In brief 
 
The neural crest (NC) gives rise to a broad variety of neural and non-neural cell 
types during vertebrate development, but whether NC cells are multipotent or rather 
a heterogeneous population of restricted progenitors is unclear. In this study, we 
performed an in vivo lineage tracing analysis of single premigratory and migrating NC 
cells and demonstrated that the majority of NC cells are multipotent in vivo 
(Baggiolini et al., 2015; Figure 19).  
Figure 19. In vivo lineage tracing of premigratory and migratory NC cells. 
We used mouse genetics to label NC cells at the premigratory and migratory stage in an 
inducible way in vivo at E9. The recombined clones were analyzed at E10.5 by determination 
of color, location and expression of differentiation markers. 
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4.1.3 Summary 
 
The neural crest (NC) is an embryonic stem/progenitor cell population that generates 
a diverse array of cell lineages, including peripheral neurons, myelinating Schwann 
cells, and melanocytes, among others. However, there is a long-standing controversy 
as to whether this broad developmental perspective reflects in vivo multipotency of 
individual NC cells or whether the NC is comprised of a heterogeneous mixture of 
lineage-restricted progenitors. Here, we resolve this controversy by performing in 
vivo fate mapping of single trunk NC cells both at premigratory and migratory stages 
using the R26R-Confetti mouse model. By combining quantitative clonal analyses 
with definitive markers of differentiation, we demonstrate that the vast majority of 
individual NC cells are multipotent, with only few clones contributing to single 
derivatives. Intriguingly, multipotency is maintained in migratory NC cells. Thus, our 
findings provide definitive evidence for the in vivo multipotency of both premigratory 
and migrating NC cells in the mouse. 
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4.1.4 Introduction 
 
Neural crest (NC) cells are a defining feature of vertebrates that give rise to many of 
the cell types that imbue them with their unique characteristics, such as jaws and 
peripheral nervous system. They represent an important population from the 
perspective of regenerative medicine, since they contribute to many critical cell types 
that are prone to both developmental birth defects and metastatic transformation in 
adults. In the embryo, NC cells arise from the dorsal margin of the neural plate 
border during neurulation (Le Douarin et al., 2008), undergo an epithelial to 
mesenchymal transition (EMT), and migrate extensively throughout the embryo to 
populate numerous derivatives. In fact, NC cells have one of the broadest 
developmental potentials of any vertebrate cell type.  
 
This has raised the important question of what underlies this remarkable ability to 
contribute to so many diverse derivatives, ranging from craniofacial cartilage to 
neurons and glia to melanocytes. One model suggests that the entire NC cell 
population is “multipotent” and capable of forming many or all of the potential 
derivatives. At the opposite extreme, the NC might instead represent a 
heterogeneous mixture of “predetermined” cells, each fated to form a particular 
derivative. Finally, the NC may be comprised of a mixture of these two types of 
precursor cells.  
 
Over several decades, there has been considerable controversy regarding the 
correct answer to this pivotal question (Dupin and Sommer 2012). Early studies 
concluded that NC cells were multipotent in vivo (Bronner-Fraser and Fraser, 1988; 
Bronner-Fraser and Fraser, 1989; McKinney et al., 2013; Serbedzija et al., 1990) and 
in vitro (Baroffio et al., 1988; Dupin et al., 2010; Stemple and Anderson, 1992). 
However, other publications instead reported that the NC was comprised of 
heterogeneous populations of restricted progenitor cells (Harris and Erickson, 2007; 
Henion and Weston, 1997; Krispin et al., 2010; Luo et al., 2003; Ziller et al., 1983). In 
particular, recent studies using vital dye microinjection or electroporation of a GFP-
reporter proposed that premigratory NC cells are fate-determined prior to 
delamination and organized according to a spatio-temporal pattern in the dorsal 
neural tube (dNT) of chick embryos (Krispin et al., 2010; Nitzan et al., 2013). In this 
model, each NC cell gives rise only to a specific cell type, depending on the timing of 
emigration and the site of origin in the dNT.  
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Despite technical differences potentially explaining these discrepancies, it has so far 
not been possible to reconcile these studies (Dupin and Sommer, 2012). Early in vivo 
lineage tracing studies lacked the ability to identify specific cell types other than by 
location in various derivatives. Whereas clonal analysis in vitro circumvents these 
problems, the culture techniques analyze cells outside of their endogenous 
environment and expose cells to culture media, which may alter cell behavior. 
Moreover, there is very little information regarding the developmental potential of NC 
cells in mammalian model systems. Lineage-tracing studies were originally 
performed in chicken embryos by vital dye injection, which is very challenging to 
carry out in mouse embryos (Serbedzija et al., 1990). With the advent of modern 
transgenic technology, it is now possible to resolve the controversy regarding NC 
potentials in the mammalian embryo. Recently, transgenic mouse models have been 
established that allow genetic lineage tracing in mammalian embryos and adult 
organs (Lescroart et al., 2010; Mathis et al., 1997; Tzouanacou et al., 2009). One of 
these models is the R26R-Confetti mouse (Snippert et al., 2010), which has proved 
very useful for mapping fates of single cells in adult tissues. Here, we use this 
approach to perform genetic in vivo fate mapping of NC cells. Our results definitively 
show that the vast majority of murine NC cells, both prior to and during migration, are 
multipotent.  
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4.1.5 Results 
 
4.1.5.1 Multicolor labeling of premigratory and migratory NC cells 
 
To achieve temporal tracing of NC cells, we used the CreER loxP system, by which 
activation of CreER recombinase can be induced in embryos in a cell type- and 
stage-dependent manner upon tamoxifen (TM) injection of pregnant females. CreER-
mediated genomic recombination of reporter alleles leads to marker expression that 
can be tracked in CreER-expressing cells and all of their daughter cells, allowing fate 
mapping of these cells in vivo. To trace the fate of premigratory NC cells, we made 
use of Wnt1-CreERT animals. Accordingly, CreERT-induced b-galactosidase 
expression in Wnt1-CreERT embryos carrying the CreERT-reporter allele R26R-
Rosa was observed in the dNT and in all NC derivatives (Figures 20A and 20B) 
(Soriano, 1999; Zervas et al., 2004). To trace NC cells that have already emigrated 
from the dNT, we used the Sox10-CreERT2 line (Simon et al., 2012). In the mouse, 
Sox10 expression follows Wnt1 expression and marks virtually all NC cells 
immediately after their delamination from the dNT (Hari et al., 2012). Therefore, TM- 
induced recombination at E.9.0 in Sox10-CreERT2 R26R-Rosa embryos resulted in 
b-galactosidase expression in all NC derivatives, but not the dNT (Figures 20C and 
20D). 
Upon CreER activation and recombination across sets of loxP sites in the R26R-
Confetti reporter mouse, one out of four fluorescent reporter proteins, nuclear GFP, 
cytoplasmic YFP, cytoplasmic RFP, or membrane-bound CFP, is expressed. To 
increase the colors available for the tracing, we used animals homozygous for the 
R26R-Confetti allele. In these animals, both alleles are recombined, which leads to 
expression of two out of the four available fluorescent proteins, allowing a total of 10 
color combinations (Figure 21). In both Wnt1-CreERT R26R-Confetti (hereafter 
called Wnt1-CreERT) (Figures 20E–20J) and in Sox10-CreERT2 R26R-Confetti 
(Sox10-CreERT2) embryos (data not shown), expression of the following single color 
combinations was readily detectable: red (rfp, Figure 20E); yellow (yfp, Figure 20F); 
and blue (cfp, Figure 20G). In addition, we observed the expression of mixed color 
combinations, such as red and blue (rfp cfp, Figure 20H), red and yellow (rfp yfp, 
Figure 20I), and yellow and blue (yfp cfp, Figure 20J). In contrast, color combinations 
with the fluorescent protein GFP were extremely rare, indicating that not all 
theoretically possible color combinations were equally represented. 
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Figure 20. Multicolor tracing of premigratory and migratory NC Cells (A–D) (A and B) b-
galactosidase expression in premigratory NC cells in E9.5 and E12.5 Wnt1-CreERT R26R 
embryos and in migratory NC cells in Sox10-CreERT2 R26R embryos ([C] and [D]). (E–J) In 
vivo expression of the single-color combinations rfp (E), yfp (F), and cfp (G) and of the mixed 
color combinations rfp cfp (H), rfp yfp (I), and yfp cfp (J). Neurofilament staining (NF, in white) 
delineates the structure of the dorsal root ganglia (DRG). 
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(K) Experimental outline for the multicolor lineage tracing approach. E0, embryonic day 0; p.i., 
post injection of TM. (L and M) Frequencies of the color combinations in the four cases 
analyzed (Wnt1-CreERT and Sox10- CreERT2 at low and high recombination densities). For 
numbers of analyzed embryos, see 4.1.7 Experimental Procedures. Scale bars: 50 mm. See 
also Figure 21 and Table 1. 
 
 
FIGURE 21: The R262-Confetti construct. 
(A) Confetti construct inserted in the Rosa26 locus. Upon Wnt1-CreERT or Sox10- CreERT2 
activation, recombination occurs across different pairs of loxP sites and results in expression 
of one out of the four possible fluorescent reporter proteins: nuclear GFP, membrane-
associated CFP, cytoplasmic RFP, cytoplasmic YFP. Recombination in embryos homozygous 
for the R26R-Confetti allele allows up to ten different fluorescent proteins combinations. For 
the single color combinations, rfp, yfp and cfp, the recombination of only one of the two 
R26R-Confetti alleles cannot be excluded, since limiting dosages of TM were used. 
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4.1.5.2 Multicolor output depends on promoter activity and recombination 
density 
 
The frequency of color combinations observed upon CreER- mediated recombination 
of a multicolor Cre reporter influences the probability of whether a cohort of cells 
marked by a single color derives from one or more founder cells. Therefore, we 
examined the frequency of different colors expressed in E10.5 R26R-Confetti 
embryos of both CreER lines (Figure 20K). A single limiting dose of TM resulted in 
few recombination events. Quantification of low-TM-dose-treated E10.5 Wnt1- 
CreERT R26R-Confetti embryos (Wnt1-CreERT low) revealed that the mixed color 
combinations were expressed in only 0.1%–0.9% of the recombined NC cells (Figure 
20L; Table 1). Similarly, in low-TM-dose-treated Sox10-CreERT2 R26R-Confetti 
embryos (Sox10-CreERT2 low), mixed colors were found at very low frequencies 
(Figure 20M; Table 1). In contrast, the pure colors red, yellow, or blue were 
consistently expressed in recombined NC cells in both CreER lines (Figures 20L and 
20M; Table 1). 
These findings prompted us to increase the level of recombination for both CreER 
lines, in order to obtain more NC cells expressing rare color combinations. For the 
Wnt1-CreERT R26R-Confetti line, higher recombination density achieved by 
elevating the TM dose (Wnt1-CreERT high) resulted in increased, but still low, 
occurrence of the rare color combinations (0.3%– 3.2% of all recombined cells) 
(Figure 20L; Table 1). Similarly, elevating the TM concentration in the Sox10-
CreERT2 R26R-Confetti line (Sox10-CreERT2 high) allowed increased 
representation of the mixed color combinations (1.0%–3.5%) (Figure 20M; Table 1). 
Summarizing, in our system we were able to trace NC cells not only at two different 
developmental stages, namely at the premigratory and at the migratory stage, but 
also at two different recombination densities producing different color outputs. The 
most frequent color combinations allowed clonal tracing when only few 
recombination events occurred. Rare fluorescent marker combinations, on the other 
hand, could be used to discern single clones at both low and high recombination 
densities. 
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TABLE 1: Frequency of color representations in NC cells traced by R26R-
Confetti. Frequency of the different color combinations represented in the Figure 20L and 
20M for Wnt1-CreERT and Sox10-CreERT2 embryos analyzed at low and high recombination 
densities. To calculate the color densities for the Wnt1-CreERT line we analyzed 7 embryos 
(14 DRG-units, 4 litters) and 18 embryos (36 DRG-units, 7 litters) at low and at high 
recombination densities respectively. To measure the color frequencies for the Sox10-
CreERT2 line we analyzed 4 embryos (9 DRG-units, 2 litters) and 10 embryos (22 DRG-units, 
5 litters) at low and high recombination densities respectively. n.o. indicates not observed 
situations. 
 
 
  
Average% SEM (+/-) Average%
SEM 
(+/-) Average%
SEM 
(+/-) Average%
SEM 
(+/-)
rfp 48.69 5.47 41.48 2.91 72.69 7.91 43.50 2.64
yfp 37.89 5.55 30.24 2.57 17.35 6.57 35.94 3.27
cfp 12.06 2.87 22.62 2.52 9.18 3.28 14.58 1.69
rfp cfp 0.95 0.37 3.25 0.85 0.33 0.33 1.43 0.29
rfp yfp 0.28 0.13 1.93 0.90 0.07 0.07 3.53 0.45
yfp cfp 0.12 0.10 0.30 0.18 n.o. n.o. 1.01 0.21
gfp n.o. n.o. 0.17 0.11 0.38 0.38 n.o. n.o.
gfp rfp n.o. n.o. n.o. n.o. n.o. n.o. n.o. n.o.
gfp yfp n.o. n.o. n.o. n.o. n.o. n.o. n.o. n.o.
gfp cfp n.o. n.o. n.o. n.o. n.o. n.o. n.o. n.o.
Wnt1-CreERT low Wnt1-CreERT high Sox10-CreERT2 low Sox10-CreERT2 high
Table S1A related to Figure 1 and S1B related to Figure 2
A
Average% SEM (+/-) Average%
SEM 
(+/-) Average%
SEM 
(+/-) Average%
SEM 
(+/-)
dNT 14.02 2.11 7.64 1.28 n.o. n.o. n.o. n.o.
DRG 40.91 3.62 49.58 1.87 38.70 4.77 50.55 1.30
SG 18.88 2.78 18.01 1.26 29.66 6.91 24.13 1.80
VR 16.63 3.10 20.88 1.53 20.44 4.00 24.48 1.74
DLP 9.55 1.83 3.88 0.86 11.19 3.90 0.84 0.40
Wnt1-CreERT low Wnt1Cre-ERT high Sox10-CreERT2 low Sox10-CreERT2 high
B
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4.1.5.3 Representation frequencies of recombined NC cells in trunk derivatives 
 
NC cells in the trunk of mouse embryos give rise to several structures, such as 
dorsal root ganglia (DRG), Schwann cells associated with peripheral nerves as, for 
instance, evident in the ventral root (VR), sympathetic ganglia (SG), and finally cells 
that migrate along the dorsal lateral pathway (DLP) to generate melanocytes. As 
expected, all these derivatives were marked in Wnt1-CreERT and Sox10-CreERT2 
embryos (Figures 22A–2F; data not shown). Moreover, tracing NC cells at the 
premigratory stage with the Wnt1-CreERT line allowed the observation of 
recombined cells in the dNT, which we defined as the most dorsal three cell layers of 
the neural tube (Figures 22A and 22B). 
The likelihood to detect daughter cells of a NC progenitor cell in different target 
structures is possibly dependent on the relative sizes of these structures: The bigger 
a given compartment, the more likely it might be for a daughter cell to end up in this 
compartment. In Wnt1-CreERT embryos, we observed 7.6%– 14.0% of recombined 
cells in the dNT (Figure 22G; Table 2), while no recombined cells were found in the 
dNT of Sox10- CreERT2 embryos. In all conditions, the majority of recombined cells 
were found in the biggest trunk NC derivative, the DRG (Figures 22C and 22G; Table 
2). The SG and the VR were populated by comparable numbers of recombined NC 
cells, while the DLP was the derivative with the lowest number of recombined cells 
(Figures 22D–22G; Table 2). Given the number of possible cell divisions in a time 
window of 41 hr (Figure 20K), the elevated numbers of some recombined cells of the 
same color in certain derivatives cannot be explained only by differential proliferation 
in these derivatives. Therefore, the fact that the majority of recombined cells were 
present in the bigger derivatives is likely due to higher numbers of migratory NC cells 
populating these derivatives. 
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Figure 22. Frequencies of genetically traced cells in trunk derivatives of the NC. (A–F) 
(A) Schematic drawing of a transverse section with NC cells (in red) in the dorsal lateral 
pathway containing cells of the melanocytic lineage (DLP), sensory dorsal root ganglia 
(DRG), sympathetic ganglia (SG), and ventral root with Schwann cells (VR). Recombined NC 
cells are found in vivo in the dNT (B), DRG (C), VR (D), SG (E), and DLP (F). (G) 
Percentages of recombined cells per derivative in Wnt1-CreERT and Sox10-CreERT2 
embryos at low and high recombination densities, respectively. For numbers of analyzed 
embryos, see 4.1.7 Experimental Procedures. Scale bars: 50 mm. See also Table 2. 
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TABLE 2: Derivative representations upon R26R-Confetti-mediated NC cell 
tracing. Percentage of recombined cells per NC derivatives for each of the four experimental 
setups. To calculate the percentage of recombined cells per derivative in the Wnt1-CreERT 
line we analyzed 7 embryos (14 DRG-units, 4 litters) and 18 embryos (36 DRG-units, 7 litters) 
at low and at high recombination densities, respectively. For the Sox10-CreERT2 line we 
analyzed 4 embryos (9 DRG-units, 2 litters) and 10 embryos (22 DRG-units, 5 litters) at low 
and high recombination densities, respectively. n.o. indicates not observed situations. 
 
  
Average% SEM (+/-) Average%
SEM 
(+/-) Average%
SEM 
(+/-) Average%
SEM 
(+/-)
rfp 48.69 5.47 41.48 2.91 72.69 7.91 43.50 2.64
yfp 37.89 5.55 30.24 2.57 17.35 6.57 35.94 3.27
cfp 12.06 2.87 22.62 2.52 9.18 3.28 14.58 1.69
rfp cfp 0.95 0.37 3.25 0.85 0.33 0.33 1.43 0.29
rfp yfp 0.28 0.13 1.93 0.90 0.07 0.07 3.53 0.45
yfp cfp 0.12 0.10 0.30 0.18 n.o. n.o. 1.01 0.21
gfp n.o. n.o. 0.17 0.11 0.38 0.38 n.o. n.o.
gfp rfp n.o. n.o. n.o. n.o. n.o. n.o. n.o. n.o.
gfp yfp n.o. n.o. n.o. n.o. n.o. n.o. n.o. n.o.
gfp cfp n.o. n.o. n.o. n.o. n.o. n.o. n.o. n.o.
Wnt1-CreERT low Wnt1-CreERT high Sox10-CreERT2 low Sox10-CreERT2 high
Table S1A related to Figure 1 and S1B related to Figure 2
A
Average% SEM (+/-) Average%
SEM 
(+/-) Average%
SEM 
(+/-) Average%
SEM 
(+/-)
dNT 14.02 2.11 7.64 1.28 n.o. n.o. n.o. n.o.
DRG 40.91 3.62 49.58 1.87 38.70 4.77 50.55 1.30
SG 18.88 2.78 18.01 1.26 29.66 6.91 24.13 1.80
VR 16.63 3.10 20.88 1.53 20.44 4.00 24.48 1.74
DLP 9.55 1.83 3.88 0.86 11.19 3.90 0.84 0.40
Wnt1-CreERT low Wnt1Cre-ERT high Sox10-CreERT2 low Sox10-CreERT2 high
B
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4.1.5.4 Qualitative assessment of multicolor fate mapping of single 
premigratory NC cells 
 
Our data reveal that CreER-mediated recombination of the R26R-Confetti allele 
allows tracking of NC cells by different color combinations at defined frequencies. We 
next exploited this system to track the fate of individual NC cells, with a first 
emphasis on premigratory cells. E10.5 embryos were collected 41 hr post-TM 
injection (Figure 20K). As previously demonstrated, the mean cell-cycle length of 
E9.5 NC cells is 10.6 hr (Gonsalvez et al., 2013). The literature does not provide 
exact error intervals for the cell division rate, and it is likely that during 41 hr of NC 
development the cell-cycle length varies and becomes cell type and derivative 
specific. Since these variations are unknown and can hardly be determined, we first 
applied a fixed assumption that NC cells could divide three times between TM-
induced recombination and the time point of analysis. Hence, we initially considered 
only equally colored cohorts of cells with a minimum of two and a maximum of eight 
cells, with the goal that such a stringent analysis would serve as a basis to establish 
and assess a statistical method able to discern between multipotency and cell fate 
restriction. 
For the analysis of putative clones, we focused on the forelimbs area, taking into 
account cells of the same color that were present in a unit defined by a trunk 
segment spanning the width of one DRG (10–14 transverse sections of 10 mm 
thickness each) (Figure 23). 3D reconstruction confirmed that our recombination 
protocol allowed marking of a small number of equally colored NC daughter cells 
disseminating over various trunk derivatives (Figure 23; data not shown). 
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FIGURE 23: DRG-unit and clone representations. 
(A) Schematic summary of an 8-cells cfp+ clone analyzed in an E10.4 Wnt1-CreERT low 
embryo. (Ai-Axii) Pictures of all transversal embryonic sections spanning the entire DRG-unit, 
in which the cfp+ clone was observed. Arrows in Ai and Axii indicate the beginning and the 
end of the DRG-unit. (B) Z 316.7 µm stack of the trunk segment of an E10.5 Wnt1-CreERT 
high embryo (data not shown). Scale bars: 100 µm. 
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Consecutive transverse sections at the level of the forelimbs were imaged (Figure 
23Ai–23Axii), and the number and location of equally colored recombined cells per 
trunk segment were assessed (Figure 24). For the different conditions used, the 
density of putative clones ranged between 0.8 ± 0.1 and 1.0 ± 0.3 clones per unit, 
with most units analyzed containing 0 or 1 clone (Table 3). Wnt1-CreER embryos 
displayed many putative clones with progeny in multiple derivatives, including 
sometimes the dNT and DLP (Figures 24A and 25A). To corroborate these results, 
we analyzed Wnt1-CreERT high embryos, in which we observed cohorts of cells (two 
to eight cells) expressing rare mixed color combinations (Figures 24A and 25C). 
Strikingly, putative clones were mostly spread over multiple derivatives (Figures 24A 
and 25C). 
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Figure 24. Lineage tracing analysis of premigratory and migratory NC cells and 
mathematical evaluation of fate determination in NC cells 
(A and B) List of the clonal frameworks for premigratory (A) and migratory (B) NC cells 
ordered by degree of evidence of multipotency. Both conditions of low and high 
recombination densities were pooled to compare exclusively premigratory versus migratory 
NC. 
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(C) Percentages of clones expressing no, weak, substantial and strong evidence of 
multipotency for both premigratory and migratory NC cells at low and high recombination 
densities. (D) Degrees of evidence of multipotency when the minimum and the maximum size 
of a clone were changed for premigratory and migratory NC at low and high recombination 
densities. (E) Sensitivity assay of the statistical evaluation method. Each of the 16 barplots 
shows the proportion of cases that changed (ranging from loss of four clones up to gain of 
four clones) upon 100 different simulations. White indicates no change, red cases that were 
added and green cases that were lost. For numbers of analyzed embryos, see 4.1.7 
Experimental Procedures. 
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FIGURE 25: Clonal observations upon lineage tracing of premigratory and migratory 
NC cells. 
Lists of the 2-8 cell clones observed in the Wnt1-CreERT and Sox10-CreERT2 embryos both 
at low (25A, 25B) and high (25C, 25D) recombination densities. For each clone the following 
information is provided: category of statistical evidence for multipotency, derivatives where 
the clone was observed, number and color of the cells comprising the clone. The clones 
observed in the Wnt1-CreERT line were obtained analyzing 7 Wnt1-CreERT low embryos (14 
DRG-units, 4 litters, 25A) and 18 Wnt1-CreERT high embryos (36 DRG-units, 7 litters, 25C). 
The clones observed in the Sox10-CreERT2 line were obtained analyzing 4 Sox10-CreERT2 
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low embryos (9 DRG- units, 2 litters, 25B) and 10 Sox10-CreERT2 high embryos (22 DRG-
units, 5 litters, 25D). 
 
 
TABLE 3: Clonal density analysis for cohorts of 2-8 cells. The total number of clones, of 
DRG-units, of embryos, and of litters analyzed for each of the four experimental setups, 
Wnt1-CreERT and Sox10-CreERT2 line both at low and at high recombination densities, are 
listed. The data refer to Figures 24 and 25. The average of clones per unit is provided ± SEM. 
To indicate the observed clonal distribution per DRG-unit, we listed the absolute numbers and 
the respective percentages of numbers of clones per DRG-unit. 
 
4.1.5.5 Multicolor fate mapping of single migratory NC cells 
 
Our findings prompted us to ask whether multipotency might be a unique 
characteristic of premigratory NC cells or whether this developmental potential is 
retained upon NC delamination and migration. Therefore, we analyzed the fate of NC 
cells in Sox10-CreERT2 embryos (Figure 20K). The clonal density found in Sox10-
CreERT2 embryos was again low (Table 1). Surprisingly, in Sox10-CreERT2 low 
embryos, many equally colored cell cohorts were dispersed over multiple NC 
derivatives, in a similar manner to what had been observed in Wnt1-CreERT 
embryos (Figures 24B and 25B). Similar results were acquired for the Sox10-
CreERT2 high embryos, suggesting that these observations are independent of the 
recombination density and the color of the cell cohort (Figures 24B and 25D). 
 
 
 
Table S2A related to Figure 3, S3 and S2B related to Figure 4, S4
A
Nr of clones Nr of units Nr of embryos Nr of litters Clones per unit
Wnt1-CreERT low 14 14 7 4 1.0 ± 0.3
Wnt1-CreERT high 29 36 18 7 0.8 ± 0.1
Sox10-CreERT2 low 11 9 4 2 2.2 ± 0.2
Sox10-CreERT2 high 36 22 10 5 1.6 ± 0.2
Nr of clones per unit 0 % 1 % 2 % 3 % >3 % Total of units
Wnt1-CreERT low 4 28.6 8 57.1 0 0 2 14.3 0 0 14
Wnt1-CreERT high 16 44.4 11 30.6 9 25.0 0 0 0 0 36
Sox10-CreERT2 low 1 11.1 5 55.6 3 33.3 0 0 0 0 9
Sox10-CreERT2 high 2 9.1 8 36.4 8 36.4 4 18.1 0 0 22
Nr of clones Nr of units Nr of embryos Nr of litters Clones per unit
Wnt1-CreERT low 11 14 7 4 1.7 ± 0.3
Wnt1-CreERT high 64 77 36 14 0.8 ± 0.1
Sox10-CreERT2 low 1 9 4 2 0.1 ± 0.1
Sox10-CreERT2 high 63 45 18 9 1.4 ± 0.2
 Clonal density for cohorts of cells belonging to the rare color category
Nr of clones per unit 0 % 1 % 2 % 3 % >3 % Total of units
Wnt1-CreERT low 7 50.0 5 35.7 0 0 2 14.3 0 0 14
Wnt1-CreERT high 32 41.5 31 40.3 9 11.7 5 6.5 0 0 77
Sox10-CreERT2 low 8 88.9 1 11.1 0 0 0 0 0 0 9
Sox10-CreERT2 high 12 26.7 13 28.9 10 22.2 10 22.2 0 0 45
 Clonal distribution per DRG-unit
 Clonal distribution per DRG-unit
B
 Clonal density for 2-8 cell cohorts
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4.1.5.6 Statistical evaluation of cell fates adopted by premigratory and 
migratory NC cells 
 
Our observations suggested that the majority of NC cells are multipotent both at the 
premigratory stage and, intriguingly, also at the migratory stage. To verify our results, 
we analyzed each data set considering the color of the observed putative clone, the 
derivative where we observed it, and its size. Defining the exact cell-cycle length and 
its variation during a period of 41 hr for each specific derivative would have been 
extremely difficult and prone to mistakes. Thus, we applied a static framework 
instead of a complete dynamic modeling approach. To distinguish between a 
predetermined and a multipotent framework for both Wnt1-CreERT and Sox10-
CreERT2 embryos, at low and high recombination levels, we calculated the 
respective probabilities of observing the specific clone configuration. Because the 
statistical model is based on count data, these probabilities are equivalent to 
likelihoods and thus twice the negative log of the likelihood ratio (deviance) was used 
to discriminate between the two frameworks (see 4.1.8 Supplemental Experimental 
statistical explanation). To simplify the interpretation, the numerical values of the 
deviance were discretized into no, weak, substantial, and strong evidence for a 
framework of multipotency (Figure 24). 
Based on this statistical evaluation, we first analyzed the cell cohorts (composed of 
two to eight cells from the same color) obtained with the Wnt1-CreERT embryos, 
pooling the data for low and high recombination densities. Strikingly, 65.1% (28 
cases out of 43) of all unicolored cell cohorts represented clones of the categories 
strong or substantial evidence for multipotency (Figures 24A and 24C). 27.9% (12 
cases out of 43) of all cohorts analyzed were multipotent clones with more than two 
fates. In 18.6% (8 cases out of 43) of the clones, a progeny remained in the dNT. 
Half of these clones also contained cells in ventral structures as well as the DLP, 
demonstrating the broad developmental potential of the corresponding mother cells. 
Moreover, all unicolored cell cohorts with derivatives in the DLP (18.6%, 8 cases out 
of 43) belonged to the category strong evidence for multipotency and contained NC-
derived cells in at least one additional structure. Of all the cases analyzed, only 
25.6% (11 cases out of 43) were belonging to the category no evidence for 
multipotency, indicating that lineage-restricted progenitor cells represent a minor 
fraction of premigratory NC cells (Figures 24A and 24C). 
Unexpectedly, clones with strong or substantial evidence for multipotency were by far 
the most frequent categories also in the Sox10-CreERT2 embryos (70.2%, 33 cases 
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out of 47) (Figures 24B and 24C). 31.9% (15 cases out of 47) of all cohorts analyzed 
were multipotent clones with progeny in only two derivatives (bi-fated) and 38.3% (18 
cases out of 47) were clones with progeny in more than two derivatives; 24.2% (8 
cases out of 33) of the unicolored cell cohorts with substantial or strong evidence for 
multipotency contributed to the DLP (Figure 24B). Of note, all of these were 
multipotent clones with cells in the DLP and in at least one other structure, and half 
of the DLP-clones contained cells in as many as three additional NC derivatives. 
Similar to premigratory NC cells, fate-restricted migratory NC cells showing no 
evidence for multipotency were 21.3% (10 out of 47) of all clones (Figures 24B and 
24C). 
To assess the robustness of our statistical evaluation, we performed a sensitivity 
analysis by altering various parameters in the calculation of the multipotency 
likelihoods. When the minimum and maximum clone sizes were varied (rather than 
considering only clones of two to eight cells), the resulting clone categories were still 
predominantly strong and substantial evidence for multipotency (Figure 24D). 
Furthermore, we perturbed the values of color frequency (rcolor) and derivative size 
(dderiv) (see 4.1.8 Supplemental statistical evaluation) by multiplying the probabilities 
and fractions by a random number between 1/3 and 3 (uniformly distributed), 
followed by rescaling. The analysis was carried out as described in 4.1.8 
Supplemental statistical evaluation, and the differences with respect to the evidence 
classification shown in Figures 24A and 24B were recorded. Figure 24E shows the 
results for 100 of such simulations and reveals that in both Wnt1-CreERT and 
Sox10-CreERT2 embryos, the categorization of the clones into no, weak, substantial, 
and strong evidence for multipotency was not (low recombination densities) or only 
moderately changed (high recombination densities). Thus, even when challenged by 
modulating various parameters, our statistical evaluation consistently revealed that 
the majority of premigratory and migratory NC cells were multipotent rather than fate 
restricted. 
The statistical analysis presented in Figure 24 was performed under the stringent 
criteria that the maximum clone size was eight cells. However, this clone size might 
not fully recapitulate the heterogeneity of embryonic cell populations, since it does 
not take into account the possibility that faster dividing cells might be present in 
distinct locations. Moreover, parameter modulation in our statistical analysis not only 
provided clear evidence for multipotency of NC cells but also predicted that cell 
cohorts larger than the chosen range of two to eight cells could also be actual clones. 
Therefore, we performed a further analysis, in which we considered all unicolored 
cell cohorts found in defined trunk segments of Wnt1-CreERT and Sox10-CreERT2 
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mice. To increase the probability of clonal tracing, we restricted this analysis to cell 
cohorts expressing rare colors only. The clonal density was low, ranging from 0.1 ± 
0.1 to 1.7 ± 0.3 clones per unit (Table 4B). 
 
 
TABLE 4: Clonal density analysis for cohorts of cells belonging to the rare color 
category (rfp cfp, rfp yfp, yfp cfp, gfp).  
List of the total number of clones, of DRG-units, of embryos, and of litters analyzed for both 
Wnt1-CreERT and Sox10-CreERT2 line at low and high recombination densities. The data 
refer to Figures 26 and 27. The average of clones per unit is provided ± SEM. The clonal 
distribution per DRG-unit is given by the absolute numbers and the respective percentages of 
numbers of clones observed per DRG- unit. 
 
By applying the statistical analysis mentioned above, we observed that the vast 
majority of the clones fell into the categories of strong or substantial evidence for 
multipotency, both in the Wnt1-CreERT line (76.4%, 42 cases out of 55) and in the 
Sox10-CreERT2 line (75%, 36 cases out of 48) (Figure 26). Thus, including larger 
clones into our analysis did not affect the proportion of multipotent clones originating 
from premigratory and migratory NC cells, respectively, further demonstrating the 
robustness of our statistical analysis. 
 
Table S2A related to Figure 3, S3 and S2B related to Figure 4, S4
A
Nr of clones Nr of units Nr of embryos Nr of litters Clones per unit
Wnt1-CreERT low 14 14 7 4 1.0 ± 0.3
Wnt1-CreERT high 29 36 18 7 0.8 ± 0.1
Sox10-CreERT2 low 11 9 4 2 2.2 ± 0.2
Sox10-CreERT2 high 36 22 10 5 1.6 ± 0.2
Nr of clones per unit 0 % 1 % 2 % 3 % >3 % Total of units
Wnt1-CreERT low 4 28.6 8 57.1 0 0 2 14.3 0 0 14
Wnt1-CreERT high 16 44.4 11 30.6 9 25.0 0 0 0 0 36
Sox10-CreERT2 low 1 11.1 5 55.6 3 33.3 0 0 0 0 9
Sox10-CreERT2 high 2 9.1 8 36.4 8 36.4 4 18.1 0 0 22
Nr of clones Nr of units Nr of embryos Nr of litters Clones per unit
Wnt1-CreERT low 11 14 7 4 1.7 ± 0.3
Wnt1-CreERT high 64 77 36 14 0.8 ± 0.1
Sox10-CreERT2 low 1 9 4 2 0.1 ± 0.1
Sox10-CreERT2 high 63 45 18 9 1.4 ± 0.2
 Clonal density for cohorts of cells belonging to the rare color category
Nr of clones per unit 0 % 1 % 2 % 3 % >3 % Total of units
Wnt1-CreERT low 7 50.0 5 35.7 0 0 2 14.3 0 0 14
Wnt1-CreERT high 32 41.5 31 40.3 9 11.7 5 6.5 0 0 77
Sox10-CreERT2 low 8 88.9 1 11.1 0 0 0 0 0 0 9
Sox10-CreERT2 high 12 26.7 13 28.9 10 22.2 10 22.2 0 0 45
 Clonal distribution per DRG-unit
 Clonal distribution per DRG-unit
B
 Clonal density for 2-8 cell cohorts
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FIGURE 26: Mathematical evaluation of NC cell fate determination for all the clones of 
the rare color category without size restriction.  
List of the clonal frameworks for premigratory (26A) and migratory (26B) NC cells ordered by 
degree of evidence for multipotency. Both conditions of low and high recombination densities 
were pooled to compare the potentials of premigratory versus migratory NC cells. We listed 
and analyzed statistically all the clones with rare colors (rfp cfp, rfp yfp, yfp cfp, gfp) that were 
observed in 25 Wnt1-CreERT embryos (50 DRG-units, 11 litters) and in 14 Sox10-CreERT2 
embryos (31 DRG-units, 7 litters), respectively. 
 
 
 
 
Figure S4 related to Figure 3
A B
strong evidence
substantial evidence
weak evidence
no evidence
s ong vidence for multipotency
substantial evidence for multipotency
weak evidence for multipotency
no evidence for multipotency
1 rfp cfp 3 14 10 2 2 31
2 rfp cfp 4 6 7 13 1 31
3 rfp yfp 9 1 4 2 1 17
4 rfp cfp 2 4 1 1 8
5 rfp yfp 3 55 3 3 64
6 rfp cfp 1 2 1 4
7 rfp cfp 1 1 1 3
8 yfp cfp 1 6 19 10 36
9 rfp yfp 1 7 8
10 rfp yfp 13 1 14
11 rfp yfp 1 1 2
12 rfp yfp 1 1 2
13 rfp yfp 7 5 5 22
14 rfp cfp 1 3 1 5
15 rfp cfp 1 1 2 4
16 rfp cfp 1 2 3 6
17 rfp cfp 11 1 1 13
18 yfp cfp 15 3 1 19
19 yfp cfp 3 6 6 15
20 rfp yfp 10 10 10 30
21 rfp cfp 2 1 2 5
22 rfp cfp 1 1 1 3
23 rfp cfp 4 2 1 7
24 rfp cfp 1 6 7
25 rfp yfp 2 1 3
26 rfp yfp 1 6 7
27 rfp cfp 10 1 11
28 rfp cfp 1 1 2
29 rfp yfp 1 3 4
30 rfp yfp 1 3 4
31 rfp yfp 1 3 4
32 rfp yfp 8 1 9
33 rfp cfp 1 2 3
34 rfp cfp 1 1 2
35 rfp cfp 1 1 2
36 rfp cfp 3 7 2 12
37 rfp cfp 7 21 6 34
38 rfp cfp 37 3 7 47
39 rfp cfp 8 7 16 31
40 rfp cfp 7 3 4 14
41 gfp 6 2 8
42 gfp 3 4 7
43 rfp cfp 2 5 7
44 rfp cfp 3 2 5
45 rfp cfp 3 2 5
46 rfp cfp 2 2 4
47 rfp yfp 9 9
48 rfp cfp 25 25
49 rfp cfp 4 4
50 rfp yfp 2 2
51 gfp 8 8
52 rfp yfp 6 6
53 rfp cfp 3 3
54 rfp cfp 5 5
55 rfp yfp 3 3
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4.1.5.7 Multipotency assessed by differentiation marker analysis 
 
During NC development, fate segregations are accompanied by spatial segregations 
of the resulting cell lineages. Therefore, a clone simultaneously located to multiple 
structures represents the progeny of a multipotent mother cell (Figures 24 and 26). 
However, additional fate decisions are made within certain NC-derived structures, 
such as the DRG and SG, where neuronal lineages segregate from satellite glia. A 
multipotent clone with cells in DRG and SG could thus be a neuron-only clone 
consisting of different types of neurons (sensory, autonomic), a glia-only clone with 
distinct types of glia (Woodhoo and Sommer, 2008), or a mixed neuron-glia clone. To 
address this issue, we performed an additional clonal analysis, taking into 
consideration not only the location of unicolored NC cells but also the expression of 
well-defined differentiation markers, such as Brn3a for sensory neurons, tyrosine 
hydroxylase (TH) for autonomic neurons, and Sox10 for glial and melanocytic cells. 
Groups of cells belonging to the rare color category were considered, without clonal 
size restriction (Figure 27). Only 4 out of 20 clones (Wnt1-CreERT embryos) and 2 
out of 16 clones (Sox10-CreERT2 embryos) were lineage restricted, respectively, 
meaning that these clones were not only confined to a single derivative, but they 
were also expressing only one marker of differentiation. Of note, of the 16 clones in 
Wnt1-CreERT embryos that were not lineage restricted, only one clone contained 
only neurons and no glia (clone ID 11; Figure 27A), while the other 14 clones were 
mixed neuron-glia clones. Likewise, one clone in Sox10-CreERT2 embryos 
contained sensory and sympathetic neurons but no glia (clone ID 11, Figure 27C), 
while all other multipotent clones were mixed neuronal and glial. Intriguingly, some of 
the cases that would have been considered to represent lineage-restricted clones 
based on their location, turned out to be at least bipotent, expressing multiple 
markers of differentiation (Figure 27A, clone IDs 13, 14, 15, and 16; Figure 27C, 
clone IDs 13 and 14). These data substantiate our findings that single premigratory, 
as well as single migratory NC cells, mostly generate daughter cells that localize to 
distinct target structures and acquire different fates. 
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Figure 27. Quantitative clonal assays combined with differentiation marker analysis  
(A and C) Lists of the clonal frameworks for premigratory (A) and migratory (C) NC cells 
ordered by degree of evidence for multipotency. Only clones belonging to the rare color 
category where analyzed, and no size restriction was applied. Each single clone was 
analyzed in regard to its location and expression of the following differentiation markers: 
Brn3a, a sensory neuron marker; TH, a sympathetic neuron marker; and Sox10 that at this 
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developmental stage labels glial and melanocytic lineages. (B and D) Schemes summarizing 
the distribution of entire clones respectively found in Wnt1-CreERT and Sox10-CreERT2 
embryos at high recombination densities. (Bi–Biii and Di–Diii) Examples of embryonic 
sections through NC derivatives that comprise rare color-expressing cells belonging to the 
clones shown in (B) and (D), respectively. For numbers of analyzed embryos, see 4.1.7 
Experimental Procedures. Scale bars: 50 mm. 
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4.1.6 Discussion 
 
A fundamental question in developmental biology is how the distinct cell types of a 
given organ are established. Although it is thought that organ formation and 
homeostasis rely on the activity of organ-specific multipotent stem cells, several 
recent publications demonstrated that heterogeneous populations of restricted 
progenitor cells, instead of multipotent mother cells, are often involved in the 
formation of vertebrate body structures (Lehoczky et al., 2011; Park et al., 2012). 
This issue is of particular interest with respect to the NC, because this structure 
represents one of the cell populations in the vertebrate embryo with the broadest 
developmental potential (Le Douarin et al., 2008). Several studies demonstrated that 
at least upon isolation, the majority of NC cells display stem cell features, being 
multipotent and able to self-renew (Dupin and Sommer, 2012). Others, however, 
reported the presence of many lineage-restricted cells in NC cell cultures (Harris and 
Erickson, 2007; Henion and Weston, 1997), suggesting that multipotency might be 
dependent on or even induced by culture conditions. The recent establishment of 
transgenic mouse lines allowing low-density genetic recombination makes it possible 
to trace the lineage of single cells without the need to expose the cells to varying 
conditions. For instance, the R26R-Confetti reporter was used to track cells in the 
postnatal gut (Snippert et al., 2010). Here we applied this system to demonstrate that 
in vivo the NC cell population is primarily composed of multipotent cells rather than of 
a mixture of lineage-restricted precursors. 
The R26R-Confetti mouse model offers the possibility to distinguish several clones 
from each other in the same specimen. Importantly, clonal analysis can be made in 
this system without prior cell isolation, transplantation, or any disturbance of the 
cellular microenvironment that might reactivate a ‘‘stemness’’ program (Snippert and 
Clevers, 2011). However, like in all retrospective lineage-tracing studies, redundant 
recombination events have to be excluded in the R26R-Confetti system to ensure 
clonal identification. To this end, we took advantage of the fact that theoretically 
equiprobable fluorescent protein combinations were expressed at different 
frequencies. In Wnt1-CreERT mice, we were able to monitor the development of 
single premigratory NC cells at a low clonal density in vivo and to compare their fates 
with those of migratory Sox10-CreERT2-traced NC cells. Surprisingly, the range of 
fates and clonal distribution was very similar for these two settings. Most clones were 
distributed over several NC target structures and only in a minority of cases 
premigratory and migratory NC cells were fate restricted. Importantly, our statistical 
evaluation revealed a very high probability for multipotency, independent of color 
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expression and recombination density. Moreover, subjecting our statistical evaluation 
to a sensitivity assay by altering multiple parameters, such as expected clone sizes 
and dimensions of the NC derivatives, confirmed the robustness of our method and 
the finding that most NC cells are multipotent. 
Furthermore, the vast majority of clonal derivatives were not only spread over distinct 
locations but also acquired distinct fates within given target structures. In particular, 
combining quantitative clonal assays with expression analysis of differentiation 
markers showed that the majority of NC cells, at least at the early stages analyzed, 
can neither be divided into ‘‘sensory-only’’ versus ‘‘sympathetic-only,’’ nor into 
‘‘neuron-only’’ versus ‘‘glia-only’’ precursors. 
In chicken embryos, DLP-colonizing NC cells are separate from ventrally migrating 
cells and belong to a late emigrating population (Erickson et al., 1992; Henion and 
Weston, 1997). We did not address here whether late emigrating NC cells 
exclusively destined to the DLP exist in mice. However, all clones with DLP 
contribution were multipotent in our study and contained cells in at least one ventral 
derivative. Thus, even after their emigration from the dNT, at least some mouse NC 
cells that will generate DLP derivatives maintain the potential to produce ventral 
neural cells. 
Previous studies proposed that premigratory NC cells of the trunk are fate restricted 
(Krispin et al., 2010; Nitzan et al., 2013). This result differed from earlier work that 
indicated the presence of multipotent premigratory NC cells, including ‘‘resident’’ 
precursor cells for both CNS and NC in the dorsal neuroepithelium (Bronner-Fraser 
and Fraser, 1988; Bronner-Fraser and Fraser, 1989). These discrepancies might 
have been due to technical challenges and to differences in the stages and location 
of the labeled premigratory NC cells in the dNT. Although we cannot exclude 
differences in mechanisms of lineage segregation between avian and mammalian 
systems, our findings support the model in which the majority of NC cells are 
multipotent not only at the population but also at the single cell level and that 
multipotency is maintained in NC cells even after their emigration from the neural 
tube. However, we cannot rigorously exclude the existence of fate-restricted NC 
cells, as we found a minority of NC cells that appeared to give rise to only one 
derivative. It is therefore possible that the NC cell population contains a fraction of 
fate-restricted cells. 
Even though most NC cells were multipotent in our study, the actual cell type 
composition varied in each clone, with some multipotent clones acquiring all possible 
fates and others producing only two cell types. This reflects the heterogeneous 
behavior of NC cells also seen in cell culture conditions permissive for multiple fates, 
	   59	  
where multipotency is frequently observed, but not fully realized by all cells (see e.g., 
Dupin et al., 2010; Stemple and Anderson, 1992). This heterogeneous behavior can 
be switched to a virtually homogeneous response when NC cells are exposed to 
instructive growth factors either in vitro (Shah et al., 1994) or in vivo (Hari et al., 
2012). It remains to be shown whether, normally, fate choices by multipotent NC 
cells in vivo are purely stochastic. 
Of note, we did not observe a pattern of restricted fate choices when we compared 
migratory with premigratory NC cells, speaking against gradual lineage restriction 
during NC development (Krispin et al., 2010; Le Douarin et al., 2008) at least during 
the time window analyzed. Therefore, the multiple and variable fates adopted by NC 
cells appear to reflect the dynamic behavior of stem cells in vertebrates as opposed 
to more deterministic lineage acquisitions observed in species such as C. elegans 
(Morrison et al., 1997). 
Upon recombination at the premigratory stage, we found clones with recombined 
cells retained in the dNT, in addition to cells in NC derivatives. This may suggest an 
asymmetric division of NC cells and that a resident ‘‘stem cell’’ population is 
established in the dorsal midline. Moreover, multipotency was maintained in 
migratory NC cells. Together, these findings are consistent with the hypothesis that 
NC stem cells (NCSCs) as originally characterized in cell culture (Stemple and 
Anderson, 1992) might not only be in vitro stem cells (Smith, 2006) but actually exist 
in vivo. In support of this hypothesis, undifferentiated NC- derived cells in the sciatic 
nerve were shown before to be able to self-renew in vivo and to maintain their 
multipotency as revealed upon isolation (Morrison et al., 1999). However, to 
demonstrate self-renewal and maintenance of multipotency by single NC cells in vivo 
without cell isolation or disturbing the cellular microenvironment would be technically 
challenging due to the dissemination of NC cells within a short time period. 
Concluding, our study demonstrates that the majority of NC cells are multipotent, 
both at the premigratory and at the migratory stage. 
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4.1.7 Experimental procedures 
 
4.1.7.1 Mice 
Mice homozygous for the R26R Confetti allele (Snippert et al., 2010) were crossed 
with the two inducible mouse lines Wnt1-CreERT (Zervas et al., 2004) and Sox10-
CreERT2 (Simon et al., 2012). All the embryos used in the analyses were derived 
from a 2 hr time-mating. Lineage tracing of premigratory NC cells at low and high 
recombination densities was achieved with pregnant Wnt1-CreERT R26R-Confetti 
homozygous females, injected at E9.0. The animals were injected intraperitoneally 
(i.p.) with a single limiting dose of 7.5 mg and 50 mg TM/g body weight for low and 
high recombination densities, respectively. Similarly, to recombine migratory NC 
cells, we injected i.p. pregnant Sox10-CreERT2 R26R-Confetti homozygous animals 
at E9.0 with a single dose of 50 mg or 150 mg TM/g body weight to induce low or 
high recombination densities, respectively. Finally, embryos were collected at E10.5, 
41 hr post- TM injection. Animal experiments were approved by the veterinary office 
of the Canton of Zurich, Switzerland. 
 
Embryo numbers Number of embryos used for data presented in Figure 20  
To calculate the color densities for the Wnt1-CreERT line we analyzed 7 embryos 
(14 DRG-unit, 4 litters) and 18 embryos (36 DRG-unit, 7 litters) at low and at high 
recombination densities, respectively. To measure the color frequencies for the 
Sox10-CreERT2 line we analyzed 4 embryos (9 DRG-units, 2 litters) and 10 embryos 
(22 DRG-units, 5 litters) at low and high recombination densities, respectively. 
Number of embryos used for data presented in Figure 22 
To calculate the percentage of recombined cells per derivative in the Wnt1-CreERT 
line we analyzed 7 embryos (14 DRG-units, 4 litters) and 18 embryos (36 DRG-units, 
7 litters) at low and high recombination densities, respectively. For the Sox10- 
CreERT2 line we analyzed 4 embryos (9 DRG-units, 2 litters) and 10 embryos (22 
DRG-units, 5 litters), respectively. 
Number of embryos used for data presented in Figure 24 
The clones observed in the Wnt1-CreERT line were obtained analyzing 7 Wnt1- 
CreERT low embryos (14 DRG-units, 4 litters) and 18 Wnt1-CreERT high embryos 
(36 DRG-units, 7 litters). The clones observed in the Sox10-CreERT2 line were 
obtained analyzing 4 Sox10-CreERT2 low embryos (9 DRG-units, 2 litters) and 10 
Sox10- CreERT2 high embryos (22 DRG-units, 5 litters). 
Number of embryos used for data presented in Figure 27 
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The clones of the Wnt1-CreERT line were obtained by analyzing 18 Wnt1-CreERT 
high embryos (41 DRG-units, 7 litters). The clones of the Sox10-CreERT2 line were 
obtained by analyzing 8 Sox10-CreERT2 high embryos (23 DRG-units, 4 litters). 
 
4.1.7.2 Immunofluorescence, whole mount staining and SeeDB clearing 
For immunohistochemistry, 10µm-thick cryosections were processed as previously 
described (John et al., 2011). Primary antibody was used as follows: mouse anti- 
NF160 (1:300; Sigma, N-5264), rabbit anti-Sox10 (1:250; Abcam, ab27655), mouse 
anti-Brn3a (1:100; Millipore, MAB1585), mouse anti-tyrosine hydroxylase (1:200; 
Sigma, T1299). As a secondary antibody the DyLight 649 Donkey anti-mouse IgG 
(H+L) (1:300; Jackson, 715-495-150), DyLight 649 Goat anti-rabbit (1:300; Jackson, 
111-495-003), Alexa Fluor 488 Goat anti-mouse (1:300; Invitrogen, A-11029). lacZ 
reporter gene expression was detected as previously described (Hari et al., 2012). 
For 3D imaging the whole mount staining with anti-NF160 (1:250; Sigma, N-5264) 
and the SeeDB clearing protocol were applied as previously described (Ke et al., 
2013). 
 
4.1.7.3 Microscopy 
Images were acquired using a Leica CTR600 microscope and a Confocal Laser 
Scanning Microscopy (Leica CLSM SP5). For the Rosa four-color imaging, scans 
were performed in a series for fluorescent protein excitation as described in Snippert 
et al. (2010). 
 
4.1.7.4 Data Analysis 
The data analysis was performed using R version 3.1.1. R Development Core Team 
(http://www.R-project.org). 
 
4.1.8 Supplemental statistical explanation 
 
4.1.8.1 Assumptions of the statistical model 
 
The statistical analysis is based on the following assumptions: 
1. Within each mouse line and recombination density, each embryo is 
independent  
2. Within each embryo, each DRG-unit is independent  
3. The development and migration is color-independent  
4. Each mother cell leads to at least two cells  
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5. There is at most one mother cell per color and corresponding derivative(s)  
These are typical assumptions and essentially imply: By 1 and 2, the individual 
sections from all embryos (within a particular mouse line and recombination) can be 
taken as replicates. The available data does not show any indication against these 
assumptions. By 3, we can – by appropriately taking into account the relative color 
frequencies – use each color individually. At our current state of knowledge there is 
no competition between the individual colored cells. Assumption 4 implies that no 
mother cell gets lost or dies and that there is at least one replication. Assumption 5 is 
justified as we restrict the analysis to at most eight cells per color (for larger cell 
numbers see below). 
 
In the following we describe in some detail how the probabilities of observing a 
particular configuration of cell counts (Figure 24, all the cohorts of 2-8 cells) in the 
five derivatives (dNT, DRG, SG, VR, DLP, Table 2) for each color (Table 1) under the 
respective framework (predetermination or multipotency) was calculated. The 
different colors appear with different relative expression frequencies, denoted by 
rcolor. Similarly, the derivative sizes vary and the relative derivative sizes are 
denoted by dderiv. These two quantities are unknown and we estimated their values 
from frequency tables (Figures 20L, 20M, 22G, and Table 1, 2). We assumed that 
each embryo and DRG-unit are independent from one another, and that embryonic 
development and cell migration are color-independent as well and thus the product 
rcolor dderiv is the probability of observing the particular color in the particular 
derivative. We represented each configuration of cell counts as a quintuple 
(corresponding to the five derivatives) with binary entries, which equaled one if cells 
were observed in the corresponding derivative and zero otherwise. We denoted such 
a binary “observed” value with ocolor.deriv for any of the colors and five derivatives. 
 
To calculate the probability of observing a particular configuration, we considered 
cases of mother cell configurations that lead to the corresponding configuration. Not 
all mother cell configurations develop with equal probability into the particular 
configuration and hence this probability has to be taken into account (this approach 
is formally termed the of law of total probability). In the case of predetermination, the 
mother cell configuration is identical to the derivative configuration and thus, one only 
needs to calculate the probability of observing an identical mother cell configuration. 
This probability consists of the product of the probabilities of having a colored cell in 
the derivative whenever we observed one and of one minus that probability 
whenever we did not observe one: 
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P( configuration ) = P( mother cell configuration ) = Πderiv (rcolordderiv)ocolor.deriv 
(1-rcolordderiv)(1-ocolor.deriv), 
where rcolor, dderiv and ocolor.deriv are as above. 
In the case of multipotent cells, it has to be taken into account that the clones migrate 
to the derivatives with probabilities according to the estimated derivative size (Figure 
22 and Table 2). The probability to observe a mother cell with a specific color is 
proportional to the relative expression frequency of that color (Figures 20L and 20M, 
Table 1). Hence, 
P( configuration ) = P( observing mother cell ) P( migration to derivatives ) = rcolor 
Πderiv dderivocolor.deriv (1-dderiv)(1-ocolor.deriv) 
where rcolor, dderiv and ocolor.deriv are as above. The precise stochastic 
assumptions of the model, a sensitivity analysis of the involved parameters and 
further technical insights are given below. 
 
4.1.8.2 Sensitivity Analysis 
 
The cutoffs to classify the deviance (twice the negative log of the likelihood ratio) are 
-2log(.1), -2log(.01), -2log(.001) resulting in the (approximate) bins (-∞, 4.6), (4.6, 
9.2), (9.2, 13.8) and (13.8, ∞) for “no”, “weak”, “substantial” and “strong” evidence. 
Choosing slightly different cutoffs does not change the result. In many cases, the 
weak and substantial bins are empty. Note that a zero deviance is equivalent to 
equal probabilities of both frameworks and thus a “no”-evidence case does not imply 
that a predetermined case was more likely. Figure 24D summarizes and compares 
the likelihoods when the minimum/maximum clone sizes are varied according to the 
pairs 4-8, 1-16, 2-16, 2-8, 2-6. The results do virtually not depend on these sizes. 
We have also perturbed the values of the relative color frequencies (rcolor) and 
relative derivative size (dderiv) by multiplying them by a random number between 1/3 
and 3 (uniformly distributed) followed by a rescaling. The analysis has been carried 
out as described above and the differences with respect to the classification for the 
evidence of multipotency has been recorded. Figure 24E shows the results for 100 of 
such simulations. Each of the 16 barplots shows the proportion of the 100 cases that 
changed, white indicates no change, redish to red cases that are added and greenish 
to green cases that are lost. For the low recombination rates, the results are virtually 
the same (white dominates the barplots). For the high recombination rates moderate 
changes occur. For example, for the results of the analysis of the Sox10-CreERT2 
high embryos, 1/36 of the cases are classified as substantial evidence (clone ID 25, 
Figure 25D). In one third of the perturbed cases this proportion has not changed. In 
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one fifth of the cases there is no case marked as substantial evidence and in 33% 
(10%, 2%) there are 2/36 (3/36 and 4/36) cases marked as substantial evidence, 
respectively. 
 
4.1.8.3 Additional Comments 
 
The presented methodology is “frequency based”. Naturally, a Bayesian framework 
would be possible. In such a framework, priori information about our beliefs in 
multipotency needs to be specified and then enters the calculations. A fully Bayesian 
specification would imply that all other parameters (relative color frequencies, relative 
derivative sizes, etc.) would need to be considered as random and would be 
equipped with a priori distribution. We do not have any priori knowledge about these 
parameters and “uniform”/uninformative priors would be the only possible choice. 
Such a uniform priori would essentially lead to the same result as a frequency 
setting. 
The calculation of the configuration probabilities for both the predetermined and 
multipotency cases can be unified through the use of the law of total probability. 
More precisely, these probabilities can be expressed as follows. 
P( configuration ) = Σk P( configuration | mother cell configuration k ) P( mother cell 
configuration k )  
In the case of predetermination, the mother cell configuration is identical to the 
derivative configuration; hence the conditional probabilities are equal to one in the 
case the derivative configuration is equal to the mother cell configuration and zero 
otherwise. A particular mother cell configuration is characterized by having or not 
having the colored cell in a particular derivative. Therefore, 
P( configuration ) = P( same mother cell configuration ) 
= Πderiv (rcolordderiv)ocolor.deriv (1-rcolordderiv)(1-ocolor.deriv), 
where rcolor, dderiv and ocolor.deriv are as in the main text. 
In the case of multi-fated cells, the mother cell configuration is derivative independent 
and consists of a particularly colored clone (all other colored cells lead to zero 
conditional probability). It has to be taken into account that the clones migrate to the 
derivatives with probabilities according to the estimated derivative size. This 
migration is color independent. Hence 
P( configuration ) = P( configuration | mother cell with appropriate color ) P( mother 
cell with appropriate color ) = Πderiv dderivocolor.deriv (1-dderiv)(1-ocolor.deriv) 
rcolor where rcolor, dderiv and ocolor.deriv are as above. 
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Assumption 5 excludes the possibility of several mother cells in the case of 
multipotency as well. These cases are (statistically) very rare compared to one single 
mother cell. Among these few cases, some would be manifested as predetermination 
and could not be used to discern the frameworks. All others would slightly increase 
the probability of observing multipotency and thus shift the deviances in direction 
towards “strong evidence”. Hence, we can safely ignore these rare cases. 
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4.2 The Roles of Sall4 in Melanoma 
Unpublished data 
Arianna Baggiolini1, Johanna Diener1, Sandra Varum1, Jessica Häusel1, Gaetana 
Restivo1, Phil Cheng2, Mitchell P. Levesque2, Mathias Treier3, Reinhard Dummer2, 
Lukas Sommer1. 
 
1Institute of Anatomy, University of Zurich, 8057 Zurich, Switzerland 
2 Department of Dermatology, University Hospital Zurich, 8091 Zurich, Switzerland. 
3 Max Delbrück Center for Molecular Medicine, 13125 Berlin-Buch, Germany. 	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4.2.1 My contribution to this work 
 
• Design of the experiments 
• Execution of all experiments and collection of data, with exception of Figure 
28 which was performed together with Sandra Varum in the frame of her 
project; Figure 29B, C, D and Figure 30A, B, C which were produced by 
Johanna Diener and Gaetana Restivo 
• Breeding of mice used in the study, including genotyping, tamoxifen injection 
and collection of mouse material 
• Production of the figures 	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4.2.2 In brief 
Sall4 is a zinc-finger transcription factor crucial for ES cell self-renewal and 
pluripotency. SALL4 has been shown to play a role in several cancer types, but its 
role in melanoma formation and progression has not been investigated so far. By 
combining mouse genetics and in vitro analysis of human melanoma cell lines, we 
found first indications suggesting that SALL4 may be an important factor in primary 
melanoma and metastasis formation. 
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4.2.3 Summary 
 
Sall4 is a zinc-finger transcription factor crucial for the maintenance of self-renewal 
and pluripotency of ES cells. Moreover, SALL4 has been be related to tumorigenesis 
and high expression of SALL4 is linked to worse patient survival and metastasis 
formation in several cancer types. 
SALL4 function in melanoma, however, has so far been unknown. In this study, we 
show that Sall4 is necessary for primary melanoma formation in the Tyr::NRasQ61K 
Ink4a-/- melanoma mouse model, but that surprisingly Sall4 loss is linked to worse 
survival performance. Interestingly, SALL4 was downregulated both in vitro and in 
xenotransplants during EMT and SALL4 knockdown in a proliferative human 
melanoma cell line induced an EMT signature. Thus, our findings suggest a novel 
role of SALL4 in tumorigenesis that is characteristic of melanoma.   
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4.2.4 Introduction 
 
Melanoma is a malignancy of the melanocytes, which are the pigment-producing 
cells of NC-origin. During development melanocytes migrate extensively through the 
embryonic body and find location mostly in the skin, as well as in the iris and the 
rectum. Cutaneous melanoma, which originates from the melanocytes of the skin, is 
a common malignancy in the Western world. Cutaneous melanoma is one of the 
most aggressive cancers and it is indeed responsible for 75% of deaths related to 
skin cancer (Schadendorf et al., 2015). One of the characteristics that makes 
melanoma particular aggressive is its high metastatic potential. Melanoma cells can 
in fact often metastasize to proximal and distant organs and their invasive capacity is 
to some extents reminiscent to the great migratory and invasive properties of the NC 
cells. This has contributed to the hypothesis that NC-derived malignant cells may 
exploit developmental regulatory programs to gain an advantage over normal non-
malignant cells and to progress to more advanced stages of the disease. Indeed, 
several studies on melanoma showed that malignant cells reactivate or exploit genes 
such as Snail, Twist and Sox10 (Shakhova et al. 2012; Shirley et al. 2012; Weiss et 
al. 2012), which are key transcription factors in the gene regulatory network 
controlling NC induction and migration (Sauka-Spengler and Bronner-Fraser, 2008).  
First we performed a microarray analysis on isolated mouse NC cells as well as on 
NC cells 6 hour primed for differentiation towards the mesenchymal, the neuronal 
and the glial lineage (Varum et al., unpublished). We obtained a list of 53 
transcription factors that were specifically expressed in the NC and that were 
downregulated in the primed NC counterparts. We decided to further study Sall4 as 
one of these 53 genes, since the zinc-finger transcription factor was known to be 
responsible for the great self-renewal and pluripotency capacities of ES cells (Zhang 
et al., 2006). 
Beyond its role in development, SALL4 was described to play a key function in a 
large number of cancers (Zhang et al., 2015). High levels of SALL4 are related to 
increased tumor proliferation, acquisition of pluripotency features, increased 
metastasis formation and overall to a worse patient outcome (Zhang et al., 2015). 
Whether SALL4 is expressed in melanoma and may play a role in this malignancy 
has not been investigated so far. In this study we now show that SALL4 is expressed 
in some proliferative human melanoma cell lines, while being absent in more invasive 
melanoma cell lines. Moreover, SALL4 is downregulated upon EMT induction both in 
vitro and in xenotransplants. Additionally, siRNA specific for SALL4 induces an EMT 
signature in proliferative melanoma cells. Interestingly, Sall4 loss in the 
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Tyr::NRasQ61K Ink4a-/- melanoma mouse model (Ackermann et al., 2005) prevents 
primary tumor formation, but unexpectedly results in worse survival of the cKO 
animals and in detection of recombined cells in their lymph nodes and lungs. 
Further investigations are now required to understand whether SALL4 loss is 
necessary and sufficient to allow EMT and whether SALL4 upregulation may prevent 
invasion.  
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4.2.5 Results 
 
4.2.5.1 Sall4 is a zinc-finger transcription factor expressed in NC cells 
 
We were initially interested in discovering new transcription factors responsible for 
the multipotency of the NC. To do this we dissected the neural tubes of wild type E9 
NRMI embryos and we derived NC explants (Figure 28A). NC cells were then 
cultured at the presence of different instructive factors for 6 hours. In particular we 
instructed NC cells to differentiate into the mesenchymal lineage (by application of 
TGF-b), the neuronal lineage (by BMP-2) and the glial lineage (by heregolin and 
forskolin). We then performed a microarray analysis compering the isolated NC cells 
(0 hours) to the NC cells that were primed for 6 hours towards a specific fate (Figure 
28B). We obtained a total of 53 transcription factors that were specifically expressed 
in NC cells and that were commonly downregulated upon the 6 hours of 
differentiation conditions (Figure 28C) (Varum et al., unpublished). 
Out of these 53 transcription factors we selected Sall4, that was one of the top ten 
mostly downregulated factors upon differentiation. Sall4 is known to be a crucial 
factor in the maintenance of the pluripotency and self-renewal of ES cells. Although, 
little is known about the function of Sall4 in NC biology, for exception of its role on the 
competence of the cranial NC cells to populate sensory ganglia (Barembaum et al., 
2004).  
To reveal the function of Sall4 in the NC, we produced Wnt1-Cre Sall4 lox/lox embryos 
in which Sall4 was specifically deleted in the premigratory NC cells. The embryos 
were not viable and they died at E 15.5 most likely by heart failure (data not shown). 
NC derivatives showed minor defects that were mostly rescued at later 
developmental stages for exception of the melanocytic lineage that was significantly 
reduced (data not shown). Most likely, the moderate phenotype was due to 
compensatory mechanisms by other members of the Sall family, phenomenon 
already documented in other contexts as during neural tube closure (Böhm et al., 
2008). 
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Figure 28. Sall4 is a transcription factor expressed in the NC cells and that is 
downregulated upon differentiation. 
(A) NC explants were isolated from the dorsal neural tube at E9. The NC cells were incubated 
for 6 hours at the presence of different instructive growth factors that induced their 
differentiation into the smooth muscle fate (TGF-b), the autonomic neuronal fate (BMP-2) and 
the glial fate (heregulin, HER, and forskolin, FSK). (B) Microarray analysis of NC cells and NC 
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cells previously incubated for 6 hours under differentiation conditions. (C) Summary of the 
microarray data indicating a total of 53 genes that were expressed in the NC cells and that 
were downregulated upon all three differentiation conditions.  
 
4.2.5.2 Increased SALL4 expression is associated with poor melanoma patient 
survival 
 
Previous results demonstrated that melanoma cells can exploit NC-specific 
regulatory programs and that these processes play an important role in melanoma 
formation and progression (Shakhova et al., 2012). Moreover, Sall4 loss during 
development seems to have a specific effect on the melanocytic lineage (data not 
shown), suggesting a possible role in melanoma. To investigate the relevance of 
SALL4 expression in skin cutaneous melanoma patients we analyzed the RNAseq 
and clinical data from the The Cancer Genome Atlas (TCGA, 
http://cancergenome.nih.gov/). Interestingly, when we compared SALL4 expression 
levels in primary tumors and lymph nodes, the patients with low levels of SALL4 
expression (SALL4 low group, 120 patients, median survival of 3587 days, Figure 
29A) showed a significantly better overall survival compared to patients with high 
SALL4 levels of expression (SALL4 high group, 120 patients, median survival of 
1960 days, Figure 29A), suggesting a potential role of SALL4 in melanoma. 
 
4.2.5.3 SALL4 is differentially expressed in human melanoma cell lines 
 
Intrigued by the fact that SALL4 expression levels may affect patient survival, we 
tested several human melanoma cell lines for its level of expression. Initially, we 
measured mRNA SALL4 levels in human melanoma cell lines and compared them to 
a human melanocytic cell line. SALL4 mRNA levels were remarkably higher in 
proliferative melanoma cell lines (defined by the Heurisic Online Phenotype 
Prediction (HOPP) analysis (Widmer et al., 2012); as e.g. M130423, M080423, 
M010817)) than in more invasive melanoma cell lines (M080310, M080214, 
M080201) when compared to SALL4 basal level of expression in a human 
melanocytic cell line (Figure 29B). 
Protein expression was reflecting mRNA levels and some highly proliferative 
melanoma cell lines expressed SALL4 protein (Figure 29C), while more invasive 
melanoma cell lines showed poor expression of its protein (Figure 29D). 
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Figure 29. Overall survival of skin cutaneous melanoma patients related to SALL4 
transcript levels and SALL4 expression in human melanoma cell lines. 
(A) Kaplan-Meier curves comparing overall survival of melanoma patients depending on the 
SALL4 transcript levels (primary melanoma and lymph node metastases) based on TCGA. 
(B) SALL4 transcript levels in human melanoma cell lines compared to a human melanocytic 
cell line. (C-D) SALL4 protein expression in human proliferative (C) and in invasive (D) 
melanoma cell lines. As a positive control we used the NTERA D1 cell line. 
 
4.2.5.4 SALL4 is downregulated in vitro and in xenotransplants during EMT 
 
The characteristic expression of SALL4 prompted us to investigate whether its 
expression would change in a human proliferative melanoma cell line, as M010817, 
under conditions that would induce EMT. We thus treated the M010817 line with 
TGFb-1, which is a known EMT inducer (Xu et al., 2009). Interestingly, concomitant 
with an increase in the transcript levels of N-cadherin and p75 neurotrophin receptor 
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(p75NTR) (data not shown), we observed a significant decrease in SALL4 expression. 
These data suggest that during the process of EMT a proliferative human melanoma 
cell line downregulates SALL4. 
To corroborate our results, we analyzed SALL4 expression in M010817 upon 
overexpression of the EMT inducer p75NTR (Restivo et al., unpublished data). We 
infected the M010817 line with an empty vector (CMVTO) and with a vector 
overexpressing p75NTR (CMVTO p75NTR) and we then xenotransplanted these cells 
into nude mice. The analysis of the xenotransplants showed that the tumor 
originating from CMVTO M010817 cells was expressing SALL4 protein (Figure 30B), 
while the xenotransplant overexpressing p75NTR (CMVTO p75NTR) completely lost 
SALL4 expression (Figure 30C). 
These data suggest that human proliferative melanoma cell lines that express SALL4 
lose its expression upon EMT induction. 
 
4.2.5.5 SALL4 loss is sufficient to induce an EMT signature 
 
We next investigated whether SALL4 downregulation was a functional event during 
EMT. For this purpose, we transfected the M010817 line with RNAi specific for 
SALL4 (siSALL4) and we analyzed the cells at different time points after transfection 
(Figure 30D-K). At 24 hours post siSALL4 treatment we analyzed the mRNA levels of 
transcription factors as ZEB1, ZEB2 and TWIST1 that are dynamically regulated in 
the first phase of EMT (Caramel et al., 2013) (Figure 30D-E). Upon SALL4 
knockdown, we observed a significant reduction in the ZEB2 transcript levels (Figure 
30D) and a significant increase in ZEB1 and TWIST1 expression (Figure 30E). At 48 
hours and 72 hours post transfection we observed a significant reduction in the 
transcript level of E-cadherin (CDH1) (Figure 30F-G) and a significant increase in the 
levels of N-cadherin (CDH2) and fibronectin (FN1) (Figure 30H). Interestingly, we 
detected a considerable increase in p75NTR expression levels (Figure 30J-K), 
reaching almost 30-fold increase after 72 hours post RNAi treatment (Figure 30K). 
Overall, these data suggest that SALL4 loss upon EMT induction (Figure 30A-C) is 
rather a functional event that is sufficient to trigger EMT. Moreover, the extensive 
increase in p75NTR expression upon SALL4 knockdown suggests the existence of a 
regulatory loop, in which p75NTR can downregulate SALL4 (Figure 30B-C), and 
SALL4 can, in turn, directly or eventually through epigenetic mediators, inhibit p75NTR 
(Figure 30J-K). 
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Figure 30. SALL4 expression in respect to EMT. 
(A-C) M010817 treatment with TGFb-1 (A) or overexpression of p75NTR (B-C) induces EMT 
and decreases transcript (A) and protein levels (C) of SALL4. (D-K) RT-qPCR data for genes 
of the EMT signature upon SALL4 knockdown by RNAi in the M010817 line. Data are mean ± 
standard deviation. Statistic performed with N ≥ 3. P-values calculated with unpaired 
Student’s t-test. 
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4.2.5.6 Sall4 expression in mouse wild type skin and in the Tyr::NRasQ61KInk4a-/- 
melanoma mouse model 
 
Sall4 was weakly expressed in the Dct+ cells in the in the hair follicle of wild type (wt) 
mouse skin (Figure 31A) and in the hyperplastic lesions of the melanoma mouse 
model Tyr::NRasQ61K Ink4a-/- (Figure 31B). In primary melanomas Sall4 was strongly 
expressed by a subpopulation of Dct+ cells. Future accurate quantifications are going 
to reveal the percentage of Sall4+ cells in the hyperplesia and in the primary tumors. 
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Figure 31. Sall4 staining in normal and tumorigenic mouse skin. 
(A-C) Immunofluorescent staining on normal skin (mouse with Sall4 lox/lox genotype), 
hyperplastic lesion and primary melanoma (mouse with Tyr::NRasQ61K Ink4a-/- genotype). 
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4.2.5.7 Sall4 is necessary for melanoma initiation 
 
To examine the possibility that Sall4 may play a role in tumor initiation we 
conditionally deleted Sall4 by five consecutive intraperitoneal (i.p.) injections of 
tamoxifen (TM) in the melanoma mouse model Tyr::NRasQ61K Ink4a-/- Tyr::CreERT2 
Sall4lox/lox R26R::GFP at one month of age before any tumor initiation (cKO animals, 
Figure 32A, C). Control animals were not injected littermates (Figure 32B). The 
animals were sacrificed at the moment that the maximum tumor size was achieved 
(diameter of 5 mm) or that any atypical behavior and/or pain was assessed. As 
expected, around 5 to 6 months of age Control animals were developing primary 
tumors (diameter ≥ 2 mm, Figure 32D). However, cKO animals barely developed any 
tumors and the few observed were never recombined (Figure 32E, G). The skin of 
the cKO animals was hyperplastic and the animals were not greying suggesting that 
Sall4 loss was not influencing melanocytes survival.  
However, the overall survival of the cKO animals was unexpectedly worse compared 
to the Control animals (Figure 32F), implying that Sall4 loss was having a negative 
effect on the survival outcome. 
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Figure 32. Sall4 function is essential for primary melanoma formation, but Sall4 loss is 
linked to worse overall survival. 
(A) Experimental setup to analyze the function of Sall4 loss in the melanocytic lineage and its 
effect on melanoma formation. (B-C) Genotype strategy for the Control (- TM) animals and 
the cKO (+ TM) animals. (D-E) Macroscopic picture of a Control and of a cKO littermate at 5 
months post TM injection. (F) Kaplan-Meier curve of the overall survival of Control and cKO 
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littermates. (G) Total number of primary skin melanoma observed in both Control and cKO 
littermates. In the cKO animals the total number of primary tumors is shown, independently 
whether recombination was observed. 
 
4.2.5.8 Recombined melanocytes in the cKO animals 
 
Intrigued by the previous results, we analyzed the skin of the cKO animals. 
Surprisingly, few recombined GFP+ cells were detected in the skin of the cKO 
animals (Figure 33 A-B). We could detect recombined cells only in the lymph nodes 
(Figure 33C) and in some lungs (data not shown) of the cKO animals. 
 
 
Figure 33. The effect of Sall4 loss in the cKO animals. 
(A-B) Immunostaining for the melanocytic marker Dct (red) and for recombined cells (GFP, 
green) showed that very few recombined cells could be detected in the skin of cKO animals 
(hair follicle, B). (C) Recombined cells (green) in the lymph node of a cKO animal. 
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The limited number of recombined cells in the in the cKO animals could suggest that 
the recombination efficiency was low. However, we could exclude this possibility by 
injecting Control littermate Sall4 wt/wt animals  (Figure 34). Recombination efficiency in 
these Control animals was in fact high (Figure 34A-B) and could confirm the validity 
of our experimental setup.  
 
 
Figure 34. Recombination efficiency in the Tyr::NRasQ61K Ink4a -/- Sall4 wt/wt R26R::GFP 
control animals. 
(A) Immunofluorescent staining for Dct (red) and GFP (green) and (B) staining for GFP 
(green) and Sall4 (red) in injected Control animals demonstrates the efficiency of the 
recombination protocol. 
 
GFP
Dct
I
I
GFP
Sall4
GFP
Sall4
Dapi
I
A
Hyperplesia: Tyr:: NRasQ61K INK4a-/- Tyr::CreERT2 Sall4wt/wt R26R::GFP 
B
Hyperplesia: Tyr:: NRasQ61K INK4a-/- Tyr::CreERT2 Sall4wt/wt R26R::GFP 
	   85	  
Another possible explanation would be that Sall4 loss in the melanocytic lineage is 
lethal in vivo. However, this interpretation would not explain the presence of 
recombined cells in the hyperplesia and in the lymph nodes of the cKO animals 
(Figure 33 B, C).  
To definitively rule out both possibilities we are going to analyze and quantify cKO 
animals sacrificed shortly after recombination before any cell dissemination may 
occur. 
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4.2.6 Discussion and Outlook 
 
Sall4 is a crucial factor in the maintenance of pluripotency and self-renewal in ES 
cells. Moreover, SALL4 upregulation has been linked to worse survival, metastasis 
formation and acquisition of pluripotent characteristics in several types of tumor (Cao 
et al., 2009; Forghanifard et al., Gao et al., 2011; 2013; Yong et al., 2013; Zhang et 
al., 2015). In this study, preliminary results suggest that SALL4 may play an 
important unknown role in melanoma. 
 
4.2.6.1 SALL4 expression in human melanoma cell lines and its influence on 
the survival rate of skin cutaneous melanoma patients.  
 
SALL4 was expressed at both mRNA and at protein level in some proliferative 
human melanoma cell lines, while it was absent in more invasive melanoma cell 
lines. Interestingly, when invasiveness was induced in a proliferative melanoma cell 
line by TGFb-1 treatment (Figure 30A) or in xenotransplants by overexpressing 
p75NTR (Figure 30B-C) SALL4 expression was significantly reduced. Moreover, 
SALL4 knockdown by RNAi treatment induced an EMT signature in a proliferative 
melanoma cell line. At 24 hours post RNAi treatment we observed a significantly 
reduced expression of ZEB2 and a significant increase in ZEB1 and TWIST1 
transcript levels (Figure 30D, E). After 48 hours and respectively 72 hours post RNAi 
treatment, we reported a reduction in the expression of the epithelial marker E-
cadherin (CDH1) and an increase in the expression of mesenchymal markers as N-
cadherin (CDH2) and fibronectin (FN1) (Figure 30F-I). Moreover, we observed a 30-
folds increase in p75NTR (NGFR) transcript levels after 72 hours post RNAi treatment 
(Figure 30K) Overall these results suggest the presence of a regulatory loop in which 
SALL4 downregulation is a functional event that is also sufficient to induce EMT. 
However, further validations in additional melanoma cell lines are indispensable. 
Moreover, to test our hypothesis we plan to induce SALL4 overexpression combined 
with TGFb-1 treatment to investigate whether we could block, or partially inhibit, the 
EMT machinery. Furthermore, given that SALL4 can act as a transcriptional 
repressor through regulation of the epigenetic machinery by direct interaction with 
the NuRD complex, we plan to check whether SALL4 knockdown is related to a 
decrease in the HDACs activity, and whether, on the contrary, treatment of a 
proliferative melanoma cell line with a HDACs inhibitor would increase p75NTR 
expression. 
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The results obtained in vitro and with the xenotranplants (Figure 30), apparently 
contradict the overall survival rate produced by the TCGA analysis, in which patients 
of the SALL4 low group show a better survival than those of the SALL4 high group  
(Figure 28). A possible hypothesis explaining this discrepancy would be that it is the 
proliferation rate of the primary melanoma and mostly of the metastases the most 
severe factor affecting patients survival. Given that SALL4 is expressed in highly 
proliferative melanoma cell lines and it is downregulated upon EMT induction, we can 
speculate that SALL4 may be important for the maintenance of proliferation in 
melanoma. SALL4 decrease would thus reduce cell proliferation, as it has already 
been shown for other tumor types (Zhang et al., 2015), and have a positive effect on 
patient survival. Further analyses of the cell cycle upon SALL4 knockdown are 
required to confirm this point.  
However in the mouse model, Sall4 loss can not be dynamically regulated. We are 
prompted, thus, to speculate that Sall4 loss may result in an even more severe 
outcome, characterized by a higher number of metastases (Figure 33). 
In the literature, SALL4 overexpression is linked to worse prognosis, increased 
metastasis formation and increased tumor proliferation in tumors other than 
melanoma (Yong et al., 2013; Zhang et al., 2015). Although, our results don’t 
suggest that high SALL4 expression is promoting a higher number of metastases, 
but actually the contrary, we have indications that SALL4 positively influences cell 
proliferation in melanoma (Figure 29B-D), as it has been proposed in other types of 
tumors (Kobayashi et al., 2011). 
 
4.2.6.2 Sall4 function in the Tyr::NRasQ61K Ink4a-/- melanoma mouse model 
 
Preliminary results in vivo suggest that Sall4 is necessary for primary melanoma 
formation and that its loss inhibits tumor development (Figure 32D, E). These results 
would suggest a function of Sall4 in cell proliferation (Kobayashi et al., 2011; Li et al., 
2015) and that its loss would unable tumorigenic cells to proliferate and give rise to 
primary tumors. 
Sall4 is heterogeneously expressed in primary melanomas of the Tyr::NRasQ61K  
Ink4a-/- mouse model (Figure 31C) and it would be interesting to investigate whether 
Sall4+ melanoma cells would have a survival advantage. 
When we analyzed the cKO animals, we surprisingly observed few recombined cells 
in the skin. We could exclude that this result was due to low recombination efficiency 
because recombined Control littermates were showing good levels of recombination 
(Figure 34). We also excluded that Sall4 loss was affecting cell survival, because of 
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the results obtained in vitro and in the xenotransplants (Figure 30) and because we 
still recorded recombined cells after 5 month post recombination (Figure 33).  
We then analyzed LNs and lungs of the cKO animals and we could always observe 
recombined cells in the LNs (Figure 33C), and in some cases in the lungs (data not 
shown). Whether cKO cells may really undergo EMT, invade the bloodstream and 
finally colonize distant organs needs extensive further investigations. To examine this 
hypothesis, we plan to produce doxycycline-inducible SALL4 overexpressing 
invasive human melanoma cell lines and to inject them into NSG mice. If it is correct 
that SALL4 loss is reducing cell proliferation and promoting metastases formation, 
we expect that SALL4 overexpression would decrease metastasis numbers when 
overexpressed shortly after injection, even though increasing primary tumor size. On 
the other side, we expect that SALL4 overexpression later after cells injection, once 
the cells have already metastasized, would produce bigger and more proliferative 
metastases. 
A further experiment that we are planning to perform is to inject tumoral cells derived 
from a Tyr::NRasQ61K Ink4a-/- Tyr::CreERT2 Sall4lox/lox R26R::GFP mouse into nude 
mice. Following tumor growth we plan to induce recombination. The derived 
recombined tumors should demonstrate whether recombined cells eventually die 
upon Sall4 loss in vivo, or whether they perform EMT, and provide material for gene 
expression analysis.  
 
4.2.6.3 SALL4 as a putative therapeutic target 
 
SALL4 is not expressed in the majority of normal adult tissues, with exception of the 
spermatogonia (Cao et al., 2009), but it is aberrantly upregulated in a vast number of 
tumors (Zhang et al., 2015). This led to the idea that SALL4 may be a good 
therapeutic target to treat cancer (Jones, 2013; Yong et al., 2013). High levels of 
SALL4 expression are indeed linked to a higher rate of tumor proliferation, 
acquisition of stem cell-like properties and high metastatic potential. These features 
result in an overall worse survival outcome, while low levels of SALL4 expression are 
correlated to lower proliferation rate, weaker metastasizing potential and better 
survival expectancy. Consequently, for some types of tumor, as hepatocellular 
carcinoma (Yong et al., 2013), it is now under discussion whether to use small-
molecule drugs to target SALL4. These treatments could consist of SALL4-peptide-
based inhibitors or other drugs, as HDAC inhibitors, that would inhibit SALL4-
activated pathways. 
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These treatments could indeed be of interest to treat numerous types of cancer. 
However, on the basis of our preliminary results their efficacy on treating melanoma 
would be highly debatable. Our prediction would be in fact that inhibiting SALL4 in an 
already formed tumor would reduce cell proliferation, but would eventually promote 
metastasis formation. Further investigations are now needed to elucidate whether 
SALL4 may really play such a unique role that seems to be characteristic of 
melanoma. 
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4.2.7 Experimental procedures 
 
4.2.7.1 Mice 
 
The experimental animals Tyr::NRasQ61K Ink4a-/- Tyr::CreERT2 Sall4lox/lox R26R::GFP 
were obtained by crossing the Tyr::NRasQ61K and the Ink4a-/- mouse line (Ackermann 
et al., 2005; Serrano et al., 1996) with the Tyr::CreERT2 (Bosenberg et al., 2006), the 
Sall4 lox (Elling et al., 2006) and the R26R::GFP (Simon et al., 2012) mouse lines 
(Table 5). Animals of both genders were put under experiment at one month of age. 
Animals were sacrificed around 5 to 6 months of age whenever affected by skin 
tumors > 5 mm, weight loss (< 15%), symptoms of pain as hunched back or any 
abnormal behavior. Animal experiments were approved by the veterinary office of the 
Canton of Zurich, Switzerland. 
 
Table 5: Mouse genotyping primers 
 
Allele Forward sequence Reverse sequence 
Cre AGGCTAAGTGCCTTCTCTACAC ACCAGGTTCGTTCACTCATGG 
Sall4lox CTCCACCAACTCTAGCTGCTAATGGC ATGGCCTTTGCACATGTGTTCTGGAG 
Sall4wt CTCCACCAACTCTAGCTGCTAATGGC GTTACAGCAATACGGAGATACACAGC 
Ink4awt ATGATGATGGGCAACGTTC CAAATATCGCACGATGTC 
Ink4a- CTATCAGGACATAGCGTTGG AGTGAGAGTTTGGGGACAGAG 
GFP CGCACCATCTTCTTCAAGGACGAC AACTCCAGCAGGACCATGTGATCG 
 
4.2.7.2 Tamoxifen injections and quantification of primary melanomas and 
metastases 
 
Sall4 was conditionally ablated at one month of age in Tyr::NRasQ61K Ink4a-/- 
Tyr::CreERT2 Sall4lox/lox R26R::GFP animals by i.p. injections of 2mg tamoxifen for five 
consecutive days. Tamoxifen (T5648, Sigma-Aldrich) was diluted in ethanol and 
sunflower oil (1:10) for a final concentration of 10mg/ml.  
When the animals were sacrificed the numbers of melanoma and of metastases was 
assessed. Melanomas were defined as kin lesion with a diameter > 2mm. 
Metastases were detected at the binocular and checked whether they were 
recombined and expressing GFP+. 
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4.2.7.3 Immunofluorescence 
 
Mouse samples were fixed in 4% formaldehyde and embedded in paraffin. For 
immunohistochemistry, paraffin sections were processed as previously described 
(Shakhova et al., 2012). See Table 6 for the list of antibodies. 
 
Table 6: Primary and secondary antibodies 
 
Primary antibodies 
Antigen Specificity Company Serial number Dilution 
DCT 
human/mou
se 
Santa Cruz Biotechnology sc-10451 1:250 
Sall4 mouse abcam ab29112 1:200 
GFP mouse Aves GFP-1020 1:400 
     
Secondary antibodies 
Fluorophore Specificity Company Serial number Dilution 
DyLight 649 goat Jackson 705-495-147 1:300 
Cy3 rabbit Jackson 711-165-152 1:300 
DyLight 549 chicken Jackson 703-505-155 1:300 
 
4.2.7.4 Cell culture 
 
Human melanoma lines were cultured with RPMI 1640 (42401, Life Technologies) 
with addition of 10% FCS (16140, Life Technologies), 4mM L-Glutamine (25030, Life 
Technologies), Penicillin-Streptomycin (15070, Life Technologies) and Fungizone 
(15290, Life Technologies). 
 
4.2.7.5 Cell transfection 
 
20 mM siRNA (Table 7) was applied to the cells in combination with jetPRIME siRNA 
Transfection Reagent (114-75, Polypus Transfection) according to manufacturer’s 
guidelines. 
The medium was exchanged after 24 hours and the cells were analyzed at 24, 48 
and 72 hours post transfection. 
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Table 7: RNAi constructs 
Target gene siRNA name Specificity Company Serial numbers 
none siCtr human Life Technologies 12935-112 
SALL4 siSALL4 human Life Technologies HSS183741, 
HSS126094, 
HSS126095 
 
4.2.7.6 RNA isolation and RT-qPCR 
 
RNA was extracted and purified using the RNeasy Mini Kit (74104, Qiagen). Purified 
RNA was measured using the nanodrop. Reverse transcription was performed using 
the Maxima First Strand cDNA Synthesis Kit (K1641, Thermo Scientific) and cDNA 
was treated with RNase H /EN0202, Thermo Scientific). Quantitative real-time PCR 
(RT-qPCR) was perfomed using the LightCycler 480 System (Roche) and the 
LightCycler 480 SYBR Green I Master (4707516001, Roche). Primers are indicated 
in Table 8. 
 
Table 8: Human RT-qPCR primers 
 
Gene Forward sequence Reverse sequence 
b-actin CGA CAA CGG CTC CGG CAT GTG C CGT CAC CGG AGT CCA TCA CGA TGC 
E-cadherin TGC CCA GAA AAT GAA AAA GG GTG TAT GTG GCA ATG CGT TC 
N-cadherin ACA GTG GCC ACC TAC AAA GG CCG AGA TGG GGT TGA TAA TG 
Fibronectin (FN1) TACCAAGGCTGGATGATGG AGATGCACTGGAGCAGGTTT 
p75NTR CCT ACG GCT ACT ACC AGG ATG CAC ACG GTG TTC TGC TTG T 
Twist1 GTC CGC AGT CTT ACG AGG AG CCA GCT TGA GGG TCT GAA TC 
Zeb1 GCA CAA CCA AGT GCA GAA GA CAT TTG CAG ATT GAG GCT GA 
Zeb2 CGC TTG ACA TCA CTG AAG GA CTT GCC ACA CTC TGT GCA TT 
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5 Discussion 
 
5.1 The NC to model and treat disease 
 
The NC is a transient embryonic multipotent cell population that during development 
of the vertebrate embryo gives rise to a variety of cell types ranging from the neurons 
and the glia of the peripheral nervous system, to the melanocytes of the skin and to 
the craniofacial cartilage, among others (Baggiolini et al., 2015; Bronner-Fraser and 
Fraser, 1988). Aberrant control of the mechanisms regulating NC cells migration, 
differentiation and proliferation often results in the onset of neurocristopathies, such 
as pigmentation defects, craniofacial abnormalities and cancer. Most of the studies 
on the NC have been performed in model organisms as the mouse, chick and 
zebrafish. However, these models are not always the most appropriate to study the 
molecular mechanisms underlying human neurocristopathies and eventually to 
screen for therapeutic targets to prevent and treat human developmental defects. 
A promising model to study disease mechanisms is the use of induced NC cells that 
can be derived from both human embryonic stem cells (hESCs) or from human 
induced pluripotent stem cells (iPSCs) (Lee et al., 2007; Lee et al., 2009). For 
instance, familial dysautonomia (FD), which is a NC-derived peripheral neuropathy 
caused by a point mutation in IKBKAP8, has been already modeled using patient-
derived iPSCs (Lee et al., 2009). This resulted in a large-scale drug-discovery screen 
on iPSCs-derived NC cells for a total of 6,912 small-molecule compounds and the 
discovery of SKF-86466, a compound able to rescue IKAP protein level and to 
rescue the FD-caused loss of autonomic neurons (Lee et al., 2012). 
The availability of patient-specific iPSCs-derived NC cells does not only provide 
material for molecular studies and drugs screening, but also opens the possibility to 
personalized cell-based therapy and cell replacement. However, because of the 
multipotent nature of the NC cells, it is still necessary to develop appropriate 
protocols to definitively commit NC cells in the required cell fate to avoid the 
appearance of undesired cell types or tumor development.  
 
5.2 The NC to understand and fight cancer 
 
Upon induction of the NC in the neural folds, NC cells undergo an epithelial to 
mensenchymal transition characterized by loss of cell-cell contacts, change of the 
actin cytoskeleton and loss of the apico-basal cell polarity. With the acquisition of the 
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mesenchymal features NC cells delaminate from the neural tube and migrate 
extensively through the embryonic body on defined paths to finally differentiate into 
varied cell types and proliferate. NC cells are, thus, highly invasive and mobile; 
characteristics that are essential during development, but that can be exploited by 
malignant cells at later stages. It is widely accepted indeed that tumoral cells may 
adopt embryonic programs to progress to further stages of malignancy (Maguire et 
al., 2015). For instance, in both the NC and in cancer, EMT occurs through a 
“cadherin switch” (Taneyhill, 2008) from E-cadherin to N-cadherin expression. 
Moreover in both systems the EMT master regulators Snail, Zeb and Twist are 
activated. NC cells activate during EMT also matrix metalloproteinases (MMPS) and 
domain-containing protein 10 (ADAM10) to break the basement membrane that 
separate the neural epithelium from the mesenchyme and to migrate through the 
developing embryo. Similarly, malignant cells upregulate MMPS and ADAMs too, to 
break the basement membrane and reach lymphatic and blood vessels and be able 
to metastasize. Furthermore, NC cells require the hypoxia inducible factor-1alpha 
(HIF-1alpha) to activate Twist and regulate the chemotaxis receptor CXCR4 (Barriga 
et al., 2013), which regulate NC cells migration. Similarly, malignant cells exploit HIF-
1alpha and activate Twist to undergo EMT (Maguire et al., 2015).  
Melanoma is a malignancy of the melanocytes, which are NC-derived. NRAS and 
especially BRAF mutations are the most occurring genetic aberrations in melanoma. 
Both mutations result in a constitutive activation of the MEK/ERK signaling pathway 
and in consequent cell proliferation and survival (Schadendorf et al., 2015). 
Melanoma cells activate as well EMT regulators known from development; in 
particular melanoma cells perform a switch from SNAIL2/ZEB2 to TWIST1/ZEB1 
expression (Caramel et al., 2013) and downregulate E-cadherin (CDH1). That 
melanoma cells adopt NC-mechanisms during malignancy is also evident from 
transplantation studies in which aggressive melanoma lines were injected in chick 
embryos. As a result, aggressive melanoma cells, but not less aggressive melanoma 
cells or melanocytes, could respond to signals in the developing embryos and 
migrate to the embryonic target structure (Kulesa et al., 2006).  
The fact that cancer cells exploit many mechanisms typical of NC development 
suggests that a deep understanding of NC biology may significantly contribute to 
treatment of this malignancy. On this line, a trancriptome analysis of premigratory 
and migratory NC cells isolated from the chick embryo has been performed and 
compared to neuroblastoma microarray data. The comparison resulted in the 
discovery of 27 genes that are NC-specific and relevant to neuroblastoma formation 
(Rabadán et al., 2013). 
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Similarly, our laboratory has recently performed a microarray analysis of isolated 
mouse NC cells and compared it to the microarray data of NC cells primed towards 
differentiation (Varum et al., unpublished). We obtained a list of 53 trancription 
factors that were specifically expressed in the NC and that were downregulated upon 
differentiation. Some of these factors, including Sall4 (4.2 The roles of Sall4 in 
melanoma), have already demonstrated to have an influence on melanoma formation 
and progression (Varum et al., unpublished). The ongoing investigations are going to 
enlighten more similarities between development and cancer and hopefully to bring 
deeper understanding of how we should apply our knowledge on embryogenesis to 
treat this malignancy. 
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